

Report of an International Workshop to Standardize Re Lymphomas

Journal of Clinical Oncology

17, 1244-1244

DOI: [10.1200/jco.1999.17.4.1244](https://doi.org/10.1200/jco.1999.17.4.1244)

Citation Report

#	ARTICLE	IF	CITATIONS
1	How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients?. <i>Annals of Oncology</i> , 1999, 10, 1141-1143.	0.6	23
2	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 889-918.	0.9	11
3	Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). <i>Annals of Oncology</i> , 1999, 10, 1485-1488.	0.6	63
4	Principles of diagnosis, staging and management. <i>Imaging</i> , 1999, 11, 214-229.	0.0	0
5	Lymphoma: monitoring response to therapy. <i>Imaging</i> , 1999, 11, 269-281.	0.0	1
6	Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 1622-1636.	0.8	416
7	Semen analysis and cryoconservation before treatment in Hodgkin's disease. <i>Annals of Oncology</i> , 2000, 11, 679-684.	0.6	42
8	Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry. , 2000, 88, 894-899.		34
9	Follicular lymphomas "a review of treatment modalities. <i>Critical Reviews in Oncology/Hematology</i> , 2000, 35, 13-32.	2.0	15
10	Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan lymphoma radiation therapy group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 161-168.	0.4	35
11	Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 1107-1110.	0.4	32
12	Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. <i>Leukemia</i> , 2000, 14, 1136-1142.	3.3	43
13	Burkitt's lymphoma in Greek adults. <i>Leukemia Research</i> , 2000, 24, 993-998.	0.4	3
14	New developments in lymphoma clinical trials. <i>Current Oncology Reports</i> , 2000, 2, 154-156.	1.8	0
15	Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1564-1578.	2.2	122
16	Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients. <i>Medical Oncology</i> , 2000, 17, 127-134.	1.2	18
17	Current trends in the management of malignant lymphoma: new WHO classification, guidelines for high-dose therapy with HSCT, and new response criteria. <i>International Journal of Clinical Oncology</i> , 2000, 5, 1-7.	1.0	0
18	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.	0.6	201

#	ARTICLE	IF	CITATIONS
19	Waldenström's Macroglobulinemia: Clinical Features, Complications, and Management. <i>Journal of Clinical Oncology</i> , 2000, 18, 214-214.	0.8	309
20	Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment. <i>Journal of Clinical Oncology</i> , 2000, 18, 3135-3143.	0.8	653
21	The Curious Case of the Baffling Biological. <i>Journal of Clinical Oncology</i> , 2000, 18, 2007-2009.	0.8	14
22	Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1309-1315.	0.8	55
23	Role of a Doxorubicin-Containing Regimen in Relapsed and Resistant Lymphomas: An 8-Year Follow-Up Study of EPOCH. <i>Journal of Clinical Oncology</i> , 2000, 18, 3633-3642.	0.8	126
24	Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2593-2602.	0.8	288
25	Response criteria for NHL: Importance of "normal" lymph node size and correlations with response rates. <i>Annals of Oncology</i> , 2000, 11, 399-408.	0.6	62
26	Randomized Trial of Fludarabine Versus Fludarabine and Idarubicin as Frontline Treatment in Patients With Indolent or Mantle-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 773-773.	0.8	89
27	Follicular lymphoma: Have we made any progress?. <i>Annals of Oncology</i> , 2000, 11, S23-S27.	0.6	56
28	High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: Experience in California. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 496-505.	2.0	13
29	Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. <i>European Journal of Cancer</i> , 2000, 36, 2360-2367.	1.3	24
30	Investigation of monoclonal antibody therapy with conventional and high-dose treatment: Current clinical trials. <i>Seminars in Hematology</i> , 2000, 37, 27-33.	1.8	4
31	Granulocyte-Colony Stimulating Factor (G-CSF) May Improve Disease Outcome in Elderly Patients with Diffuse Large Cell Lymphoma (DLCL) Treated with CHOP Chemotherapy. <i>Leukemia and Lymphoma</i> , 2000, 39, 67-75.	0.6	21
33	Rituximab/CHOP Induction Therapy in Newly Diagnosed Patients with Mantle-Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 27-28.	2.1	18
34	Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000, 1, 146-151.	2.1	11
35	A Multicenter Trial of Infusional Etoposide, Doxorubicin, and Vincristine with Cyclophosphamide and Prednisone (EPOCH) in Patients with Relapsed Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2001, 1, 285-292.	2.1	13
36	Phase II Trial of Remitogen, Φ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 188-190.	2.1	26
37	Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2001, 345, 241-247.	13.9	509

#	ARTICLE	IF	CITATIONS
38	Clinical stage IIA orbital lymphomas: outcomes in the era of modern staging and treatment. <i>Radiotherapy and Oncology</i> , 2001, 59, 145-151.	0.3	56
39	Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. <i>American Journal of Medicine</i> , 2001, 111, 704-711.	0.6	62
40	The fusion of anatomic and physiologic imaging in the management of patients with cancer. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 191-205.	2.5	73
41	Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 561-567.	2.0	22
42	Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (± Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2001, 3, 203-210.	0.3	24
43	Liposomal Daunorubicin (Daunoxome) in Combination with Cyclophosphamide, Vincristine and Prednisolone (COP-X) as Salvage Therapy in Poor-Prognosis Non-Hodgkins Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 42, 89-98.	0.6	14
44	Rituximab: An innovative therapy for non-Hodgkin's lymphoma. <i>American Journal of Health-System Pharmacy</i> , 2001, 58, 215-229.	0.5	19
46	Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2001, 12, 923-927.	0.6	28
47	Primary Gastrointestinal Non-Hodgkin's Lymphoma: I. Anatomic and Histologic Distribution, Clinical Features, and Survival Data of 371 Patients Registered in the German Multicenter Study GIT NHL 01/92. <i>Journal of Clinical Oncology</i> , 2001, 19, 3861-3873.	0.8	432
48	Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides. <i>Journal of Clinical Oncology</i> , 2001, 19, 779-784.	0.8	109
49	Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management. <i>Journal of Clinical Oncology</i> , 2001, 19, 1855-1864.	0.8	129
50	Rational Approaches to Design of Therapeutics Targeting Molecular Markers. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 443-462.	0.9	19
52	Treatment of Aggressive Non-Hodgkin's Lymphoma With Dose-Intensified Epirubicin in Combination of Cyclophosphamide, Vincristine, and Prednisone (CEOP-100). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 570-575.	0.6	8
53	Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. <i>Anti-Cancer Drugs</i> , 2001, 12, 725-729.	0.7	94
54	Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2001, 12, 1439-1443.	0.6	41
55	Fludarabine and mitoxantrone: Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. <i>Annals of Oncology</i> , 2001, 12, 1455-1460.	0.6	28
56	Natural Killer/Natural Killer-Like T-Cell Lymphoma, CD56+, Presenting in the Skin: An Increasingly Recognized Entity With an Aggressive Course. <i>Journal of Clinical Oncology</i> , 2001, 19, 2179-2188.	0.8	153
57	Myelodysplastic syndromes standardized response criteria: further definition. <i>Blood</i> , 2001, 98, 1985-1986.	0.6	35

#	ARTICLE	IF	CITATIONS
58	Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose (¹⁸ F) After First-Line Chemotherapy in Non-Hodgkin's Lymphoma: Is ¹⁸ F-FDG-PET a Valid Alternative to Conventional Diagnostic Methods?. <i>Journal of Clinical Oncology</i> , 2001, 19, 414-419.	0.8	455
59	Autologous Stem-Cell Transplantation for Hodgkin's Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 1395-1404.	0.8	225
62	Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: Clinical features, management, and prognosis of 66 patients. <i>Annals of Oncology</i> , 2001, 12, 53-58.	0.6	77
63	T-Cell-Rich B-Cell Lymphoma. <i>Oncology</i> , 2001, 61, 257-264.	0.9	11
64	Immunotherapy of Non-Hodgkin's Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 221-240.	0.9	72
65	Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1482-1488.	3.3	11
66	New drug development in non-hodgkin lymphomas. <i>Current Oncology Reports</i> , 2001, 3, 250-259.	1.8	4
67	Positron emission tomography and gallium metabolic imaging in lymphoma. <i>Current Oncology Reports</i> , 2001, 3, 266-270.	1.8	12
68	Stellenwert der Strahlentherapie bei nodalen Non-Hodgkin-Lymphomen in lokalen und fortgeschrittenen Stadien. <i>Onkologie</i> , 2001, 7, 960-968.	0.7	3
69	Relapse patterns of localized non-Hodgkin's lymphoma of the head and neck after clinical remission: results of a strict follow-up procedure. <i>International Journal of Clinical Oncology</i> , 2001, 6, 302-305.	1.0	5
70	Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 128-134.	1.2	38
71	Assessment of Prognostic Factors in Follicular Lymphoma Patients. <i>International Journal of Hematology</i> , 2001, 73, 363-368.	0.7	19
72	Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 17-22.	0.4	46
73	Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 743-749.	0.4	28
74	Long-term results with radiotherapy for stage I-II follicular lymphomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 1219-1227.	0.4	156
75	Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 113, 772-778.	1.2	90
76	Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 114, 333-341.	1.2	34
77	Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 115, 793-800.	1.2	196

#	ARTICLE	IF	CITATIONS
78	The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 195-201.	2.0	85
79	Rituximab: perspective on single agent experience, and future directions in combination trials. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 40, 3-16.	2.0	72
80	Pretargeted radioimmunotherapy (PRIT [®]) for treatment of non-Hodgkin's lymphoma (NHL). <i>Critical Reviews in Oncology/Hematology</i> , 2001, 40, 37-51.	2.0	54
81	Comparison of MALT and non-MALT primary large cell lymphoma of the stomach. <i>Cancer</i> , 2001, 91, 49-56.	2.0	11
82	Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. <i>Cancer</i> , 2001, 91, 1557-1562.	2.0	22
83	Lymphoproliferative disorders in renal transplant patients in Japan. <i>International Journal of Cancer</i> , 2001, 91, 869-875.	2.3	118
84	Localized non-Hodgkin's lymphoma of Waldeyer's ring: Clinical features, management, and prognosis of 130 adult patients. <i>Head and Neck</i> , 2001, 23, 547-558.	0.9	99
85	Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. <i>Cancer</i> , 2001, 91, 2440-2446.	2.0	26
86	Reproducibility of Tumor Response Evaluation in Patients with High-Grade Malignant non-Hodgkin's Lymphoma. <i>Medical Oncology</i> , 2001, 18, 137-140.	1.2	3
87	How accurate is helical CT volumetric assessment in renal tumors?. <i>European Radiology</i> , 2001, 11, 1435-1438.	2.3	17
88	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. <i>Leukemia</i> , 2001, 15, 1941-1949.	3.3	49
89	Monoclonal Antibody Therapy for Lymphoma. An Update. <i>Cancer Practice</i> , 2001, 9, 71-80.	0.8	37
90	Non-Hodgkin's Lymphoma of the Ocular Adnexa. <i>Acta Oncologica</i> , 2001, 40, 485-490.	0.8	44
91	Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. <i>Blood</i> , 2001, 97, 101-106.	0.6	506
92	Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy. <i>Bone Marrow Transplantation</i> , 2001, 27, 531-536.	1.3	17
93	Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 42, 1015-1022.	0.6	75
94	Mediastinal Lymphoma: Quantitative Changes in Gadolinium Enhancement at MR Imaging after Treatment. <i>Radiology</i> , 2001, 219, 621-628.	3.6	36
95	Tyrosine Kinase Inhibitors Suppress the Growth of Non-Hodgkin B Lymphomas. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 163-171.	1.3	4

#	ARTICLE	IF	CITATIONS
96	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. <i>Blood</i> , 2002, 99, 4336-4342.	0.6	257
97	The prognostic significance of CA \times 125 in patients with non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2002, 69, 221-226.	1.1	34
98	T-cell Rich B-cell Lymphoma: Clinical Distinctiveness and Response to Treatment in 45 Patients. <i>Leukemia and Lymphoma</i> , 2002, 43, 1573-1580.	0.6	8
99	Randomized Controlled Trial of Yttrium-90 \times Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin \times s Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2453-2463.	0.8	1,069
100	Evaluation of response: new and standard criteria. <i>Annals of Oncology</i> , 2002, 13, 127-129.	0.6	72
101	Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin \times s lymphoma. <i>Annals of Oncology</i> , 2002, 13, 1356-1363.	0.6	376
102	Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3545-3557.	0.8	104
103	Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. <i>Bone Marrow Transplantation</i> , 2002, 29, 769-775.	1.3	44
104	Rituximab: clinical development and future directions. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 97-110.	1.4	36
105	A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 29, 647-652.	1.3	2
106	Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. <i>Leukemia</i> , 2002, 16, 260-267.	3.3	110
107	Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. <i>Leukemia</i> , 2002, 16, 268-275.	3.3	36
108	Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma. <i>Bone Marrow Transplantation</i> , 2002, 29, 615-620.	1.3	13
109	Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2472-2479.	0.8	194
110	Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity?. <i>Annals of Oncology</i> , 2002, 13, 86-91.	0.6	50
111	Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin \times s lymphoma. <i>Annals of Oncology</i> , 2002, 13, 1285-1289.	0.6	86
112	Impact of Highly Active Antiretroviral Therapy in the Treatment of HIV \times Infected Patients with Systemic Non-Hodgkin \times s Lymphoma. <i>Acta Oncol\timesgica</i> , 2002, 41, 192-196.	0.8	12
113	Treatment of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type With Cladribine: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 3872-3877.	0.8	127

#	ARTICLE	IF	CITATIONS
114	Pyothorax-Associated Lymphoma: A Review of 106 Cases. <i>Journal of Clinical Oncology</i> , 2002, 20, 4255-4260.	0.8	244
115	Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. <i>Annals of Oncology</i> , 2002, 13, 523-530.	0.6	42
116	T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Distinct Clinicopathologic Entity. <i>Journal of Clinical Oncology</i> , 2002, 20, 1269-1277.	0.8	50
117	Progress and Promise in the Treatment of Indolent Lymphomas. <i>Oncologist</i> , 2002, 7, 217-225.	1.9	23
118	T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Distinct Clinicopathologic Entity. <i>Journal of Clinical Oncology</i> , 2002, 20, 1269-1277.	0.8	73
119	Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma—a phase II study. <i>Anti-Cancer Drugs</i> , 2002, 13, 395-403.	0.7	11
120	The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas. <i>Anti-Cancer Drugs</i> , 2002, 13, 907-913.	0.7	15
121	Rituximab for Aggressive Non-Hodgkin's Lymphomas Relapsing After or Refractory to Autologous Stem Cell Transplantation. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 371-376.	1.0	23
122	Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 67-74.	0.6	149
123	Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. <i>Blood</i> , 2002, 99, 1517-1526.	0.6	519
124	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. <i>Blood</i> , 2002, 99, 754-758.	0.6	1,819
125	Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. <i>Blood</i> , 2002, 99, 2685-2693.	0.6	292
126	Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. <i>Blood</i> , 2002, 100, 4351-4357.	0.6	59
127	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2002, 100, 1559-1565.	0.6	89
128	Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3262-3269.	0.8	624
129	CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 235-242.	13.9	4,928
130	Pre- and post-treatment evaluation of non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 429-447.	0.7	12
131	Efficacy of Fludarabine/Mitoxantrone/Dexamethasone Alternating with CHOP in Bulky Follicular Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2002, 2, 229-237.	2.1	10

#	ARTICLE	IF	CITATIONS
132	90Y Ibritumomab Tiuxetan. American Journal of Cancer, 2002, 1, 341-348.	0.4	3
133	Favorable Impact of Virological Response to Highly Active Antiretroviral Therapy on Survival in Patients with AIDS-related Lymphoma. Leukemia and Lymphoma, 2002, 43, 1837-1842.	0.6	19
134	Outcomes Using Doxorubicin-Based Chemotherapy with or without Radiotherapy for Early-Stage Peripheral T-cell Lymphomas. Leukemia and Lymphoma, 2002, 43, 1769-1775.	0.6	11
135	Bendamustine Mitoxantrone and Rituximab (BMR): A New Effective Regimen for Refractory or Relapsed Indolent Lymphomas. Leukemia and Lymphoma, 2002, 43, 327-331.	0.6	26
136	Oral Cyclophosphamide Therapy for Patients with Residual or Relapsed Indolent-Type Lymphoma after Initial Treatment for Aggressive Lymphomas. A Sub-group of Patients with Apparent Transformed Indolent Lymphoma. Leukemia and Lymphoma, 2002, 43, 1803-1806.	0.6	1
137	Diffuse Large B-cell Non-Hodgkin's Lymphoma Presenting as Sister Joseph's Nodule. Leukemia and Lymphoma, 2002, 43, 2055-2057.	0.6	16
138	Rituximab and other emerging monoclonal antibody therapies for lymphoma. Expert Opinion on Emerging Drugs, 2002, 7, 289-302.	1.0	10
139	Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Review of Anticancer Therapy, 2002, 2, 485-493.	1.1	86
140	Measuring the clinical response. What does it mean?. European Journal of Cancer, 2002, 38, 1817-1823.	1.3	119
142	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002, 100, 1648-1654.	0.6	184
143	Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease. Journal of Clinical Oncology, 2002, 20, 2344-2352.	0.8	82
144	Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival. Journal of Clinical Oncology, 2002, 20, 1288-1294.	0.8	317
145	Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Seminars in Oncology, 2002, 29, 56-69.	0.8	51
146	Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. European Journal of Haematology, 2002, 68, 144-149.	1.1	20
147	Detection of relapse in non-Hodgkin's lymphoma: Role of routine follow-up studies. American Journal of Hematology, 2002, 69, 41-44.	2.0	62
148	Cisplatin, fludarabine, and cytarabine. Cancer, 2002, 94, 585-593.	2.0	30
149	Diagnostic utility of bilateral bone marrow examination. Cancer, 2002, 94, 1522-1531.	2.0	116
150	International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer, 2002, 94, 3083-3088.	2.0	47

#	ARTICLE	IF	CITATIONS
151	Monoclonal Antibody Therapy for B-Cell Lymphoma. <i>International Journal of Hematology</i> , 2002, 76, 385-393.	0.7	34
152	Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan. <i>International Journal of Hematology</i> , 2002, 76, 411-419.	0.7	23
153	MR detection of iliac bone marrow involvement by malignant lymphoma with various MR sequences including diffusion-weighted echo-planar imaging. <i>Skeletal Radiology</i> , 2002, 31, 263-269.	1.2	64
154	Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. <i>Annals of Hematology</i> , 2002, 81, 20-25.	0.8	140
155	Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission. <i>Annals of Hematology</i> , 2002, 81, 575-581.	0.8	13
156	High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002, 128, 603-609.	1.2	86
157	High-dose therapy for indolent lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 225-239.	2.0	11
158	A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2002, 116, 229-235.	1.2	54
159	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002, 117, 828-834.	1.2	131
160	The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. <i>British Journal of Haematology</i> , 2002, 118, 218-228.	1.2	19
161	Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2002, 30, 103-111.	1.3	77
162	Pegylated Liposomal Doxorubicin in Combination Chemotherapy in the Treatment of Previously Untreated Aggressive Diffuse Large-B-Cell Lymphoma. <i>Medical Oncology</i> , 2002, 19, 55-58.	1.2	20
163	Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3940-3947.	0.8	1,245
164	Antibody therapy of non-Hodgkin's B-cell lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 257-280.	2.0	46
165	Advancing role of radiolabeled antibodies in the therapy of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 281-296.	2.0	92
166	Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 2003, 82, 481-486.	0.8	10
167	Dynamics of circulating t(14;18)-positive cells during first-line and subsequent lines of treatment in follicular lymphoma. <i>Annals of Hematology</i> , 2003, 82, 743-749.	0.8	11
168	Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 90-96.	1.1	1

#	ARTICLE	IF	CITATIONS
169	Assessment of response to therapy using conventional imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, S56-S64.	3.3	32
170	Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, S65-S81.	3.3	55
171	Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma. <i>International Journal of Clinical Oncology</i> , 2003, 8, 212-223.	1.0	12
172	Hematologic malignancies in patients with cryoglobulinemia: Association with autoimmune and chronic viral diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 33, 19-28.	1.6	46
173	Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 127-131.	0.8	86
174	Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?. <i>Seminars in Oncology</i> , 2003, 30, 329-331.	0.8	0
175	Post-treatment surveillance of patients with lymphoma treated with curative intent. <i>Seminars in Oncology</i> , 2003, 30, 375-381.	0.8	7
176	Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. <i>Seminars in Oncology</i> , 2003, 30, 434-447.	0.8	32
177	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area. <i>Cancer</i> , 2003, 97, 2236-2241.	2.0	90
178	Phase II study of alemtuzumab in chronic lymphoproliferative disorders. <i>Cancer</i> , 2003, 98, 773-778.	2.0	122
179	Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. <i>Cancer</i> , 2003, 98, 993-1001.	2.0	211
180	Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting. <i>Cancer</i> , 2003, 98, 983-992.	2.0	18
181	Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. <i>Cancer</i> , 2003, 98, 1611-1619.	2.0	40
182	Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. <i>Hematological Oncology</i> , 2003, 21, 99-108.	0.8	7
183	Flow cytometry in the bone marrow staging of mature B-cell neoplasms. <i>Cytometry</i> , 2003, 54B, 10-18.	1.8	32
184	Stage III follicular lymphoma: long-term follow-up and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 748-754.	0.4	13
185	Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. <i>British Journal of Haematology</i> , 2003, 120, 978-985.	1.2	98
186	Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 120, 970-977.	1.2	56

#	ARTICLE	IF	CITATIONS
187	Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 123, 271-277.	1.2	30
188	Predictive value of early 18 F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. <i>British Journal of Haematology</i> , 2003, 123, 282-287.	1.2	54
189	18 FDG positron emission tomography versus 67 Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 123, 454-462.	1.2	37
190	Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. <i>Bone Marrow Transplantation</i> , 2003, 31, 121-128.	1.3	15
191	High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2003, 31, 441-446.	1.3	15
192	Reduced-intensity rituximab-BEAM-CAMPATH allogeneic hematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions. <i>Bone Marrow Transplantation</i> , 2003, 31, 551-557.	1.3	23
193	Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2003, 31, 775-782.	1.3	14
194	High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. <i>Bone Marrow Transplantation</i> , 2003, 32, 131-137.	1.3	22
195	Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2003, 32, 681-686.	1.3	7
196	Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1485-1507.	0.9	39
197	Rituximab. <i>Drugs</i> , 2003, 63, 803-843.	4.9	412
198	Initial Trials of Anti-CD80 Monoclonal Antibody (Galiximab) Therapy for Patients with Relapsed or Refractory Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2003, 3, 257-259.	2.1	32
199	Results of a Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Low-Grade B-Cell Non-Hodgkin's Lymphoma: An Effective and Minimally Toxic Regimen. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 169-175.	2.1	19
200	A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders. <i>Journal of Clinical Pathology</i> , 2003, 56, 129-132.	1.0	52
201	Hodgkin's lymphoma. <i>Lancet, The</i> , 2003, 361, 943-951.	6.3	150
202	Thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in follicular lymphoma patients. <i>Radiotherapy and Oncology</i> , 2003, 69, 323-328.	0.3	9
203	Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 162-169.	2.0	41
204	Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 20-27.	0.8	420

#	ARTICLE	IF	CITATIONS
205	ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 801-806.	0.6	10
206	Diffuse Large B-cell Lymphoma Arising in Nodular Lymphocyte Predominant Hodgkin Lymphoma. A Report of 21 Cases from the Nebraska Lymphoma Study Group. <i>Leukemia and Lymphoma</i> , 2003, 44, 1903-1910.	0.6	28
207	Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). <i>Blood</i> , 2003, 101, 4279-4284.	0.6	483
208	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 101, 78-84.	0.6	356
209	Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 477-481.	0.6	29
210	Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. <i>Annals of Oncology</i> , 2003, 14, 273-276.	0.6	52
211	Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3051-3059.	0.8	245
212	Presentation Serum Selenium Predicts for Overall Survival, Dose Delivery, and First Treatment Response in Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 2335-2341.	0.8	56
213	Efficacy of Vinblastine, Bleomycin, Methotrexate (VBM) Combination Chemotherapy with Involved Field Radiotherapy in Early Stage (I-IIA) Hodgkin Disease Patients. <i>Leukemia and Lymphoma</i> , 2003, 44, 1919-1923.	0.6	13
214	Dynamic Infrared Imaging of Newly Diagnosed Malignant Lymphoma Compared with Gallium-67 and Fluorine-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography. <i>Technology in Cancer Research and Treatment</i> , 2003, 2, 571-577.	0.8	32
215	Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I-II Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 2115-2122.	0.8	122
216	Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. <i>Blood</i> , 2003, 102, 4284-4289.	0.6	306
217	Efficacy and Toxicity of Liposomal Daunorubicin Included in PVABEC Regimen for Aggressive NHL of the Elderly. <i>Leukemia and Lymphoma</i> , 2003, 44, 465-469.	0.6	8
218	131I-Anti CD20 Radioimmunotherapy of Relapsed or Refractory Non-Hodgkins Lymphoma: A Phase II Clinical Trial of a Nonmyeloablative Dose Regimen of Chimeric Rituximab Radiolabeled in a Hospital. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 513-524.	0.7	43
219	T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Outcome After Chemotherapy: A Matched-Control Analysis. <i>Journal of Clinical Oncology</i> , 2003, 21, 1271-1277.	0.8	60
220	Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. <i>Blood</i> , 2003, 101, 4653-4659.	0.6	364
221	Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. <i>Annals of Oncology</i> , 2003, 14, 1762-1767.	0.6	149
222	A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. <i>The Hematology Journal</i> , 2003, 4, 399-409.	2.0	4

#	ARTICLE	IF	CITATIONS
223	Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. <i>Annals of Oncology</i> , 2003, 14, 745-751.	0.6	40
224	Ibritumomab Tiuxetan: The Cancer Smart Bomb. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2003, 43, 437-438.	0.7	0
225	Rituximab (Rituxan®/MabThera®): the first decade (1993-2003). <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 767-779.	1.1	57
226	Prognostic Significance of Microvessel Density and Vascular Endothelial Growth Factor (VEGF) Expression in non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 2089-2093.	0.6	67
227	Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 1740-1745.	0.8	261
228	Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study. <i>Anti-Cancer Drugs</i> , 2003, 14, 809-815.	0.7	9
229	Traditional Treatment Approaches in B-cell Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S6-S14.	0.6	15
230	Post-transplant Burkitt's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial). <i>Leukemia and Lymphoma</i> , 2003, 44, 1541-1543.	0.6	23
231	Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. <i>Blood</i> , 2003, 101, 2489-2495.	0.6	494
232	Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. <i>Blood</i> , 2003, 101, 3413-3415.	0.6	247
233	Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). <i>Blood</i> , 2003, 102, 749-755.	0.6	193
234	Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. <i>Blood</i> , 2003, 101, 4285-4289.	0.6	191
235	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2003, 102, 2741-2745.	0.6	391
236	Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. <i>Blood</i> , 2003, 102, 53-59.	0.6	217
237	Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. <i>Blood</i> , 2003, 101, 420-424.	0.6	145
238	Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 102, 1989-1996.	0.6	235
239	Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. <i>Oncology Reports</i> , 2003, 10, 1915-7.	1.2	9
240	Phase II Trial of Irinotecan (CPT-11) in Relapsed or Refractory Non-Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 2003, 44, 1529-1533.	0.6	12

#	ARTICLE	IF	CITATIONS
241	Quimioterapia associada À terapia anti-retroviral de alta eficácia no tratamento dos linfomas não-Hodgkin agressivos relacionados À Síndrome da Imunodeficiência Adquirida. Revista Brasileira De Hematologia E Hemoterapia, 2004, 26, 177.	0.7	2
242	Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma. Journal of Korean Medical Science, 2004, 19, 820.	1.1	2
243	Feasibility and Results of a Multimodality Approach in Elderly Patients with Localized Intermediate to High-Grade Non-Hodgkin's Lymphomas. Tumori, 2004, 90, 289-293.	0.6	1
244	A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group. Brazilian Journal of Medical and Biological Research, 2004, 37, 719-728.	0.7	2
245	Radioimmunotherapy of non-Hodgkin's lymphoma: Clinical development of the Zevalin regimen. Biotechnology Annual Review, 2004, 10, 265-295.	2.1	19
246	Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies. Leukemia and Lymphoma, 2004, 45, 937-944.	0.6	29
247	Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs, 2004, 13, 577-607.	1.9	6
248	Diffuse Large B-cell Lymphoma Arising in Nodular Lymphocyte Predominant Hodgkin Lymphoma: a Report of 21 Cases from the Nebraska Lymphoma Study Group. Leukemia and Lymphoma, 2004, 45, 1551-1557.	0.6	67
249	Cyclooxygenase-2 (Cox-2) Expression in Lymphomas. Leukemia and Lymphoma, 2004, 45, 1395-1399.	0.6	47
250	Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study. Leukemia and Lymphoma, 2004, 45, 2445-2449.	0.6	65
251	Ifosfamide, Epirubicin and Etoposide (IEV) Regimen as Salvage and Mobilization Therapy for Refractory or Early Relapsing Patients with Aggressive Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2004, 45, 1605-1609.	0.6	17
252	Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment. Leukemia and Lymphoma, 2004, 45, 339-344.	0.6	50
253	The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Annals of Oncology, 2004, 15, 1495-1503.	0.6	17
254	Primary Pulmonary Non-Hodgkin's Lymphoma. Japanese Journal of Clinical Oncology, 2004, 34, 510-514.	0.6	103
255	Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells. Journal of Clinical Oncology, 2004, 22, 2172-2176.	0.8	301
256	Failure of the International Prognostic Index to prognosticate outcome in primary gastric DLBC lymphoma. Annals of Oncology, 2004, 15, 841.	0.6	0
257	Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes. Journal of Clinical Oncology, 2004, 22, 1460-1468.	0.8	116
258	Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 2004, 103, 3684-3688.	0.6	365

#	ARTICLE	IF	CITATIONS
259	Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 2654-2661.	0.8	130
260	Plasma Glutathione S-Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin's Lymphoma (Stages III and IV). <i>Clinical Cancer Research</i> , 2004, 10, 7934-7940.	3.2	21
261	Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma and Hodgkin's Disease. <i>Clinical Cancer Research</i> , 2004, 10, 5432-5438.	3.2	100
262	Phase I Study of Rituximab-CHOP Regimen in Combination with Granulocyte Colony-Stimulating Factor in Patients with Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 4077-4082.	3.2	31
263	Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 2253-2264.	3.2	155
264	Nonmyeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients With Non-Hodgkin's Lymphoma Whose Disease Has Failed a Prior Autologous Transplantation. <i>Journal of Clinical Oncology</i> , 2004, 22, 2419-2423.	0.8	106
265	Prognostic Factors in Patients With Aggressive Non-Hodgkin's Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2004, 22, 2826-2834.	0.8	59
266	Combination Immunotherapy of B-Cell Non-Hodgkin's Lymphoma with Rituximab and Interleukin-2. <i>Clinical Cancer Research</i> , 2004, 10, 6101-6110.	3.2	74
267	All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Annals of Oncology</i> , 2004, 15, 1790-1797.	0.6	52
268	Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 1469-1479.	0.8	109
269	Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. <i>Annals of Oncology</i> , 2004, 15, 1484-1489.	0.6	66
270	Gemcitabine and Cisplatin in Refractory Malignant Lymphoma. <i>Oncology</i> , 2004, 66, 197-200.	0.9	19
271	Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. <i>Blood</i> , 2004, 103, 4429-4431.	0.6	181
272	Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. <i>British Journal of Cancer</i> , 2004, 91, 850-854.	2.9	94
273	Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society. <i>British Journal of Cancer</i> , 2004, 90, 2256-2260.	2.9	145
274	Correlation Between Histological Subtype and Type of bcl-2/IgH Rearrangement in Follicular Lymphomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 331-338.	0.6	2
275	Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2004, 22, 4711-4716.	0.8	327
276	Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases. <i>Annual Review of Medicine</i> , 2004, 55, 477-503.	5.0	203

#	ARTICLE	IF	CITATIONS
277	Treatment for Waldenstrom's macroglobulinemia. <i>Annals of Oncology</i> , 2004, 15, 550-558.	0.6	15
278	Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. <i>Annals of Oncology</i> , 2004, 15, 821-830.	0.6	99
279	Comments on "Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma" by M. Binn, A. Ruskonen-Fourmestreaux, E. Lepage et al. (<i>Ann Oncol</i> 2003; 14: 1751-1757). <i>Annals of Oncology</i> , 2004, 15, 841-842.	0.6	1
280	High Level of Glutathione-S-Transferase Expression in Mantle Cell Lymphomas. <i>Clinical Cancer Research</i> , 2004, 10, 3029-3034.	3.2	44
281	Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. <i>The Hematology Journal</i> , 2004, 5, 341-346.	2.0	64
282	Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. <i>Annals of Oncology</i> , 2004, 15, 1691-1698.	0.6	102
283	Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. <i>The Hematology Journal</i> , 2004, 5, 467-471.	2.0	23
284	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. <i>The Hematology Journal</i> , 2004, 5, 472-474.	2.0	17
285	Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. <i>Annals of Oncology</i> , 2004, 15, 283-290.	0.6	89
286	Reply to Letter to the Editor on "Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma" by M. Binn, A. Ruskonen-Fourmestreaux, E. Lepage et al. (<i>Ann Oncol</i> 2003; 14: 1751-1757). <i>Annals of Oncology</i> , 2004, 15, 842.	0.6	0
287	Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma. <i>International Journal of Clinical Practice</i> , 2004, 58, 139-143.	0.8	28
288	Positron emission tomography scanning in the assessment of patients with lymphoma. <i>Internal Medicine Journal</i> , 2004, 34, 388-397.	0.5	34
289	ChlVPP/ABVVP, a first line "hybrid" combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. <i>British Journal of Haematology</i> , 2004, 125, 584-589.	1.2	10
290	Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). <i>Histopathology</i> , 2004, 45, 268-274.	1.6	37
291	Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2004, 33, 291-298.	1.3	92
292	High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. <i>Bone Marrow Transplantation</i> , 2004, 33, 629-634.	1.3	27
293	Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. <i>Leukemia</i> , 2004, 18, 146-155.	3.3	50
294	Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL). <i>Leukemia</i> , 2004, 18, 1102-1107.	3.3	37

#	ARTICLE	IF	CITATIONS
295	Improving Second-Line Therapy in Aggressive Non-Hodgkin's Lymphoma. <i>Seminars in Oncology</i> , 2004, 31, 12-16.	0.8	16
296	A randomized phase II trial of amifostine for head and neck irradiation in lymphoma. <i>Seminars in Oncology</i> , 2004, 31, 20-24.	0.8	80
297	Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. <i>Pathology International</i> , 2004, 54, 667-674.	0.6	22
298	What Is New in Lymphoma?. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 260-272.	157.7	37
299	Detection of t(14;18) in follicular lymphoma by dual-color fluorescence in situ hybridization on paraffin-embedded tissue sections. <i>Cancer Genetics and Cytogenetics</i> , 2004, 150, 22-26.	1.0	41
300	Intensive Chemotherapy in the Treatment of Aggressive Diffuse Large B-Cell Lymphoma: Malignant Lymphoma. <i>Medical Oncology</i> , 2004, 21, 269-272.	1.2	6
301	CD10 expression in diffuse large B-cell lymphomas does not influence survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 545-551.	1.4	32
302	Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 107-113.	1.2	42
304	High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. <i>Annals of Hematology</i> , 2004, 83, 356-363.	0.8	15
305	Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 468-474.	1.1	7
306	T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2004, 28, 229-236.	0.4	40
307	Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. <i>Cancer</i> , 2004, 100, 2181-2189.	2.0	25
308	Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2004, 100, 2408-2414.	2.0	18
309	Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2004, 101, 1835-1842.	2.0	118
310	Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors. <i>Hematological Oncology</i> , 2004, 22, 143-158.	0.8	129
311	Lymphoproliferative disorders in autoimmune diseases in Japan: Analysis of clinicopathological features and Epstein-Barr virus infection. <i>International Journal of Cancer</i> , 2004, 108, 443-449.	2.3	60
312	Biallelic IgH rearrangements in patients with indolent lymphoproliferative disorders: Molecular and practical implications. <i>Journal of Cellular Physiology</i> , 2004, 199, 217-226.	2.0	8
313	Clinicopathological features and prognostic factors of Japanese patients with peripheral T-cell lymphoma, unspecified—diagnosed according to the WHO classification. <i>Leukemia Research</i> , 2004, 28, 1287-1292.	0.4	40

#	ARTICLE	IF	CITATIONS
314	Detection and Possible Prognostic Relevance of p53 Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature. <i>Leukemia and Lymphoma</i> , 2004, 45, 2071-2078.	0.6	37
315	High-Dose Therapy with Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: The Bologna Experience. <i>Leukemia and Lymphoma</i> , 2004, 45, 321-326.	0.6	5
316	Interferon Alpha 2b as Maintenance Therapy Improves Outcome In Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 2247-2251.	0.6	17
317	Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 478-481.	0.7	27
318	Possible Influence of Clinical Stage and Type of Treatment in the Persistence of Residual Circulating t(14;18)-Positive Cells in Follicular Lymphoma Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 539-545.	0.6	6
319	Effectiveness of Fludarabine, Idarubicin and Cyclophosphamide (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 1815-1819.	0.6	7
320	Bortezomib: clinical profile in lymphoproliferative malignancies. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 18-24.	2.2	0
321	Pilot Study of Fixed-Infusion Rate Gemcitabine with Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 45-49.	2.1	38
322	Yttrium 90 ^{â€} -Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 98-101.	2.1	117
323	Progress in the Prognosis of Adult Hodgkin's Lymphoma in the Past 35 Years Through Clinical Trials in Argentina: A GATLA Experience. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 102-109.	2.1	4
324	Dose-Intense Cyclophosphamide and Etoposide for Patients with Refractory or High-Risk Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 116-122.	2.1	1
325	Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. <i>Blood</i> , 2004, 104, 634-641.	0.6	649
326	Detection of bone marrow infiltration of lymphoma cells by fluorescence in situ hybridization. <i>Clinica Chimica Acta</i> , 2004, 344, 79-82.	0.5	4
327	Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. <i>Blood</i> , 2004, 104, 626-633.	0.6	436
328	Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. <i>Blood</i> , 2004, 104, 3865-3871.	0.6	280
329	BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. <i>Blood</i> , 2004, 103, 428-434.	0.6	171
330	Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2004, 104, 227-236.	0.6	131
331	Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. <i>Blood</i> , 2004, 104, 642-648.	0.6	53

#	ARTICLE	IF	CITATIONS
332	Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. <i>Blood</i> , 2004, 104, 2269-2271.	0.6	156
333	The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2004, 104, 3064-3071.	0.6	558
334	Successful Treatment of Diffuse Large B-cell Lymphoma Following Waldenstroem's Macroglobulinemia with CHOP Chemotherapy Followed by Combination Therapy of CHOP with Rituximab. <i>Internal Medicine</i> , 2004, 43, 131-134.	0.3	5
335	IIVP Salvage Regimen Induces High Response Rates in Patients With Relapsed Lymphoma Before Autologous Stem Cell Transplantation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 264-269.	0.6	6
336	Rituximab: Clinical Development of the First Therapeutic Antibody for Cancer. , 2005, , 211-229.		1
337	Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon- γ / I^2 inducible gene expression, without significant toxicity. <i>Blood</i> , 2005, 105, 489-495.	0.6	155
338	Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. <i>Blood</i> , 2005, 105, 301-307.	0.6	208
339	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. <i>Blood</i> , 2005, 105, 1417-1423.	0.6	896
340	High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. <i>Blood</i> , 2005, 105, 3817-3823.	0.6	176
341	AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. <i>Blood</i> , 2005, 106, 1762-1769.	0.6	68
342	[^{18}F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. <i>Blood</i> , 2005, 106, 1376-1381.	0.6	482
343	Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIe extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , 2005, 106, 3785-3790.	0.6	165
344	Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 175-184.	0.4	11
345	A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage Iâ€“III follicular lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 188-193.	0.4	6
346	Japanese multicenter phase II study of CHOP followed by radiotherapy in stage III1, diffuse large B-cell lymphoma of the stomach. <i>Cancer Science</i> , 2005, 96, 349-352.	1.7	40
347	Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibrutumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. <i>Cancer Science</i> , 2005, 96, 903-910.	1.7	17
348	Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. <i>British Journal of Haematology</i> , 2005, 130, 363-372.	1.2	52
349	Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*. <i>British Journal of Haematology</i> , 2005, 131, 223-230.	1.2	78

#	ARTICLE	IF	CITATIONS
350	Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2005, 131, 338-340.	1.2	32
351	Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. <i>British Journal of Cancer</i> , 2005, 92, 1352-1357.	2.9	56
352	Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. <i>Nature Medicine</i> , 2005, 11, 986-991.	15.2	106
353	Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study. <i>Bone Marrow Transplantation</i> , 2005, 35, 479-487.	1.3	11
354	Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. <i>Leukemia</i> , 2005, 19, 945-952.	3.3	53
355	Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. <i>Experimental Hematology</i> , 2005, 33, 920-927.	0.2	40
356	Cost-effectiveness of rituximab (MabTheraR) in diffuse large B-cell lymphoma in the Netherlands. <i>European Journal of Haematology</i> , 2005, 74, 194-202.	1.1	39
357	International harmonization of trial parameters in malignant lymphoma. <i>European Journal of Haematology</i> , 2005, 75, 53-54.	1.1	13
358	Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. <i>European Journal of Haematology</i> , 2005, 75, 124-129.	1.1	24
359	An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma. <i>Cancer</i> , 2005, 103, 978-984.	2.0	11
360	Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2005, 103, 970-977.	2.0	8
361	Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. <i>Cancer</i> , 2005, 104, 345-353.	2.0	23
362	Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. <i>Cancer</i> , 2005, 104, 781-787.	2.0	34
363	Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. <i>Cancer</i> , 2005, 104, 1434-1441.	2.0	35
364	Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. <i>Cancer</i> , 2005, 104, 2437-2441.	2.0	149
365	Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. <i>Cancer</i> , 2005, 104, 2735-2742.	2.0	23
366	Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. <i>Arthritis and Rheumatism</i> , 2005, 52, 2740-2750.	6.7	462
367	Radioimmunotherapy using ¹³¹ I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1225-1233.	3.3	16

#	ARTICLE	IF	CITATIONS
368	Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2005, 84, 510-516.	0.8	44
369	Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study. <i>Annals of Hematology</i> , 2005, 84, 796-801.	0.8	19
370	Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 73-79.	1.2	56
371	Prognostic significance of CD40 expression in malignant lymphoma developing in rheumatoid arthritis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 797-802.	1.2	2
372	Modelling intervention effects after cancer relapses. <i>Statistics in Medicine</i> , 2005, 24, 3959-3975.	0.8	12
373	Clinical Studies of Immunotherapy With Rituximab (Rituxan®) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin®) in B-Cell Lymphoid Malignancies. , 2005, , 677-709.		0
374	Role of imaging to choose treatment. <i>Cancer Imaging</i> , 2005, 5, S113-S119.	1.2	10
375	Quantitative CT analysis for assessing response in lymphoma. <i>Cancer Imaging</i> , 2005, 5, S102-S106.	1.2	13
376	Localized Extranodal Lymphoma of the Head and Neck: Retrospective Analysis of a Series of 107 Patients from a Single Institution. <i>Tumori</i> , 2005, 91, 456-462.	0.6	18
377	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2005, 16, i58-i59.	0.6	14
378	Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. <i>Annals of Oncology</i> , 2005, 16, 1508-1513.	0.6	46
379	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1979-1983.	0.8	265
380	Phase I Trial of Iodine-131 Tositumomab With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Relapsed Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 461-467.	0.8	161
381	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2005, 106, 3725-3732.	0.6	1,221
382	Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 694-704.	0.8	140
383	Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 8413-8417.	3.2	9
384	Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5034-5043.	0.8	729
385	Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 4390-4398.	0.8	143

#	ARTICLE	IF	CITATIONS
386	Long-term follow-up of a randomized trial of fludarabine+mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. <i>Annals of Oncology</i> , 2005, 16, 466-472.	0.6	17
387	Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3923-3931.	0.8	871
388	Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 1103-1108.	0.8	187
389	Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. <i>Annals of Oncology</i> , 2005, 16, 1941-1948.	0.6	37
390	Multifocal Extranodal Non-Hodgkin Lymphoma: A Clinicopathologic Study of 37 Cases in Greece, a Hellenic Cooperative Oncology Group Study. <i>Oncologist</i> , 2005, 10, 734-738.	1.9	22
391	Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. <i>Blood</i> , 2005, 106, 1538-1543.	0.6	390
392	Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?. <i>Annals of Oncology</i> , 2005, 16, 1524-1529.	0.6	48
393	Prognostic Significance of BACH2 Expression in Diffuse Large B-Cell Lymphoma: A Study of the Osaka Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 8012-8017.	0.8	41
394	Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma. <i>Oncology</i> , 2005, 68, 146-153.	0.9	12
395	Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5347-5356.	0.8	509
396	A Comparison of Whole-Body MRI and CT for the Staging of Lymphoma. <i>American Journal of Roentgenology</i> , 2005, 185, 711-716.	1.0	86
397	Should radioimmunotherapy be an initial treatment option in advanced-stage follicular lymphoma?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 346-347.	4.3	1
398	ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma. <i>New England Journal of Medicine</i> , 2005, 352, 1197-1205.	13.9	311
399	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2005, 16, 1352-1358.	0.6	48
400	Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma. <i>Annals of Oncology</i> , 2005, 16, 786-792.	0.6	44
401	Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review. <i>Leukemia and Lymphoma</i> , 2005, 46, 851-860.	0.6	5
402	Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. <i>Annals of Oncology</i> , 2005, 16, 625-633.	0.6	198
403	Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. <i>Leukemia and Lymphoma</i> , 2005, 46, 549-552.	0.6	30

#	ARTICLE	IF	CITATIONS
404	Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. <i>British Journal of Cancer</i> , 2005, 92, 1226-1230.	2.9	86
405	Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18 ^{18F} Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2005, 23, 4652-4661.	0.8	364
406	Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3912-3922.	0.8	389
408	Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 2240-2247.	0.8	127
409	Chemoradiotherapy for Localized Non-Hodgkin's Lymphoma: Lessons From Old Studies. <i>Journal of Clinical Oncology</i> , 2005, 23, 3161-3162.	0.8	2
410	High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. <i>Journal of Clinical Oncology</i> , 2005, 23, 7013-7023.	0.8	523
412	Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 667-675.	0.8	517
413	Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 676-684.	0.8	562
414	Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin's Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network. <i>Journal of Clinical Oncology</i> , 2005, 23, 1500-1506.	0.8	39
415	Activity of Cladribine Combined with Etoposide in Heavily Pretreated Patients with Indolent Lymphoid Malignancies. <i>Chemotherapy</i> , 2005, 51, 247-251.	0.8	7
416	Phase II Study of Oxaliplatin for Treatment of Patients With Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 8442-8446.	0.8	51
417	Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 468-473.	0.8	241
418	Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 6719-6729.	0.8	262
419	Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network. <i>Journal of Clinical Oncology</i> , 2005, 23, 1088-1095.	0.8	315
420	Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, ⁹⁰ Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab. <i>Clinical Cancer Research</i> , 2005, 11, 5215-5222.	3.2	109
421	Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5044-5051.	0.8	164
422	Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkin's Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. <i>Journal of Clinical Oncology</i> , 2005, 23, 3793-3801.	0.8	21
423	Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards. <i>Clinical Cancer Research</i> , 2005, 11, 5223-5232.	3.2	126

#	ARTICLE	IF	CITATIONS
424	Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development. <i>Clinical Cancer Research</i> , 2005, 11, 2785-2808.	3.2	582
425	Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2005, 23, 1096-1102.	0.8	124
426	Immunohistochemical Expression of Multidrug Resistance Proteins as a Predictor of Poor Response to Chemotherapy and Prognosis in Patients with Nodal Diffuse Large B-Cell Lymphoma. <i>Oncology</i> , 2005, 68, 422-431.	0.9	48
427	Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2005, 23, 4117-4126.	0.8	1,316
428	Initial Staging of Lymphoma With Positron Emission Tomography and Computed Tomography. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 165-175.	2.5	78
429	Splenic Volume Change and Nodal Tumor Response in Non-Hodgkin's Lymphoma Patients after Radioimmunotherapy Using Radiolabeled Lym-1 Antibody. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 662-670.	0.7	8
430	Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 1477-1487.	0.6	10
431	Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients. <i>Leukemia and Lymphoma</i> , 2005, 46, 1471-1476.	0.6	20
432	Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 1437-1440.	0.6	8
433	IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2005, 46, 1743-1748.	0.6	9
434	Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 1441-1448.	0.6	9
435	Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study. <i>Cancer Investigation</i> , 2005, 23, 13-18.	0.6	17
436	Treatment Results in Localized Primary Gastric Lymphoma: Data of Patients Registered Within the German Multicenter Study (GIT NHL 02/96). <i>Journal of Clinical Oncology</i> , 2005, 23, 7050-7059.	0.8	232
437	Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. <i>Leukemia and Lymphoma</i> , 2005, 46, 1839-1841.	0.6	5
438	Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim. <i>Leukemia and Lymphoma</i> , 2005, 46, 1523-1526.	0.6	34
439	The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 1287-1294.	0.6	23
440	Gemcitabine in the Treatment of Relapsed and Refractory Hodgkin's Disease. <i>Oncology Research and Treatment</i> , 2005, 28, 567-571.	0.8	11
441	Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 297-306.	2.0	9

#	ARTICLE	IF	CITATIONS
442	Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 314-318.	2.0	55
443	Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplantation in Chemotherapy-Refractory Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 593-599.	2.0	28
444	A New Schedule of CHOP/Rituximab Plus Granulocyte-Macrophage Colony-Stimulating Factor Is an Effective Rescue for Patients with Aggressive Lymphoma Failing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 627-636.	2.0	21
445	Ifosfamide, Idarubicin, and Etoposide in Relapsed/Refractory Hodgkin Disease or Non-Hodgkin Lymphoma: A Salvage Regimen with High Response Rates before Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 688-697.	2.0	14
446	Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy. <i>European Journal of Cancer</i> , 2005, 41, 1402-1408.	1.3	152
447	Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. <i>European Journal of Cancer</i> , 2005, 41, 1724-1730.	1.3	53
448	Fludarabine phosphate+CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: A dose-finding study. <i>European Journal of Cancer</i> , 2005, 41, 2630-2636.	1.3	5
449	A Randomized Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin as Salvage Chemotherapy Followed by Posttransplantation Rituximab Maintenance Therapy Versus Observation for Treatment of Aggressive B-Cell and T-Cell Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 56-60.	2.1	14
450	Treatment and Survival of Patients with Thyroid Lymphoma: A Population-Based Study with Clinical and Pathologic Reviews. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 240-247.	1.4	10
451	What is remission in follicular lymphoma and what is its relevance?. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 27-56.	0.7	24
452	Novel Approaches to the Management of Non-Hodgkin Lymphoma. <i>American Journal of Cancer</i> , 2005, 4, 145-158.	0.4	1
453	Diagnostic Imaging Modalities for Assessment of Lymphoma with Special Emphasis on CT, MRI, and Ultrasound. <i>PET Clinics</i> , 2006, 1, 219-230.	1.5	5
454	Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma. <i>Oncology</i> , 2006, 70, 411-417.	0.9	54
455	High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1545-1552.	0.6	17
456	Bone marrow involvement in follicular lymphoma: Comparison of histology and flow cytometry as staging procedures. <i>Leukemia and Lymphoma</i> , 2006, 47, 1857-1862.	0.6	37
457	Treatment of primary intraocular lymphoma with radiation therapy: A multi-institutional survey in Japan. <i>Leukemia and Lymphoma</i> , 2006, 47, 1800-1805.	0.6	49
458	Targeting the proteasome in mantle cell lymphoma: A promising therapeutic approach. <i>Leukemia and Lymphoma</i> , 2006, 47, 195-205.	0.6	21
459	Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors. <i>Leukemia and Lymphoma</i> , 2006, 47, 1295-1305.	0.6	22

#	ARTICLE	IF	CITATIONS
460	AIDS-associated Burkitt or Burkitt-like lymphoma: Short intensive polychemotherapy is feasible and effective. <i>Leukemia and Lymphoma</i> , 2006, 47, 1872-1880.	0.6	25
461	Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2155-2162.	0.6	11
462	Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. <i>Leukemia and Lymphoma</i> , 2006, 47, 1265-1273.	0.6	42
463	Cytogenetic and clinicopathological characterization by fluorescence in situ hybridization on paraffin-embedded tissue sections of twenty-six cases with malignant lymphoma of small intestine. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 212-222.	0.6	13
464	CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2174-2180.	0.6	53
465	Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: A phase II study. <i>Leukemia and Lymphoma</i> , 2006, 47, 1327-1332.	0.6	8
466	Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2344-2350.	0.6	24
467	Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. <i>Leukemia and Lymphoma</i> , 2006, 47, 1830-1840.	0.6	27
468	Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 481-485.	0.6	17
469	Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient. <i>Leukemia and Lymphoma</i> , 2006, 47, 353-356.	0.6	2
470	Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). <i>Leukemia and Lymphoma</i> , 2006, 47, 2140-2146.	0.6	128
471	Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. <i>Leukemia and Lymphoma</i> , 2006, 47, 1048-1052.	0.6	5
472	Anti-angiogenesis and diffuse large B-cell lymphoma: a new treatment opportunity?. <i>Leukemia and Lymphoma</i> , 2006, 47, 961-962.	0.6	2
473	Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1041-1047.	0.6	5
474	DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. <i>Leukemia and Lymphoma</i> , 2006, 47, 2558-2566.	0.6	33
475	Standard Treatment of Advanced-Stage Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2006, 43, 213-220.	1.8	23
476	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group. <i>Lancet Oncology</i> , The, 2006, 7, 379-391.	5.1	1,840
477	Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. <i>Radiotherapy and Oncology</i> , 2006, 78, 6-9.	0.3	78

#	ARTICLE	IF	CITATIONS
478	Rituximab. <i>Drugs</i> , 2006, 66, 791-820.	4.9	92
479	Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 380-383.	1.4	107
480	Cytomegalovirus Infection in Patients with Lymphoma: An Important Cause of Morbidity and Mortality. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 393-398.	1.4	34
481	Prognostic Impact of Pretransplantation Computed Tomography and Gallium Scans in Patients with Hodgkin Lymphoma with Poor Prognosis Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 217-225.	1.4	6
482	Treatment of Non-Hodgkin's Lymphoma: A Look over the Past Decade. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, S7-S13.	1.4	30
484	Radioimmunotherapy for B-cell non-Hodgkin lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 655-668.	0.7	36
485	Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 612-618.	0.8	560
486	Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 629-636.	0.6	83
487	PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma. <i>British Journal of Radiology</i> , 2006, 79, 365-367.	1.0	6
488	The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. <i>Annals of Oncology</i> , 2006, 17, 1539-1545.	0.6	107
489	Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 172-183.	2.0	135
490	Cytoreduction of Lymphoid Malignancies and Mobilization of Blood Hematopoietic Progenitor Cells with High Doses of Cyclophosphamide and Etoposide Plus Filgrastim. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 316-324.	2.0	13
491	Phase I Clinical Trial of Costimulated, IL-4 Polarized Donor CD4+ T Cells as Augmentation of Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1150-1160.	2.0	65
492	Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1270-1276.	2.0	55
493	Comparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin's Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1326-1334.	2.0	98
494	Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma. <i>Cancer Treatment Reviews</i> , 2006, 32, 487-490.	3.4	1
495	RECIST revisited: A review of validation studies on tumour assessment. <i>European Journal of Cancer</i> , 2006, 42, 1031-1039.	1.3	393
496	Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. <i>European Journal of Cancer</i> , 2006, 42, 2976-2981.	1.3	30

#	ARTICLE	IF	CITATIONS
497	Results of CHOP chemotherapy for diffuse large B-cell lymphoma. Brazilian Journal of Medical and Biological Research, 2006, 39, 1315-1322.	0.7	7
498	The Clinical Characteristics and Treatment Results of Ocular Adnexal Lymphoma. Korean Journal of Ophthalmology: KJO, 2006, 20, 7.	0.5	26
499	PET in lymphoma. Cancer Imaging, 2006, 6, S63-S70.	1.2	13
500	High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma: an Eight-Year Experience. Yonsei Medical Journal, 2006, 47, 604.	0.9	4
501	FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood, 2006, 108, 2720-2725.	0.6	206
502	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood, 2006, 107, 3053-3057.	0.6	390
503	Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood, 2006, 107, 3058-3064.	0.6	60
504	AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood, 2006, 107, 3832-3840.	0.6	133
505	Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood, 2006, 107, 4636-4642.	0.6	54
506	The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood, 2006, 108, 1504-1508.	0.6	203
507	Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood, 2006, 108, 2540-2544.	0.6	230
508	Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 2006, 108, 4003-4008.	0.6	432
509	Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood, 2006, 108, 4163-4169.	0.6	120
510	High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 2006, 108, 2957-2964.	0.6	448
511	Chronic lymphoproliferative disorders and malignant lymphoma. , 0, , 93-109.		0
512	Postchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast Cancer. Cancer Journal (Sudbury, Mass), 2006, 12, 212-221.	1.0	52
513	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. Journal of Immunotherapy, 2006, 29, 558-568.	1.2	145
514	Radioimmunotherapy of Non-Hodgkins Lymphomas. Current Drug Targets, 2006, 7, 1293-1300.	1.0	24

#	ARTICLE	IF	CITATIONS
515	Prognostic Factors in Diffuse Large Bcell Lymphoma Treated by Riskadapted Therapy. Internal Medicine, 2006, 45, 247-252.	0.3	8
516	Treatment of Cutaneous T Cell Lymphoma Stage II with Interferon- α 2a and Extracorporeal Photochemotherapy. Annals of the New York Academy of Sciences, 2001, 941, 210-213.	1.8	7
517	Pegylated Doxorubicin for Primary Cutaneous T Cell Lymphoma. Annals of the New York Academy of Sciences, 2001, 941, 214-216.	1.8	16
518	Survival of Patients with Cutaneous T Cell Lymphoma after Treatment with Extracorporeal Photochemotherapy. Annals of the New York Academy of Sciences, 2001, 941, 217-219.	1.8	2
519	Lymphoma Imaging ? What has Been Achieved ? What Needs to be Done. Imaging Decisions (Berlin, Germany), 2006, 10, 22-31.	0.2	0
520	The Role of Imaging in Malignant Lymphoma: A Critical View on PET Scanning in Current Clinical Practice. Imaging Decisions (Berlin, Germany), 2006, 10, 22-31.	0.2	0
521	Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device. British Journal of Haematology, 2006, 132, 42-55.	1.2	27
522	cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. British Journal of Haematology, 2006, 132, 560-570.	1.2	45
523	Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. British Journal of Haematology, 2006, 133, 628-633.	1.2	14
524	Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?. British Journal of Haematology, 2006, 134, 391-398.	1.2	55
525	Absolute lymphocyte count predicts overall survival in follicular lymphomas. British Journal of Haematology, 2006, 134, 596-601.	1.2	99
526	Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Science, 2006, 97, 305-312.	1.7	28
527	Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma. Cancer Science, 2006, 97, 933-937.	1.7	14
528	Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. British Journal of Cancer, 2006, 94, 1770-1776.	2.9	33
529	Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target. Bone Marrow Transplantation, 2006, 37, 811-817.	1.3	14
530	Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2006, 37, 1017-1022.	1.3	52
531	A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2006, 38, 217-222.	1.3	11
532	Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 211-216.	1.3	85

#	ARTICLE	IF	CITATIONS
533	Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. <i>Leukemia</i> , 2006, 20, 1533-1538.	3.3	235
534	Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. <i>Leukemia</i> , 2006, 20, 1840-1847.	3.3	18
535	A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 217-222.	0.4	10
536	Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1168-1177.	0.4	22
537	Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. <i>Leukemia Research</i> , 2006, 30, 707-712.	0.4	89
538	Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome. <i>Leukemia Research</i> , 2006, 30, 1253-1258.	0.4	10
539	Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin's Lymphoma. <i>International Journal of Hematology</i> , 2006, 84, 174-181.	0.7	19
540	Outcome of Involved-Field Radiotherapy for Stage 1 Follicular Lymphoma. <i>International Journal of Hematology</i> , 2006, 83, 370-372.	0.7	1
541	Non-Hodgkin's Lymphoma among Patients Infected with Human Immunodeficiency Virus: The Experience of a Single Center in Brazil. <i>International Journal of Hematology</i> , 2006, 84, 337-342.	0.7	2
542	Primary Mediastinal Large B-Cell Lymphoma: A Single-Center Study of Clinicopathologic Characteristics. <i>International Journal of Hematology</i> , 2006, 83, 331-336.	0.7	12
543	Outcome for Young High-Risk Aggressive B-Cell Lymphoma Patients Treated with CHOEP-14 and Rituximab (R-CHOEP-14). <i>Medical Oncology</i> , 2006, 23, 283-294.	1.2	16
544	Predictive Value of Prognostic Indices in Patients with Follicular Lymphomas. <i>Medical Oncology</i> , 2006, 23, 533-542.	1.2	3
546	Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 22-26.	3.3	91
547	Multicenter phase II study of the CycLOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. <i>Annals of Hematology</i> , 2006, 85, 374-380.	0.8	22
548	Treatment results of chemoradiation therapy for localized aggressive lymphomas: a retrospective 20-year study. <i>Annals of Hematology</i> , 2006, 85, 523-529.	0.8	4
549	Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2006, 85, 597-603.	0.8	28
550	FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. <i>Annals of Hematology</i> , 2006, 85, 759-767.	0.8	61
551	Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2006, 85, 769-779.	0.8	13

#	ARTICLE	IF	CITATIONS
552	A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003. <i>Annals of Hematology</i> , 2006, 85, 849-856.	0.8	16
553	Methylenetetrahydrofolate reductase C677T polymorphism in adult patients with lymphoproliferative disorders and its effect on chemotherapy. <i>Annals of Hematology</i> , 2006, 85, 863-868.	0.8	24
554	Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. <i>Annals of Hematology</i> , 2006, 86, 95-100.	0.8	32
555	Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 624-630.	1.1	54
556	CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 35-39.	1.1	60
557	Hodgkin's Lymphoma. <i>Current Problems in Cancer</i> , 2006, 30, 107-158.	1.0	12
558	Treatment of PTLD with Rituximab or Chemotherapy. <i>American Journal of Transplantation</i> , 2006, 6, 569-576.	2.6	220
559	PTLD Visualization by FDG-PET: Improved Detection of Extranodal Localizations. <i>American Journal of Transplantation</i> , 2006, 6, 1984-1985.	2.6	45
560	Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. <i>European Journal of Haematology</i> , 2006, 76, 58-63.	1.1	36
561	The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. <i>European Journal of Haematology</i> , 2006, 76, 473-480.	1.1	104
562	Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2006, 77, 217-225.	1.1	34
563	Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma. <i>European Journal of Haematology</i> , 2006, 77, 304-308.	1.1	10
564	Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. <i>Cancer</i> , 2006, 106, 353-360.	2.0	93
565	Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphoma. <i>Cancer</i> , 2006, 106, 2412-2420.	2.0	85
566	Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. <i>Cancer</i> , 2006, 107, 125-135.	2.0	114
567	Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. <i>Cancer</i> , 2006, 107, 433-438.	2.0	19
568	Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. <i>Cancer</i> , 2006, 107, 1542-1550.	2.0	50
569	FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. <i>Cancer</i> , 2006, 107, 2678-2687.	2.0	165

#	ARTICLE	IF	CITATIONS
570	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. <i>Cancer</i> , 2006, 107, 2826-2832.	2.0	44
571	Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation. <i>Hematological Oncology</i> , 2006, 24, 73-77.	0.8	6
572	Multicenter phase II study of CycLOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma. <i>Hematological Oncology</i> , 2006, 24, 220-226.	0.8	1
573	Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability. <i>International Journal of Cancer</i> , 2006, 119, 2768-2774.	2.3	32
574	A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. <i>Hematology</i> , 2006, 11, 25-29.	0.7	19
575	An audit of imaging test utilization for the management of lymphoma in an oncology hospital: implications for resource planning?. <i>British Journal of Radiology</i> , 2006, 79, 116-122.	1.0	5
576	Bone Marrow Histopathological and Molecular Changes of Small B-Cell Lymphomas after Rituximab Therapy: Comparison with Clinical Response and Patients' Outcome. <i>International Journal of Immunopathology and Pharmacology</i> , 2006, 19, 421-431.	1.0	30
577	Staging Accuracy in Mycosis Fungoides and SÅ©zary Syndrome Using Integrated Positron Emission Tomography and Computed Tomography. <i>Archives of Dermatology</i> , 2006, 142, 577-84.	1.7	81
578	The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). <i>Annals of Oncology</i> , 2006, 17, 676-682.	0.6	5
579	Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1712-1719.	0.8	60
580	Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. <i>Annals of Oncology</i> , 2006, 17, 1296-1300.	0.6	137
581	Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2006, 24, 166-173.	0.8	382
582	Phase II Study of Oral Fludarabine Phosphate in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 174-180.	0.8	36
583	Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin's Lymphoma Resulting in Durable Clinical Responses. <i>Journal of Clinical Oncology</i> , 2006, 24, 3107-3112.	0.8	85
584	Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2006, 24, 2343-2351.	0.8	250
585	A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 7046-7053.	3.2	100
586	Phase I Trial of a Novel Intradermal Idiotype Vaccine in Patients with Advanced B-Cell Lymphoma: Specific Immune Responses Despite Profound Immunosuppression. <i>Cancer Research</i> , 2006, 66, 4496-4502.	0.4	48
587	Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1292-1301.	3.0	155

#	ARTICLE	IF	CITATIONS
588	Liposomal Doxorubicin, Cyclophosphamide, and Etoposide and Antiretroviral Therapy for Patients with AIDS-Related Lymphoma: A Pilot Study. <i>Oncologist</i> , 2006, 11, 666-673.	1.9	10
589	Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. <i>Annals of Oncology</i> , 2006, 17, 1418-1423.	0.6	101
590	Dose-Dense CHOP plus Rituximab (R-CHOP14) for the Treatment of Elderly Patients with High-Risk Diffuse Large B Cell Lymphoma: A Pilot Study. <i>Acta Haematologica</i> , 2006, 115, 22-27.	0.7	14
591	Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 460-464.	3.2	129
592	Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. <i>Annals of Oncology</i> , 2006, 17, 1018-1023.	0.6	30
593	High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 5190-5198.	3.2	106
594	Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 181-189.	0.8	327
595	Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4123-4128.	0.8	199
596	Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. <i>Clinical Cancer Research</i> , 2006, 12, 6056-6063.	3.2	52
597	Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study. <i>Leukemia and Lymphoma</i> , 2006, 47, 2547-2557.	0.6	32
598	Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906. <i>Leukemia and Lymphoma</i> , 2006, 47, 1511-1517.	0.6	9
599	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1253-1259.	0.6	18
600	Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. <i>Cancer Investigation</i> , 2006, 24, 593-600.	0.6	55
601	Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. <i>Leukemia and Lymphoma</i> , 2006, 47, 473-479.	0.6	14
602	Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?. <i>Leukemia and Lymphoma</i> , 2006, 47, 1260-1264.	0.6	16
603	Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4867-4874.	0.8	675
604	Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3880-3886.	0.8	148
605	Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity. <i>Journal of Clinical Oncology</i> , 2006, 24, 2105-2112.	0.8	163

#	ARTICLE	IF	CITATIONS
606	Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 1376-1382.	0.8	199
607	Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2006, 17, 330-333.	0.6	7
608	Multicenter Phase II Clinical Study of Iodine-131 ^{131I} -Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4418-4425.	0.8	89
609	Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2007, 99, 706-714.	3.0	344
610	Cancer du sujet \AA g \AA ©. , 2007, , .		1
611	Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2172-2178.	0.6	47
612	Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). <i>Haematologica</i> , 2007, 92, 568-569.	1.7	29
613	Newly diagnosed large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007, 18, ii55-ii56.	0.6	2
614	Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 1986-1992.	0.8	471
615	Evaluation of theMDR1,ABCG2,Topoisomerases II \pm andGST π gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. <i>Leukemia and Lymphoma</i> , 2007, 48, 1502-1509.	0.6	15
616	Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1736-1744.	0.6	13
617	Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 571-578.	0.8	1,275
618	Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 564-569.	0.6	14
619	High-Dose [¹³¹ I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults \geq 60 Years Old With Relapsed or Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1396-1402.	0.8	112
620	Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas \AA ” results of a randomized comparison by the German Low-Grade Lymphoma Study Group. <i>Annals of Oncology</i> , 2007, 18, 136-142.	0.6	13
621	Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4293-4297.	0.8	268
622	Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). <i>Hematology</i> , 2007, 12, 149-153.	0.7	13
623	Comparison of ¹⁸ F Fludeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 699-707.	0.6	54

#	ARTICLE	IF	CITATIONS
624	Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. <i>Annals of Oncology</i> , 2007, 18, 931-939.	0.6	47
625	PET and PET/CT for response evaluation in lymphoma: Current practice and developments. <i>Leukemia and Lymphoma</i> , 2007, 48, 270-282.	0.6	39
626	Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 683-690.	0.6	35
627	Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2007, 18, 1842-1850.	0.6	38
628	Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat. <i>Leukemia and Lymphoma</i> , 2007, 48, 1667-1669.	0.6	9
629	High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). <i>Leukemia and Lymphoma</i> , 2007, 48, 1299-1306.	0.6	91
630	Community-Based Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR) Biochemotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 185-193.	0.7	11
631	The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma—a population-based study. <i>Leukemia and Lymphoma</i> , 2007, 48, 736-745.	0.6	37
632	Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 35-41.	1.7	216
633	Rituximab and Escalated Chemotherapy in Elderly Patients with Aggressive Diffuse Large-Cell Lymphoma: A Controlled Clinical Trial. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 194-199.	0.7	14
634	Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. <i>Annals of Oncology</i> , 2007, 18, 1363-1368.	0.6	134
635	Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 381-388.	0.6	12
636	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 787-792.	0.8	239
637	Phase II study of gemcitabine+dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. <i>Annals of Oncology</i> , 2007, 18, 370-375.	0.6	38
638	Characterization of Bone Marrow Lymphoid Infiltrates After Immunochemotherapy for Follicular Lymphoma. <i>American Journal of Clinical Pathology</i> , 2007, 128, 974-980.	0.4	10
639	Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2426-2433.	0.8	348
640	Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody. <i>Anti-Cancer Drugs</i> , 2007, 18, 725-731.	0.7	11
641	Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center. <i>Journal of Clinical Oncology</i> , 2007, 25, 4648-4656.	0.8	80

#	ARTICLE	IF	CITATIONS
642	Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 1570-1575.	0.8	184
643	Peripheral blood natural killer cell count is associated with clinical outcome in patients with a $2\text{--}3$ diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2007, 18, 1209-1215.	0.6	86
644	Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1626-1632.	2.8	357
645	Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 1732-1740.	0.8	108
646	Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. <i>Annals of Oncology</i> , 2007, 18, 647-651.	0.6	18
647	A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. <i>Annals of Oncology</i> , 2007, 18, 116-121.	0.6	151
648	A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy. <i>Clinical Cancer Research</i> , 2007, 13, 958-964.	3.2	150
649	A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. <i>Annals of Oncology</i> , 2007, 18, 1216-1223.	0.6	103
650	Primary Bone Lymphoma: A New and Detailed Characterization of 28 Patients in a Single-Institution Study. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 216-223.	0.6	74
651	Bortezomib for the Treatment of Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 5291-5294.	3.2	309
652	Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1767-1776.	2.8	81
653	Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). <i>Haematologica</i> , 2007, 92, 627-634.	1.7	83
654	FC γ RIIIA and FC γ RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2007, 92, 998-999.	1.7	57
655	The adjusted International Prognostic Index and β 2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2007, 92, 1067-1074.	1.7	71
656	Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. <i>Haematologica</i> , 2007, 92, 686-689.	1.7	56
657	Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. <i>Haematologica</i> , 2007, 92, 42-49.	1.7	63
658	Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. <i>Haematologica</i> , 2007, 92, 784-794.	1.7	172
660	Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. <i>Blood</i> , 2007, 109, 486-491.	0.6	123

#	ARTICLE	IF	CITATIONS
661	Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2007, 109, 2183-2189.	0.6	63
662	Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). <i>Blood</i> , 2007, 109, 2759-2766.	0.6	38
663	TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and SÅ©zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 479-484.	0.6	452
664	Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. <i>Blood</i> , 2007, 110, 1123-1131.	0.6	584
665	A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. <i>Blood</i> , 2007, 109, 5160-5163.	0.6	33
666	Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. <i>Blood</i> , 2007, 110, 54-58.	0.6	171
667	Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. <i>Blood</i> , 2007, 110, 2316-2323.	0.6	293
668	The role of FDG-PET scans in patients with lymphoma. <i>Blood</i> , 2007, 110, 3507-3516.	0.6	285
669	Inference in ensemble experiments. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2007, 365, 2133-2143.	1.6	44
671	Prognostic relevance of serum Å² microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. <i>Haematologica</i> , 2007, 92, 1482-1488.	1.7	38
672	CEOP-21 Versus CEOP-14 Chemotherapy With or Without Rituximab for the First-Line Treatment of Patients With Aggressive Lymphomas: Results of the HE22A99 Trial of the Hellenic Cooperative Oncology Group. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 327-334.	1.0	15
673	Computed Tomography Scans Do Not Improve the Predictive Power of 1996 National Cancer Instituteâ€”Sponsored Working Group Chronic Lymphocytic Leukemia Response Criteria. <i>Journal of Clinical Oncology</i> , 2007, 25, 5624-5629.	0.8	21
674	A single unit lymphoma experience â€” Outcome in a Cape Town academic centre. <i>Transfusion and Apheresis Science</i> , 2007, 37, 93-102.	0.5	5
675	Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. <i>American Journal of Geriatric Pharmacotherapy</i> , 2007, 5, 247-262.	3.0	15
676	Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: A possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring. <i>European Journal of Radiology</i> , 2007, 63, 427-435.	1.2	64
677	The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkinâ€™s Lymphoma in Second Complete or Partial Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 486-492.	2.0	47
678	Comparable Antileukemia/Lymphoma Effects in Nonremission Patients Undergoing Allogeneic Hematopoietic Cell Transplantation with a Conventional Cyto-reductive or Reduced-Intensity Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 932-941.	2.0	28
679	Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1324-1337.	2.0	12

#	ARTICLE	IF	CITATIONS
682	From: 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006, Orlando, FL. Clinical Lymphoma and Myeloma, 2007, 7, 338-344.	1.4	0
683	Dexa-BEAM as salvage therapy in patients with primary refractory aggressive Non-Hodgkin lymphoma. Leukemia and Lymphoma, 2007, 48, 349-356.	0.6	11
684	Hodgkin's and Non-Hodgkin's Lymphomas. Radiologic Clinics of North America, 2007, 45, 69-83.	0.9	29
685	Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood, 2007, 109, 951-953.	0.6	34
686	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood, 2007, 110, 972-978.	0.6	283
687	Revisions to the staging and classification of mycosis fungoides and SÅ©zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 2007, 110, 1713-1722.	0.6	1,243
688	Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria. Leukemia and Lymphoma, 2007, 48, 1539-1547.	0.6	68
689	Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria. Leukemia and Lymphoma, 2007, 48, 1522-1530.	0.6	43
690	VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. Leukemia and Lymphoma, 2007, 48, 2167-2171.	0.6	11
691	The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. Leukemia and Lymphoma, 2007, 48, 2121-2136.	0.6	28
692	A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma. Leukemia and Lymphoma, 2007, 48, 1755-1763.	0.6	1
693	Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leukemia and Lymphoma, 2007, 48, 513-520.	0.6	17
694	Overcoming mechanisms of RECISTance in lymphoma. Leukemia and Lymphoma, 2007, 48, 447-448.	0.6	2
695	Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes. Leukemia and Lymphoma, 2007, 48, 584-595.	0.6	65
696	Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma. Leukemia and Lymphoma, 2007, 48, 897-904.	0.6	13
697	Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leukemia and Lymphoma, 2007, 48, 1332-1337.	0.6	16
698	Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. Leukemia and Lymphoma, 2007, 48, 1313-1319.	0.6	64
699	A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. Leukemia and Lymphoma, 2007, 48, 39-45.	0.6	10

#	ARTICLE	IF	CITATIONS
700	Mucosa associated lymphoid tissue lymphoma of the lung: The Royal Marsden Hospital experience. <i>Leukemia and Lymphoma</i> , 2007, 48, 547-550.	0.6	17
701	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 6168-6174.	3.2	111
702	Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. <i>Annals of Oncology</i> , 2007, 18, 1071-1079.	0.6	232
703	Revised Response Criteria for Malignant Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 579-586.	0.8	4,061
704	FDG-PET Lymphoma Demonstration Project Invitational Workshop. <i>Academic Radiology</i> , 2007, 14, 330-339.	1.3	27
705	The International Harmonization Project for Response Criteria in Lymphoma Clinical Trials. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 841-854.	0.9	115
706	Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. <i>Leukemia and Lymphoma</i> , 2007, 48, 1721-1727.	0.6	129
707	Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2764-2769.	0.8	247
708	Fludarabine. <i>Drugs</i> , 2007, 67, 1633-1655.	4.9	37
709	Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 291-295.	1.4	44
710	Efficacy and Safety of Rituximab Combined with ESHAP Chemotherapy for the Treatment of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 406-412.	1.4	19
711	Weight-Based Dosing of Yttrium 90 Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 514-517.	1.4	7
712	Bronchus-Associated Lymphoid Tissue Lymphomas: An Update of a Rare Extranodal Maltoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 566-572.	1.4	19
713	Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. <i>Digestive and Liver Disease</i> , 2007, 39, 634-641.	0.4	72
714	Lymphomes et autres tumeurs h�matologiques. , 2007, , 179-206.		1
715	The Relevance of PET in Diagnostic Oncology. , 2007, , 360-391.		0
716	Radioimmunotherapy. , 2007, , 467-490.		0
717	Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1092-1101.	0.6	10

#	ARTICLE	IF	CITATIONS
718	Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2007, 92, 778-783.	1.7	24
719	Rituximab and ESHAP as Second-line Therapy for Relapsed or Primary Refractory Diffuse Large B Cell Lymphoma: The Experience of a Single Center in Korea. <i>The Korean Journal of Hematology</i> , 2007, 42, 309.	0.7	0
720	Overview of early response assessment in lymphoma with FDG-PET. <i>Cancer Imaging</i> , 2007, 7, 10-18.	1.2	71
721	Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 2007, 57, 161-170.	6.7	66
722	Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study. <i>American Journal of Hematology</i> , 2007, 82, 122-127.	2.0	27
723	Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases. <i>American Journal of Hematology</i> , 2007, 82, 446-452.	2.0	41
724	Diffuse large B-cell lymphoma in the young in Japan: A study by the Osaka Lymphoma Study Group. <i>American Journal of Hematology</i> , 2007, 82, 893-897.	2.0	19
725	Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: Relationship with type of latent Epstein-Barr virus infection. <i>American Journal of Hematology</i> , 2007, 82, 1106-1109.	2.0	86
726	Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. <i>Hematological Oncology</i> , 2007, 25, 198-203.	0.8	57
727	High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma. <i>Cancer</i> , 2007, 109, 60-67.	2.0	14
728	Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. <i>Cancer</i> , 2007, 109, 77-83.	2.0	48
729	Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma. <i>Cancer</i> , 2007, 109, 1146-1151.	2.0	14
730	Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. <i>Cancer</i> , 2007, 109, 2481-2489.	2.0	138
731	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. <i>Cancer</i> , 2007, 110, 121-128.	2.0	41
732	The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-pet with 67gallium scintigraphy in the evaluation of lymphoma. <i>Cancer</i> , 2007, 110, 652-659.	2.0	190
733	The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. <i>Cancer</i> , 2007, 110, 1361-1369.	2.0	77
734	A Multicenter Phase II Study of Local Radiation Therapy for Stage IEA Mucosa-Associated Lymphoid Tissue Lymphomas: A Preliminary Report From the Japan Radiation Oncology Group (JAROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1181-1186.	0.4	41
735	Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. <i>Leukemia Research</i> , 2007, 31, 359-364.	0.4	41

#	ARTICLE	IF	CITATIONS
736	RAF-1 over-expression does condition survival of patients affected by aggressive mantle cell lymphoma. <i>Leukemia Research</i> , 2007, 31, 1595-1597.	0.4	3
737	P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. <i>Pathology Research and Practice</i> , 2007, 203, 1-7.	1.0	7
738	Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2007, 40, 919-924.	1.3	31
739	The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2007, 40, 1039-1044.	1.3	15
740	Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. <i>Leukemia</i> , 2007, 21, 515-523.	3.3	136
741	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). <i>Leukemia</i> , 2007, 21, 1802-1811.	3.3	66
742	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. <i>Leukemia</i> , 2007, 21, 2316-2323.	3.3	142
743	Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. <i>Leukemia</i> , 2007, 21, 2563-2566.	3.3	39
744	Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. <i>Leukemia</i> , 2007, 21, 2324-2331.	3.3	138
745	Adjuvant radiotherapy to an initial bulky mass in diffuse large B-cell lymphoma: lack of survival benefit. <i>International Journal of Laboratory Hematology</i> , 2007, 30, 070219115231001-???	0.2	5
746	Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. <i>Internal Medicine Journal</i> , 2007, 37, 070602000936001-???	0.5	32
747	Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. <i>British Journal of Haematology</i> , 2007, 136, 276-285.	1.2	41
748	Modern management of non-Hodgkin lymphoma in HIV-infected patients. <i>British Journal of Haematology</i> , 2007, 136, 685-698.	1.2	57
749	Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2007, 137, 329-336.	1.2	30
750	The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2007, 137, 364-373.	1.2	66
751	Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. <i>British Journal of Haematology</i> , 2007, 137, 409-415.	1.2	55
752	G-CSF is not necessary to maintain over 99% dose?intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. <i>British Journal of Haematology</i> , 2007, 137, 545-552.	1.2	71
753	Phase II trial of the combination of denileukin diftiox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2007, 138, 502-505.	1.2	30

#	ARTICLE	IF	CITATIONS
754	Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2007, 139, 90-93.	1.2	15
755	Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. <i>International Journal of Laboratory Hematology</i> , 2007, 30, 070129105256005-???.	0.2	10
756	Clinical outcome of low-grade NHL patients with bone marrow involvement. <i>European Journal of Clinical Investigation</i> , 2007, 37, 305-309.	1.7	10
757	Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. <i>Cancer Science</i> , 2007, 98, 109-112.	1.7	7
758	Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Cancer Science</i> , 2008, 99, 179-184.	1.7	36
759	B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. <i>Clinical Immunology</i> , 2007, 122, 139-145.	1.4	167
760	Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. <i>European Journal of Haematology</i> , 2007, 78, 322-329.	1.1	24
761	Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience. <i>European Journal of Haematology</i> , 2007, 78, 290-296.	1.1	59
762	Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. <i>European Journal of Haematology</i> , 2007, 79, 32-38.	1.1	138
763	Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia. <i>European Journal of Haematology</i> , 2007, 79, 1-7.	1.1	23
764	Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2007, 79, 100-106.	1.1	12
765	Plasma MMP-2 and TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. <i>European Journal of Haematology</i> , 2008, 80, 46-54.	1.1	11
766	GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large B-cell lymphoma: a phase II study. <i>European Journal of Haematology</i> , 2008, 80, 127-132.	1.1	90
767	2-[18F]Fluoro-2-Deoxyglucose Positron-Emission Tomography in Staging, Response Evaluation, and Treatment Planning of Lymphomas. <i>Seminars in Radiation Oncology</i> , 2007, 17, 190-197.	1.0	48
768	Biweekly CHOP therapy improves therapeutic effect in the non-GCB subtype of diffuse large B-cell lymphoma. <i>Open Medicine (Poland)</i> , 2007, 2, 488-498.	0.6	2
769	Effectiveness and Limitation of Gamma Knife Radiosurgery for Relapsed Central Nervous System Lymphoma: A Retrospective Analysis in One Institution. <i>International Journal of Hematology</i> , 2007, 85, 333-337.	0.7	19
770	Advanced Stage Is the Most Important Prognostic Factor for Survival in Patients with Systemic Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphoma Treated with CHOP and Highly Active Antiretroviral Therapy. <i>International Journal of Hematology</i> , 2007, 86, 337-342.	0.7	8
771	Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. <i>Medical Oncology</i> , 2007, 24, 85-89.	1.2	18

#	ARTICLE	IF	CITATIONS
772	EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with ⁹⁰ Y-radiolabelled ibritumomab tiuxetan (Zevalin). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 616-622.	3.3	74
773	Early assessment of therapy response in malignant lymphoma with the thymidine analogue [¹⁸ F]FLT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1775-1782.	3.3	62
774	Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. <i>Annals of Hematology</i> , 2007, 86, 639-645.	0.8	15
775	Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 129-134.	1.1	107
776	Proteasome inhibitor, bortezomib, for myeloma and lymphoma. <i>International Journal of Clinical Oncology</i> , 2007, 12, 318-326.	1.0	42
777	Imaging Proliferation to Monitor Early Response of Lymphoma to Cytotoxic Treatment. <i>Molecular Imaging and Biology</i> , 2008, 10, 349-355.	1.3	42
778	BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. <i>Annals of Hematology</i> , 2008, 87, 43-48.	0.8	75
779	Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide,) Tj ETQq1 1 0.784314 rgBT ⁵ /Overlo	0.8	5
780	Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 299-304.	1.1	5
782	Prognostic impact of pre-transplantation computed tomography and ⁶⁷ gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation. <i>Annals of Nuclear Medicine</i> , 2008, 22, 251-260.	1.2	1
783	Clinical significance of ¹⁸ F-FDG uptake by primary sites in patients with diffuse large B cell lymphoma in the head and neck: a pilot study. <i>Annals of Nuclear Medicine</i> , 2008, 22, 645-651.	1.2	12
784	¹⁸ F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence. <i>Annals of Nuclear Medicine</i> , 2008, 22, 795-802.	1.2	15
785	T/NK cell lymphoma presenting as a "blocked nose". <i>European Archives of Oto-Rhino-Laryngology</i> , 2008, 265, 1131-1134.	0.8	9
786	The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: A retrospective analysis of enrolled cases in Japan. <i>Pediatric Blood and Cancer</i> , 2008, 51, 188-192.	0.8	34
787	A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium- ⁹⁰ ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. <i>Cancer</i> , 2008, 112, 856-862.	2.0	43
788	Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. <i>Cancer</i> , 2008, 112, 831-836.	2.0	69
789	Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Cancer</i> , 2008, 112, 1288-1295.	2.0	35
790	Primary central nervous system lymphoma. <i>Cancer</i> , 2008, 112, 1812-1820.	2.0	23

#	ARTICLE	IF	CITATIONS
791	Prednisone, etoposide, procarbazine, and cyclophosphamide (PEPâ€œ) oral combination chemotherapy regimen for recurring/refractory lymphoma: Lowâ€œdose metronomic, multidrug therapy. <i>Cancer</i> , 2008, 112, 2228-2232.	2.0	57
792	Longâ€œterm results of the treatment of patients with mantle cell lymphoma with cladribine (2â€œCDA) alone (95â€œ80â€œ53) or 2â€œCDA and rituximab (N0189) in the North Central Cancer Treatment Group. <i>Cancer</i> , 2008, 113, 108-116.	2.0	68
793	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated lowâ€œgrade Bâ€œcell nonâ€œHodgkin lymphoma patients. <i>Cancer</i> , 2008, 113, 367-375.	2.0	22
794	Lowâ€œdose, singleâ€œagent temsirolimus for relapsed mantle cell lymphoma. <i>Cancer</i> , 2008, 113, 508-514.	2.0	220
795	Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive Bâ€œcell nonâ€œHodgkin lymphoma. <i>Cancer</i> , 2008, 113, 2496-2503.	2.0	66
796	Phase 2 trial of rituximab plus hyperâ€œCVAD alternating with rituximab plus methotrexateâ€œcytarabine for relapsed or refractory aggressive mantle cell lymphoma. <i>Cancer</i> , 2008, 113, 2734-2741.	2.0	31
797	Durable complete responses from therapy with combined epratuzumab and rituximab. <i>Cancer</i> , 2008, 113, 2714-2723.	2.0	102
798	A multicenter phase 2 study of riskâ€œadjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. <i>Cancer</i> , 2008, 113, 3192-3198.	2.0	11
799	R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. <i>Hematological Oncology</i> , 2008, 26, 27-32.	0.8	15
800	Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GELâ€œTAMO experience. <i>Hematological Oncology</i> , 2008, 26, 171-178.	0.8	30
801	A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. <i>Hepatology</i> , 2008, 47, 844-853.	3.6	277
802	Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDGâ€œPET scan before transplantation. <i>American Journal of Hematology</i> , 2008, 83, 477-481.	2.0	17
803	Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy. <i>Leukemia Research</i> , 2008, 32, 1183-1195.	0.4	14
804	Impact of [18F] Fluorodeoxyglucose Positron Emission Tomography on Staging and Management of Early-Stage Follicular Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 213-219.	0.4	120
805	Results of Hematopoietic Stem Cell Transplantation After Treatment With Different High-Dose Total-Body Irradiation Regimens in Five Dutch Centers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1444-1454.	0.4	11
806	MACOP-B and Involved-Field Radiotherapy Is an Effective and Safe Therapy for Primary Mediastinal Large B Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1154-1160.	0.4	40
807	The Incremental Value of Fâ€œ18 FDG PET and PET/CT in Malignant Lymphoma. <i>Imaging Decisions (Berlin)</i> , Tj ETQq0 0,0 rgBT /Overlock 1	0.2	2
808	Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. <i>Laboratory Investigation</i> , 2008, 88, 38-47.	1.7	87

#	ARTICLE	IF	CITATIONS
809	Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 42, 529-534.	1.3	16
810	Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. <i>Bone Marrow Transplantation</i> , 2008, 42, 601-608.	1.3	21
811	Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 42, 649-657.	1.3	19
812	Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) â€“ a new perspective. <i>Histopathology</i> , 2008, 52, 340-347.	1.6	14
813	Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. <i>Bone Marrow Transplantation</i> , 2008, 41, 779-784.	1.3	44
814	Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. <i>International Journal of Laboratory Hematology</i> , 2008, 30, 230-239.	0.7	67
815	British HIV Association guidelines for HIV-associated malignancies 2008. <i>HIV Medicine</i> , 2008, 9, 336-388.	1.0	158
816	Increased acquired activated protein C resistance in unselected patients with hematological malignancies. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1482-1487.	1.9	29
817	Phase I study of dexamethasone, methotrexate, ifosfamide, asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. <i>Cancer Science</i> , 2008, 99, 1016-1020.	1.7	193
818	ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. <i>Cancer Science</i> , 2008, 99, 2496-2501.	1.7	33
819	Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patients. <i>British Journal of Dermatology</i> , 2008, 159, 1148-51.	1.4	18
820	A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. <i>British Journal of Haematology</i> , 2008, 140, 385-393.	1.2	47
821	Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. <i>British Journal of Haematology</i> , 2008, 140, 516-526.	1.2	145
822	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. <i>British Journal of Haematology</i> , 2008, 140, 313-319.	1.2	26
823	Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. <i>British Journal of Haematology</i> , 2008, 140, 411-419.	1.2	107
824	Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 235-243.	1.2	44
825	Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. <i>British Journal of Haematology</i> , 2008, 141, 631-640.	1.2	43
826	Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 142, 52-56.	1.2	68

#	ARTICLE	IF	CITATIONS
827	A multicentre phase II clinical experience with the novel aza ϵ -epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non ϵ -Hodgkin lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 201-209.	1.2	17
828	Phase II multicenter study of oblimersen sodium, a Bcl ϵ 2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B ϵ cell non ϵ -Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 355-360.	1.2	93
829	Non ϵ -myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B ϵ cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008, 143, 395-403.	1.2	97
830	Diffuse large B ϵ cell lymphoma showing an interfollicular pattern of proliferation: a study of the Osaka Lymphoma Study Group. <i>Histopathology</i> , 2008, 52, 731-737.	1.6	9
831	Activation of the NF ϵ κ B signalling pathway in diffuse large B ϵ cell lymphoma: clinical implications. <i>Histopathology</i> , 2008, 53, 441-449.	1.6	24
832	Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2008, 8, 115.	1.1	56
833	Fc γ R1a polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. <i>Cancer Genetics and Cytogenetics</i> , 2008, 183, 35-40.	1.0	40
834	Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL ϵ TAMO Study Group. <i>European Journal of Haematology</i> , 2008, 80, 227-235.	1.1	17
835	Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2008, 80, 296-298.	1.1	8
836	PET/CT in the management of haematological malignancies. <i>European Journal of Haematology</i> , 2008, 80, 369-380.	1.1	41
837	CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non ϵ -Hodgkin lymphoma (meta ϵ analysis). <i>European Journal of Haematology</i> , 2008, 80, 477-482.	1.1	12
838	A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. <i>European Journal of Haematology</i> , 2008, 81, 170-176.	1.1	163
839	High ϵ dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B ϵ cell lymphoma. <i>European Journal of Haematology</i> , 2008, 81, 425-431.	1.1	35
840	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the extracranial head and neck region: A high rate of dissemination and disease recurrence. <i>Oral Oncology</i> , 2008, 44, 949-955.	0.8	30
841	Cost-Effectiveness Analysis of the??Addition of Rituximab to CHOP??in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma. <i>Clinical Drug Investigation</i> , 2008, 28, 55-65.	1.1	29
842	[18F]Fluorodeoxyglucose Positron Emission Tomography Scanning for Staging, Response Assessment, and Disease Surveillance in Patients with Mantle Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 159-165.	1.4	38
844	Value of [18F]Fluorodeoxyglucose Positron Emission Tomography in the Management of Follicular Lymphoma: The End of a Dilemma?. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 287-293.	1.4	60
846	Staging and Evaluation of the Patient with Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 825-837.	0.9	25

#	ARTICLE	IF	CITATIONS
847	Imaging of Abdominal Lymphoma. Radiologic Clinics of North America, 2008, 46, 265-285.	0.9	41
848	How to assess anti-tumour efficacy by imaging techniques. European Journal of Cancer, 2008, 44, 39-45.	1.3	38
849	Role of FDG PET in the management of childhood lymphomas – case proven or is the jury still out?. European Journal of Cancer, 2008, 44, 663-673.	1.3	37
850	Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: Whole-body MRI, PET/CT and bone marrow biopsy. European Journal of Radiology, 2008, 66, 325-331.	1.2	65
851	Dose-Reduced Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation for Human Immunodeficiency Virus-Associated Lymphoma: AIDS Malignancy Consortium Study 020. Biology of Blood and Marrow Transplantation, 2008, 14, 59-66.	2.0	85
852	High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 50-58.	2.0	94
853	Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non-Hodgkin Lymphoma: Effect of Histological Grade and Follicular International Prognostic Index. Biology of Blood and Marrow Transplantation, 2008, 14, 36-42.	2.0	65
854	Similar and Promising Outcomes in Lymphoma Patients Treated with Myeloablative or Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 538-545.	2.0	56
855	Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience. Biology of Blood and Marrow Transplantation, 2008, 14, 741-747.	2.0	99
856	Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 775-782.	2.0	22
857	Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study. Biology of Blood and Marrow Transplantation, 2008, 14, 807-816.	2.0	141
858	Impact of T Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2008, 14, 1148-1155.	2.0	40
859	Response assessment in lymphoma. Clinical Radiology, 2008, 63, 125-135.	0.5	30
860	Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma. Cytokine, 2008, 43, 71-75.	1.4	22
861	Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 4473-4479.	0.8	333
862	Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study. Journal of Clinical Oncology, 2008, 26, 204-210.	0.8	271
863	The significance of a uniform definition of pathological lymph nodes in Hodgkin lymphoma: Impact of different thresholds for positive lymph nodes in CT imaging on staging and therapy. Radiotherapy and Oncology, 2008, 87, 74-81.	0.3	8
864	The conundrum of hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiotherapy and Oncology, 2008, 88, 202-210.	0.3	113

#	ARTICLE	IF	CITATIONS
865	High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 440-446.	0.8	226
866	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). <i>Lancet Oncology</i> , The, 2008, 9, 105-116.	5.1	1,001
867	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , The, 2008, 9, 352-358.	5.1	80
868	Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. <i>Lancet Oncology</i> , The, 2008, 9, 435-444.	5.1	190
869	New Staging and Response Criteria for Non-Hodgkin Lymphoma and Hodgkin Lymphoma. <i>Radiologic Clinics of North America</i> , 2008, 46, 213-223.	0.9	30
870	Variables Involved in Measuring Cancer Response to Treatment. <i>PET Clinics</i> , 2008, 3, 13-36.	1.5	0
871	R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study. <i>Leukemia and Lymphoma</i> , 2008, 49, 1081-1086.	0.6	52
872	Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. <i>Leukemia and Lymphoma</i> , 2008, 49, 1530-1536.	0.6	11
873	Prognostic value of T-cell receptor β rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2008, 49, 237-246.	0.6	10
874	Targeting the follicular lymphoma microenvironment through blockade of TNF α with etanercept. <i>Leukemia and Lymphoma</i> , 2008, 49, 902-909.	0.6	11
875	Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. <i>Leukemia and Lymphoma</i> , 2008, 49, 247-256.	0.6	91
876	Alemtuzumab in clinical practice: A British Columbia experience. <i>Leukemia and Lymphoma</i> , 2008, 49, 218-226.	0.6	12
877	Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1062-1073.	0.6	43
878	Marginal zone B-cell lymphoma arising in donor cells in a Hepatitis-C virus infected patient over 20 years after allogeneic bone marrow transplantation. <i>Leukemia and Lymphoma</i> , 2008, 49, 2219-2221.	0.6	0
879	Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group. <i>Leukemia and Lymphoma</i> , 2008, 49, 1074-1080.	0.6	50
880	A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 924-931.	0.6	10
881	Plant-produced idiotypic vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10131-10136.	3.3	173
882	Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 67 Td (Ara Refractory Lymphoma. <i>Cancer Investigation</i> , 2008, 26, 401-406.	0.6	41

#	ARTICLE	IF	CITATIONS
883	Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. <i>Annals of Oncology</i> , 2008, 19, 1477-1484.	0.6	147
884	PET Imaging for Response Assessment in Lymphoma: Potential and Limitations. <i>Radiologic Clinics of North America</i> , 2008, 46, 225-241.	0.9	39
885	A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. <i>Annals of Oncology</i> , 2008, 19, 769-773.	0.6	72
886	Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. <i>Annals of Oncology</i> , 2008, 19, 951-957.	0.6	2
887	Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. <i>Annals of Oncology</i> , 2008, 19, 1331-1335.	0.6	40
888	New response criteria for lymphomas in clinical trials. <i>Annals of Oncology</i> , 2008, 19, iv35-iv38.	0.6	25
889	Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). <i>Annals of Oncology</i> , 2008, 19, 545-552.	0.6	44
890	Reticuloendothelium Malignancy: Current Role of Imaging. <i>Cancer Treatment and Research</i> , 2008, 143, 455-468.	0.2	0
891	Role of Immunohistochemistry in Staging Diffuse Large B-cell Lymphoma (DLBCL). <i>Journal of Histochemistry and Cytochemistry</i> , 2008, 56, 893-900.	1.3	15
892	Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5980-5987.	0.8	137
893	Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). <i>Annals of Oncology</i> , 2008, 19, 780-786.	0.6	34
894	Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey. <i>Journal of Clinical Oncology</i> , 2008, 26, 3166-3175.	0.8	68
895	Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment. <i>Acta Haematologica</i> , 2008, 120, 36-46.	0.7	9
896	¹⁸ F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2008, 49, 13-21.	2.8	142
897	Characteristics and Outcome of AIDS-Related Hodgkin Lymphoma Before and After the Introduction of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 422-428.	0.9	79
898	Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy. <i>Hematology</i> , 2008, 13, 261-266.	0.7	26
899	R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. <i>Haematologica</i> , 2008, 93, 1829-1836.	1.7	158
900	Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. <i>Journal of Clinical Oncology</i> , 2008, 26, 2717-2724.	0.8	267

#	ARTICLE	IF	CITATIONS
901	Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1745-1751.	0.6	96
902	Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations. <i>Radiographics</i> , 2008, 28, 329-344.	1.4	219
903	A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 2756-2762.	3.2	233
904	High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 218-224.	0.8	129
905	Phase III Trial of Consolidation Therapy With Yttrium-90- ⁹⁰ Y-ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5156-5164.	0.8	431
906	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. <i>Annals of Oncology</i> , 2008, 19, 560-565.	0.6	7
907	Report of Aids-related Lymphoma in South Korea. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 134-139.	0.6	4
908	Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy. <i>Annals of Oncology</i> , 2008, 19, 254-258.	0.6	5
909	Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. <i>Annals of Oncology</i> , 2008, 19, 538-544.	0.6	17
910	Positron emission tomography and CT in the management of lymphoma. <i>Imaging</i> , 2008, 20, 169-175.	0.0	1
911	Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 196-203.	0.8	145
912	Bortezomib: A novel chemotherapeutic agent for hematologic malignancies. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 1221-1231.	0.5	48
913	Prognostic Value of Tumor ¹⁸ F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1783-1789.	2.8	68
914	Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy. <i>Annals of Oncology</i> , 2008, 19, 1915-1920.	0.6	8
915	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 211-217.	0.8	186
916	Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 43-48.	0.6	2
917	Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. <i>Annals of Oncology</i> , 2008, 19, 774-779.	0.6	120
918	A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 6697-6703.	3.2	149

#	ARTICLE	IF	CITATIONS
919	Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 2079-2083.	0.6	68
920	Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 958-963.	0.6	182
921	Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 242-246.	0.6	51
922	Treatment of Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma with Two Ifosfamide-Based Regimens, IMVP and ICE. <i>Journal of Chemotherapy</i> , 2008, 20, 640-644.	0.7	3
923	Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4952-4957.	0.8	376
924	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 447-454.	0.8	159
925	The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. <i>Annals of Oncology</i> , 2008, 19, 553-559.	0.6	21
926	Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. <i>Annals of Oncology</i> , 2008, 19, 1935-1940.	0.6	73
927	Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 68-74.	0.6	13
928	Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 447-450.	0.6	38
929	Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 88-94.	0.6	21
930	A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 247-253.	0.6	92
931	B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after ⁹⁰ Y- ¹²⁵ Ibritumomab Tiuxetan Radioimmunotherapy: Initial Experience. <i>Radiology</i> , 2008, 246, 895-902.	3.6	28
932	Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 1105-1110.	3.2	37
933	Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4579-4586.	0.8	555
934	Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2725-2731.	0.8	77
935	Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , 2008, 19, 1774-1786.	0.6	57
936	Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1329-1336.	0.6	88

#	ARTICLE	IF	CITATIONS
937	Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2008, 19, 1759-1764.	0.6	40
938	Pre-transplant 18F-FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2008, 49, 727-733.	0.6	27
939	Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1501-1509.	0.6	31
940	Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group. <i>Leukemia and Lymphoma</i> , 2008, 49, 102-112.	0.6	60
941	Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1893-1898.	0.6	10
942	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. <i>Haematologica</i> , 2008, 93, 390-397.	1.7	45
943	Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. <i>Haematologica</i> , 2008, 93, 951-952.	1.7	82
944	A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. <i>Blood</i> , 2008, 111, 1848-1854.	0.6	189
945	Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2008, 111, 4463-4470.	0.6	292
946	Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. <i>Blood</i> , 2008, 111, 537-543.	0.6	142
947	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008, 111, 5486-5495.	0.6	247
948	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. <i>Blood</i> , 2008, 112, 2261-2271.	0.6	628
949	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i> , 2008, 111, 5530-5536.	0.6	294
950	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Blood</i> , 2008, 111, 5509-5514.	0.6	93
951	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo "purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. <i>Blood</i> , 2008, 112, 2687-2693.	0.6	571
952	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. <i>Blood</i> , 2008, 112, 4824-4831.	0.6	304
953	Prospective, multicenter randomized GITMO/III trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008, 111, 4004-4013.	0.6	243
954	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2008, 93, 207-214.	1.7	24

#	ARTICLE	IF	CITATIONS
956	Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1040-1048.	1.8	43
957	Serum IL-6, IL-8, IL-10 and Beta ₂ -Microglobulin in Association with International Prognostic Index in Diffuse Large B Cell Lymphoma. <i>Tumori</i> , 2008, 94, 511-517.	0.6	20
958	Role of serial quantitative gallium-67 tumor uptake in assessing response rates for chemotherapy in lymphoma patients. <i>Nuclear Medicine Communications</i> , 2008, 29, 527-534.	0.5	3
959	SIRT1 Expression is Associated With Poor Prognosis of Diffuse Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1523-1531.	2.1	137
960	A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients. <i>Anti-Cancer Drugs</i> , 2008, 19, 309-315.	0.7	10
961	18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. <i>Haematologica</i> , 2008, 93, 128-131.	1.7	28
962	Primary Systemic Anaplastic Large Cell Lymphoma in Korean Adults: 11 Years' Experience at Asan Medical Center. <i>Yonsei Medical Journal</i> , 2008, 49, 601.	0.9	9
963	Molecular Imaging in Early Therapy Monitoring. , 2008, , 29-37.		1
966	La place de l'ATP au FDG dans l'évaluation des lymphomes. <i>Hematologie</i> , 2009, 15, 305-312.	0.0	0
967	Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2009, 50, 998-1004.	0.6	12
968	The persistence of t(14;18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for a lymphoma stem cell™. <i>Leukemia and Lymphoma</i> , 2009, 50, 1102-1109.	0.6	9
969	Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 37-46.	0.6	39
970	A phase II study of bortezomib in patients with MALT lymphoma. <i>Haematologica</i> , 2009, 94, 738-742.	1.7	70
971	Role of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1781-1787.	0.8	160
972	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 349-356.	0.6	12
973	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3036-3043.	0.8	132
974	Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. <i>Annals of Oncology</i> , 2009, 20, 503-507.	0.6	73
975	Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2009, 27, 453-459.	0.8	485

#	ARTICLE	IF	CITATIONS
976	¹⁸ F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy. Journal of Nuclear Medicine, 2009, 50, 8-17.	2.8	66
977	Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2009, 27, 5404-5409.	0.8	259
978	Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909. Journal of Clinical Oncology, 2009, 27, 6101-6108.	0.8	182
979	PET imaging in lymphoma. Expert Review of Hematology, 2009, 2, 261-276.	1.0	3
980	Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Clinical Oncology, 2009, 27, 904-910.	0.8	203
981	Clinicopathologic Characteristics and Therapeutic Outcomes of Primary Gastrointestinal Non-Hodgkin's Lymphomas: 10 Years of Experience from a Single Center in Eastern Anatolia. Medical Principles and Practice, 2009, 18, 399-406.	1.1	8
982	Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma. Journal of Clinical Oncology, 2009, 27, 5023-5030.	0.8	96
983	Bone Marrow. , 2009, , 1536-1593.		0
984	Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology, 2009, 20, 520-525.	0.6	302
985	Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2009, 27, 1653-1659.	0.8	101
986	Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Cancer Research, 2009, 15, 6446-6453.	3.2	297
987	Interaction between BCL2 and Interleukin-10 Gene Polymorphisms Alter Outcomes of Diffuse Large B-Cell Lymphoma following Rituximab Plus CHOP Chemotherapy. Clinical Cancer Research, 2009, 15, 2107-2115.	3.2	28
988	Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results. Journal of Clinical Oncology, 2009, 27, 3346-3353.	0.8	154
989	Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211. Journal of Clinical Oncology, 2009, 27, 5594-5600.	0.8	315
990	¹⁸ F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response. Journal of Nuclear Medicine, 2009, 50, 88-99.	2.8	287
991	Diffuse Large B Cell Lymphoma without Immunoglobulin Light Chain Restriction by Flow Cytometry. Acta Haematologica, 2009, 121, 196-201.	0.7	20
992	Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2009, 27, 426-432.	0.8	152
993	Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2009, 27, 4371-4377.	0.8	175

#	ARTICLE	IF	CITATIONS
994	Contrast-enhanced Harmonic Compound US of the Spleen to Increase Staging Accuracy in Patients with Hodgkin Lymphoma: A Prospective Study. <i>Radiology</i> , 2009, 251, 574-582.	3.6	37
995	Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders. <i>Hematology</i> , 2009, 14, 187-197.	0.7	1
996	Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 527-533.	2.8	229
997	Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2009, 50, 1647-1660.	0.6	34
998	Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. <i>Leukemia and Lymphoma</i> , 2009, 50, 1718-1720.	0.6	7
999	Staging bone marrow in diffuse large B-cell lymphoma: the role of ancillary investigations. <i>Pathology</i> , 2009, 41, 214-222.	0.3	22
1000	Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. <i>Annals of Oncology</i> , 2009, 20, 526-533.	0.6	55
1001	Phase II Study of Yttrium-90- ¹²⁵ Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5213-5218.	0.8	87
1002	Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2009, 20, 1985-1992.	0.6	64
1003	Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 3503-3510.	3.2	58
1004	Phase II study of 'high dose' celecoxib and metronomic 'low dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma. <i>Ecancermedalscience</i> , 2009, 3, 144.	0.6	1
1005	Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2009, 101, 248-255.	3.0	227
1006	Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma. <i>Oncologist</i> , 2009, 14, 30-40.	1.9	51
1007	Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5410-5417.	0.8	687
1008	PET/CT for Therapy Response Assessment in Lymphoma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 21S-30S.	2.8	193
1009	The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. <i>Clinical Cancer Research</i> , 2009, 15, 6462-6471.	3.2	14
1010	Salvage Therapy in Hodgkin's Lymphoma. <i>Oncologist</i> , 2009, 14, 425-432.	1.9	29
1011	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. <i>Journal of Clinical Oncology</i> , 2009, 27, 4555-4562.	0.8	613

#	ARTICLE	IF	CITATIONS
1012	Dosimetry of ⁹⁰ Y-ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1837-1843.	2.8	22
1013	Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4365-4370.	0.8	123
1014	Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. <i>Annals of Oncology</i> , 2009, 20, 1080-1085.	0.6	132
1015	Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2009, 27, 3951-3958.	0.8	160
1016	Phase II-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2009, 27, 4357-4364.	0.8	163
1017	Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. <i>Experimental Cell Research</i> , 2009, 315, 3281-3293.	1.2	4
1018	Temsirolimus in Mantle Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes. <i>Seminars in Oncology</i> , 2009, 36, S37-S45.	0.8	23
1019	Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2009, 84, 93-97.	2.0	66
1020	Primary breast non-Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors. <i>American Journal of Hematology</i> , 2009, 84, 133-139.	2.0	87
1021	Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. <i>American Journal of Hematology</i> , 2009, 84, 484-487.	2.0	62
1022	Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. <i>Hematological Oncology</i> , 2009, 27, 11-16.	0.8	35
1023	A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. <i>Hematological Oncology</i> , 2009, 27, 154-159.	0.8	10
1024	Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2009, 115, 3475-3482.	2.0	149
1025	Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma. <i>Cancer</i> , 2009, 115, 4540-4546.	2.0	51
1026	Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. <i>Cancer</i> , 2009, 115, 5210-5217.	2.0	78
1027	Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 106-114.	2.0	217
1028	Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Und Physiologie Und Fur Klinische Medizin, 2009, 455, 285-293.	1.4	9
1029	Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 53-59.	1.2	31

#	ARTICLE	IF	CITATIONS
1030	Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1421-1428.	1.2	15
1031	Radioisotopic Localization of ⁹⁰ Yttrium- ⁹⁰ Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin's Lymphoma. <i>Molecular Imaging and Biology</i> , 2009, 11, 39-45.	1.3	14
1032	Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma. <i>Medical Oncology</i> , 2009, 26, 16-21.	1.2	9
1033	Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. <i>Clinical and Translational Oncology</i> , 2009, 11, 604-608.	1.2	4
1034	The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. <i>International Journal of Hematology</i> , 2009, 89, 326-331.	0.7	8
1035	Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. <i>International Journal of Hematology</i> , 2009, 89, 538-545.	0.7	8
1036	Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. <i>International Journal of Hematology</i> , 2009, 90, 74-80.	0.7	25
1037	Evaluation of non-vascular mediastinal masses in infants and children: an evidence-based practical approach. <i>Pediatric Radiology</i> , 2009, 39, 184-190.	1.1	47
1038	Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. <i>Annals of Hematology</i> , 2009, 88, 133-139.	0.8	18
1039	Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. <i>Annals of Hematology</i> , 2009, 88, 417-424.	0.8	8
1040	The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2009, 88, 425-432.	0.8	28
1041	Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city—a retrospective 14-year study. <i>Annals of Hematology</i> , 2009, 88, 633-637.	0.8	6
1042	Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin's lymphoma: the single-institute experience in Taiwan. <i>Annals of Hematology</i> , 2009, 88, 839-846.	0.8	16
1043	Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population. <i>Annals of Hematology</i> , 2009, 88, 863-869.	0.8	13
1044	A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 27-33.	1.1	9
1045	Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 907-916.	1.1	65
1046	A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2009, 52, 177-181.	0.8	158
1047	Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients. <i>BMC Ear, Nose and Throat Disorders</i> , 2009, 9, 11.	2.6	13

#	ARTICLE	IF	CITATIONS
1048	Japanese phase II study of rituximab plus bendamustine in patients with relapsed or refractory indolent B-cell lymphoma. <i>Cancer Science</i> , 2009, 100, 158-164.	1.7	35
1049	Clinical significance of t(8q24;q38) MYC translocation in diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2009, 100, 233-237.	1.7	45
1050	Phase II and pharmacokinetic study of cladribine with rituximab infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. <i>Cancer Science</i> , 2009, 100, 1344-1350.	1.7	7
1051	Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. <i>Cancer Science</i> , 2009, 100, 1951-1956.	1.7	8
1052	Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. <i>Cancer Science</i> , 2009, 100, 1842-1847.	1.7	88
1053	Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. <i>British Journal of Haematology</i> , 2009, 145, 34-39.	1.2	72
1054	Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2009, 145, 344-349.	1.2	247
1055	A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. <i>British Journal of Haematology</i> , 2009, 145, 741-748.	1.2	75
1056	A Phase II study of SGN30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 171-179.	1.2	230
1057	Phase II study of a TLR9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 282-291.	1.2	75
1058	Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 652-655.	1.2	47
1059	Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2009, 147, 89-96.	1.2	22
1060	Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2009, 147, 97-101.	1.2	89
1061	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 561-573.	1.1	19
1062	Bcl-10 protein highly correlates with the expression of phosphorylated p65 NF- κ B in peripheral T-cell lymphomas and is associated with clinical outcome. <i>Histopathology</i> , 2009, 54, 478-485.	1.6	20
1063	Bcl-xL Gene Expression Correlated with Lower Apoptotic Cell Numbers and Shorter Progression-Free Survival in PCFCL. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1703-1709.	0.3	13
1064	Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. <i>Leukemia</i> , 2009, 23, 162-169.	3.3	69
1065	The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). <i>Leukemia</i> , 2009, 23, 153-161.	3.3	151

#	ARTICLE	IF	CITATIONS
1066	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. <i>Leukemia</i> , 2009, 23, 1118-1126.	3.3	104
1067	The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1131-1138.	3.3	111
1068	Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 + anti-CD20 antibody and donor lymphocyte infusion. <i>Bone Marrow Transplantation</i> , 2009, 43, 383-397.	1.3	46
1069	Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 43, 701-708.	1.3	66
1070	Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. <i>Bone Marrow Transplantation</i> , 2009, 44, 89-96.	1.3	14
1071	Atacept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. <i>British Journal of Cancer</i> , 2009, 101, 1051-1058.	2.9	71
1072	USE OF ¹⁸ F-FLUOROTHYMININE PET/CT FOR EVALUATING RESPONSE TO CYTOTOXIC CHEMOTHERAPY IN DOGS WITH NON-HODGKIN'S LYMPHOMA. <i>Veterinary Radiology and Ultrasound</i> , 2009, 50, 660-668.	0.4	44
1073	Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 601-608.	1.0	26
1074	Evaluation of lymph nodes with RECIST 1.1. <i>European Journal of Cancer</i> , 2009, 45, 261-267.	1.3	233
1075	Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 118-125.	2.0	49
1076	Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non-Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 223-230.	2.0	40
1077	Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 432-438.	2.0	26
1078	Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 547-553.	2.0	39
1079	Le radiopharmaceutique: situation et perspectives depuis la 8e Conférence internationale de l'ACOMEN (Bordeaux, 11-13 mai 2005). <i>Medecine Nucleaire</i> , 2009, 33, 115-121.	0.2	3
1081	Stratégies de consolidation par Zevalin® en traitement des lymphomes malins non Hodgkiniens. <i>Medecine Nucleaire</i> , 2009, 33, 491-498.	0.2	1
1082	From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 122S-150S.	2.8	3,047
1083	A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 7085-7091.	3.2	269
1084	Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 74-76.	1.4	25

#	ARTICLE	IF	CITATIONS
1085	CD43 Expression Is an Adverse Prognostic Factor in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 133-137.	1.4	21
1086	Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 223-228.	1.4	56
1087	Favorable Consolidative Effect of High-Dose Melphalan and Total-Body Irradiation Followed by Autologous Peripheral Blood Stem Cell Transplantation After Rituximab-Containing Induction Chemotherapy With In Vivo Purging in Relapsed or Refractory Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 443-448.	1.4	5
1088	Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 106-113.	0.8	380
1089	R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. <i>Journal of Hematology and Oncology</i> , 2009, 2, 14.	6.9	28
1090	Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). <i>Journal of Hematology and Oncology</i> , 2009, 2, 49.	6.9	18
1091	Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review. <i>Journal of Clinical Oncology</i> , 2009, 27, 1906-1914.	0.8	242
1092	Non-Hodgkin lymphoma response evaluation with MRI texture classification. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 87.	3.5	42
1093	High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. <i>Blood</i> , 2009, 114, 1306-1313.	0.6	130
1094	Prognostic tools in follicular lymphomas. <i>Expert Review of Hematology</i> , 2009, 2, 549-562.	1.0	10
1095	Early and Late Therapy Response Assessment With [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4385-4391.	0.8	150
1096	High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. <i>Annals of Oncology</i> , 2009, 20, 309-318.	0.6	137
1097	High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1470-1476.	0.8	273
1098	Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1494-1500.	0.6	31
1099	Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. <i>Leukemia and Lymphoma</i> , 2009, 50, 723-727.	0.6	32
1100	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 757-763.	0.6	63
1101	A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. <i>Leukemia and Lymphoma</i> , 2009, 50, 728-735.	0.6	84
1102	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1824-1829.	0.6	5

#	ARTICLE	IF	CITATIONS
1103	Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucemie (GIMURELL) study. <i>Leukemia and Lymphoma</i> , 2009, 50, 1475-1481.	0.6	1
1104	Influence of <i>MBL-2</i> mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2009, 50, 1283-1289.	0.6	6
1105	A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract. <i>Radiotherapy and Oncology</i> , 2009, 93, 492-497.	0.3	20
1106	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009, 374, 1512-1520.	6.3	588
1107	Standardised tumour, node and metastasis reporting of oncology CT scans. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2009, 53, 345-352.	0.9	4
1108	Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 381-385.	1.4	70
1109	Phase III Study to Evaluate Temozolomide Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3822-3829.	0.8	625
1110	Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 366-373.	1.0	13
1111	Rituximab Immunotherapy for Ocular Adnexal Lymphoma: Clinicopathologic Correlation With 5-Year Follow-Up. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2009, 25, 322-324.	0.4	9
1113	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009, 94, 1250-1258.	1.7	65
1114	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2009, 113, 6069-6076.	0.6	474
1115	High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. <i>Blood</i> , 2009, 113, 995-1001.	0.6	144
1116	Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. <i>Blood</i> , 2009, 113, 4885-4893.	0.6	217
1117	Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. <i>Blood</i> , 2009, 113, 1412-1421.	0.6	79
1118	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. <i>Blood</i> , 2009, 113, 4144-4152.	0.6	196
1119	Anti-idiotypic antibody response after vaccination correlates with better overall survival in follicular lymphoma. <i>Blood</i> , 2009, 113, 5743-5746.	0.6	49
1120	Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. <i>Blood</i> , 2009, 114, 4771-4776.	0.6	83
1122	Exhaled Nitric Oxide and Nitric Oxide Synthase Expression in Hodgkin's Disease. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 1027-1034.	1.0	9

#	ARTICLE	IF	CITATIONS
1123	Prediction of Lymph Node Manifestations in Malignant Lymphoma. <i>Journal of Computer Assisted Tomography</i> , 2010, 34, 564-569.	0.5	21
1124	Prediction and Monitoring of Therapeutic Response by Molecular Imaging. <i>Current Medical Imaging</i> , 2010, 6, 29-32.	0.4	0
1125	Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. <i>Aids</i> , 2010, 24, 851-856.	1.0	54
1126	A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2010, 3, 13-17.	0.6	13
1127	A Phase 2 Trial of Immunotherapy With Mitumprotimut-T (Id-KLH) and GM-CSF Following Rituximab in Follicular B-cell Lymphoma. <i>Journal of Immunotherapy</i> , 2010, 33, 178-184.	1.2	10
1128	Role of early PET in the management of diffuse large B-cell lymphoma. <i>Current Opinion in Oncology</i> , 2010, 22, 414-418.	1.1	17
1129	Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. <i>Haematologica</i> , 2010, 95, 1176-1182.	1.7	63
1131	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 288-334.	2.3	233
1132	Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. <i>Haematologica</i> , 2010, 95, 1496-1502.	1.7	16
1133	Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. <i>Blood</i> , 2010, 115, 3664-3670.	0.6	194
1134	Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2010, 115, 3008-3016.	0.6	254
1135	Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. <i>Blood</i> , 2010, 115, 475-480.	0.6	76
1136	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). <i>Blood</i> , 2010, 115, 1530-1533.	0.6	167
1137	The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 115, 3017-3024.	0.6	204
1138	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. <i>Haematologica</i> , 2010, 95, 1350-1357.	1.7	36
1139	Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. <i>International Journal of Hematology</i> , 2010, 91, 258-266.	0.7	20
1140	Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. <i>European Radiology</i> , 2010, 20, 2027-2038.	2.3	145
1141	Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 494-504.	3.3	78

#	ARTICLE	IF	CITATIONS
1142	Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1633-1642.	3.3	76
1143	A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil. <i>Annals of Hematology</i> , 2010, 89, 45-51.	0.8	7
1144	The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. <i>Annals of Hematology</i> , 2010, 89, 171-177.	0.8	26
1145	Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2010, 89, 263-272.	0.8	16
1146	Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2010, 89, 273-282.	0.8	6
1147	Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 571-577.	1.1	15
1148	Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Étude des Lymphomes de l'Adulte trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 781-790.	1.1	16
1149	Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 1039-1049.	1.1	62
1150	Plasma TNF- α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 131-141.	1.0	37
1151	Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 65-70.	1.2	22
1152	CHOP-21 for unfavorable Hodgkin's lymphoma. An exploratory study. <i>Medical Oncology</i> , 2010, 27, 262-267.	1.2	4
1153	Diffuse large B-cell lymphoma: experience from a tertiary care center in north India. <i>Medical Oncology</i> , 2010, 27, 310-318.	1.2	14
1154	Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma. <i>Medical Oncology</i> , 2010, 27, 798-806.	1.2	42
1155	Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia. <i>Medical Oncology</i> , 2010, 27, 820-825.	1.2	13
1156	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. <i>International Journal of Hematology</i> , 2010, 91, 456-463.	0.7	22
1157	Targeted treatment and new agents in peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2010, 92, 33-44.	0.7	26
1158	Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2010, 92, 563-570.	0.7	23
1159	Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. <i>International Journal of Hematology</i> , 2010, 92, 732-743.	0.7	37

#	ARTICLE	IF	CITATIONS
1160	Clinical analysis of 13 cases with Burkitt lymphoma or Burkitt-like lymphoma. <i>Clinical Oncology and Cancer Research</i> , 2010, 7, 110-115.	0.1	0
1161	Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. <i>Investigational New Drugs</i> , 2010, 28, 171-177.	1.2	10
1162	Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Investigational New Drugs</i> , 2010, 28, 516-522.	1.2	15
1164	Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. <i>BMC Cancer</i> , 2010, 10, 321.	1.1	73
1165	Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors. <i>BMC Cancer</i> , 2010, 10, 358.	1.1	32
1166	DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population. <i>Cancer Genetics and Cytogenetics</i> , 2010, 196, 31-37.	1.0	15
1167	Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2010, 198, 40-46.	1.0	41
1168	Serum concentration of <sc>L</sc>-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>European Journal of Haematology</i> , 2010, 84, 304-309.	1.1	70
1169	Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. <i>European Journal of Haematology</i> , 2010, 84, 310-315.	1.1	11
1170	THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. <i>European Journal of Haematology</i> , 2010, 84, 391-397.	1.1	19
1171	Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. <i>European Journal of Haematology</i> , 2010, 85, 321-328.	1.1	49
1172	Nodular, lymphocyte-predominant Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 631-639.	2.0	175
1173	Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. <i>Cancer</i> , 2010, 116, 852-862.	2.0	11
1174	Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 1495-1501.	2.0	30
1175	The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. <i>Cancer</i> , 2010, 116, 2201-2207.	2.0	89
1176	Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. <i>Cancer</i> , 2010, 116, 2655-2664.	2.0	55
1177	A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma. <i>Cancer</i> , 2010, 116, 3438-3446.	2.0	56
1178	Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. <i>Cancer</i> , 2010, 116, 4573-4579.	2.0	28

#	ARTICLE	IF	CITATIONS
1179	Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naïve, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden. <i>Cancer</i> , 2010, 116, 4299-4308.	2.0	15
1180	Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. <i>Cancer</i> , 2010, 116, 5667-5675.	2.0	14
1181	Marginal zone lymphomas. <i>Cancer</i> , 2010, 116, 4291-4298.	2.0	42
1182	Pretransplantation [¹⁸ F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. <i>Cancer</i> , 2010, 116, 5001-5011.	2.0	36
1183	Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 4541-4548.	2.0	88
1184	Phase I trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 5432-5439.	2.0	45
1185	A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2010, 85, 320-324.	2.0	197
1186	Primary pulmonary non-Hodgkin's lymphoma: A retrospective analysis of 29 cases in a Chinese population. <i>American Journal of Hematology</i> , 2010, 85, 523-525.	2.0	6
1187	Diffuse large B-cell lymphoma in the spinal epidural space: A study of the Osaka Lymphoma Study Group. <i>Pathology Research and Practice</i> , 2010, 206, 439-444.	1.0	11
1188	Detection of circulating lymphoma cells in patients with non-Hodgkin lymphoma using MAGE-A3 gene expression in peripheral blood. <i>Leukemia Research</i> , 2010, 34, 1127-1131.	0.4	9
1189	Imaging in pediatric patients: Time to think again about surveillance. <i>Pediatric Blood and Cancer</i> , 2010, 55, 407-413.	0.8	35
1190	Standard-versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. <i>Transfusion</i> , 2010, 50, 2432-2446.	0.8	14
1191	Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus document. <i>Veterinary and Comparative Oncology</i> , 2010, 8, 28-37.	0.8	210
1192	Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 367-375.	1.1	9
1193	Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. <i>Cancer Science</i> , 2010, 101, 196-200.	1.7	68
1194	First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors. <i>Cancer Science</i> , 2010, 101, 1199-1203.	1.7	48
1195	Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. <i>Cancer Science</i> , 2010, 101, 1309-1313.	1.7	66
1196	DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. <i>Cancer Science</i> , 2010, 101, 1722-1730.	1.7	77

#	ARTICLE	IF	CITATIONS
1197	Phase I study of inotuzumab ozogamicin (CMC544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. <i>Cancer Science</i> , 2010, 101, 1840-1845.	1.7	55
1198	Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>Cancer Science</i> , 2010, 101, 2054-2058.	1.7	35
1199	Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>Cancer Science</i> , 2010, 101, 2059-2064.	1.7	61
1200	Stage IV marginal zone B-cell lymphoma " prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Cancer Science</i> , 2010, 101, 2443-2447.	1.7	8
1201	Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. <i>Cancer Science</i> , 2010, 101, 2579-2585.	1.7	14
1202	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). <i>British Journal of Haematology</i> , 2010, 148, 235-244.	1.2	38
1203	Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 480-482.	1.2	69
1204	High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>British Journal of Haematology</i> , 2010, 149, 560-568.	1.2	71
1205	Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. <i>British Journal of Haematology</i> , 2010, 150, 226-229.	1.2	72
1206	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. <i>British Journal of Haematology</i> , 2010, 150, 170-178.	1.2	44
1207	Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. <i>British Journal of Haematology</i> , 2010, 150, 189-195.	1.2	59
1208	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 200-208.	1.2	213
1209	Phase II trial of zanolimumab (HuMaxCD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 565-573.	1.2	73
1210	Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2010, 151, 346-353.	1.2	63
1211	Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. <i>British Journal of Cancer</i> , 2010, 102, 673-677.	2.9	73
1212	A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2010, 103, 1783-1787.	2.9	125
1215	Accuracy and Relative Value of Bone Marrow Aspiration in the Detection of Lymphoid Infiltration in non-Hodgkin Lymphoma. <i>Tumori</i> , 2010, 96, 24-27.	0.6	14
1216	Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2010, 1, 733-738.	0.8	8

#	ARTICLE	IF	CITATIONS
1217	Whole-body diffusion-weighted imaging in lymphoma. <i>Cancer Imaging</i> , 2010, 10, S172-S178.	1.2	36
1218	Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. <i>The Korean Journal of Hematology</i> , 2010, 45, 253.	0.7	7
1219	Prognostic Factors in Follicular Lymphoma: The Importance of beta-2 Microglobulin. <i>Tumori</i> , 2010, 96, 117-121.	0.6	10
1220	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3709-3716.	0.8	106
1221	Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. <i>Annals of Oncology</i> , 2010, 21, 860-863.	0.6	162
1222	Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 1046-1052.	0.6	182
1223	Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 2578-2585.	0.6	687
1224	High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis. <i>Annals of Oncology</i> , 2010, 21, 1064-1071.	0.6	14
1225	Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1591-1598.	0.8	351
1226	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 412-417.	0.8	75
1227	Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary. <i>Clinical Cancer Research</i> , 2010, 16, 4921-4927.	3.2	51
1228	Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease. <i>Journal of Clinical Oncology</i> , 2010, 28, 3701-3708.	0.8	195
1229	High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 406-414.	0.6	16
1230	Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes. <i>Clinical Cancer Research</i> , 2010, 16, 719-726.	3.2	46
1231	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience. <i>Acta Haematologica</i> , 2010, 123, 48-54.	0.7	15
1232	The Significance of Bone Marrow Involvement in Aggressive Lymphomas: A Retrospective Comparison of Clinical Outcomes between Peripheral T Cell Lymphoma and Diffuse Large B Cell Lymphoma in China. <i>Acta Haematologica</i> , 2010, 124, 239-244.	0.7	7
1233	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2085-2093.	0.8	306
1234	Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1415-1421.	0.8	71

#	ARTICLE	IF	CITATIONS
1235	Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3987-3993.	0.8	169
1236	Temsirolimus Has Activity in Non-â€“Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2010, 28, 4740-4746.	0.8	181
1237	Improvement of Early ¹⁸ F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1857-1862.	2.8	86
1238	High-Dose Therapy and Autologous Stem-Cell Transplantation in WaldenstrÃ¶m Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 2227-2232.	0.8	131
1239	Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 4184-4190.	0.8	1,331
1240	Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. <i>Leukemia and Lymphoma</i> , 2010, 51, 747-755.	0.6	52
1241	Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-â€“intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. <i>Leukemia and Lymphoma</i> , 2010, 51, 1668-1677.	0.6	2
1242	Assessment of Metabolic Response to Radioimmunotherapy with ⁹⁰ Y-â€“Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-â€“Hodgkin Lymphoma. <i>Radiology</i> , 2010, 254, 245-252.	3.6	29
1243	Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1113-1127.	1.9	12
1244	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. <i>Blood</i> , 2010, 116, 2040-2045.	0.6	1,193
1245	Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. <i>Leukemia and Lymphoma</i> , 2010, 51, 399-405.	0.6	19
1246	Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas. <i>Clinical Cancer Research</i> , 2010, 16, 5892-5899.	3.2	87
1247	Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. <i>Annals of Oncology</i> , 2010, 21, 1032-1040.	0.6	228
1248	Nonpegylated liposomal doxorubicin (Myocetâ„¢) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO18 trial. <i>Annals of Oncology</i> , 2010, 21, 1492-1499.	0.6	81
1249	Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2010, 28, 418-423.	0.8	84
1250	Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. <i>Neuro-Oncology</i> , 2010, 12, 409-417.	0.6	57
1251	Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-13.	3.3	29
1252	Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. <i>Annals of Oncology</i> , 2010, 21, 1870-1876.	0.6	119

#	ARTICLE	IF	CITATIONS
1253	Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. <i>Annals of Oncology</i> , 2010, 21, 833-841.	0.6	23
1254	Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Response Assessment Before High-Dose Chemotherapy for Lymphoma: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2010, 15, 750-759.	1.9	50
1255	Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2010, 21, 1891-1897.	0.6	12
1256	Overcoming Drug Resistance in Mantle Cell Lymphoma Using a Combination of Dose-Dense and Intense Therapy. <i>Cancer Investigation</i> , 2010, 28, 654-660.	0.6	2
1257	High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2010, 21, 2255-2261.	0.6	30
1258	A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2010, 51, 447-455.	0.6	29
1259	Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. <i>Bone Marrow Transplantation</i> , 2010, 45, 1147-1153.	1.3	44
1260	Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. <i>Annals of Oncology</i> , 2010, 21, 1217-1221.	0.6	22
1261	Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2010, 3, 30.	6.9	16
1262	Rituximab. <i>Drugs</i> , 2010, 70, 1445-1476.	4.9	163
1263	Brief-Duration Rituximab/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 44-50.	0.2	30
1264	The Role of Histone Deacetylase Inhibitors in the Treatment of Patients With Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 98-109.	0.2	25
1265	Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 110-117.	0.2	20
1266	ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 125-128.	0.2	21
1267	Yttrium-90 Ibritumomab Tiuxetan as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 258-261.	0.2	12
1268	Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 262-269.	0.2	52
1269	Surveillance Computed Tomography Scans for Patients With Lymphoma: Is the Risk Worth the Benefits?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 270-277.	0.2	34
1270	Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 379-384.	0.2	11

#	ARTICLE	IF	CITATIONS
1271	Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 452-457.	0.2	50
1272	Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5). <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 13-19.	0.7	129
1273	Treatment of Hodgkin Lymphoma. , 2010, , 367-389.		2
1274	Imaging Evaluation of Mediastinal Masses in Infants and Children. , 2010, , 381-399.		1
1275	Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2010, 21, 126-132.	0.6	85
1276	Retroperitoneal neoplasms within the perirenal space in infants and children: Differentiation of renal and non-renal origin in enhanced CT images. <i>European Journal of Radiology</i> , 2010, 75, 279-286.	1.2	16
1277	Front-line High-Dose Chemotherapy with Rituximab Showed Excellent Long-Term Survival in Adults with Aggressive Large B-Cell Lymphoma: Final Results of a Phase II GOELAMS Study. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 672-677.	2.0	15
1278	HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma (NHL). <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1302-1308.	2.0	60
1279	Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. <i>Cell</i> , 2010, 142, 699-713.	13.5	894
1280	Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. <i>Lancet Oncology</i> , The, 2010, 11, 1149-1159.	5.1	696
1281	Measuring the "Unmeasurable". <i>Academic Radiology</i> , 2010, 17, 1175-1185.	1.3	5
1282	Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010, 51, 1225-1232.	0.6	36
1283	Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 2208-2214.	0.6	15
1284	Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. <i>Leukemia and Lymphoma</i> , 2010, 51, 1241-1250.	0.6	16
1285	FDG PET/CT versus CT, MR Imaging, and 67Ga Scintigraphy in the Posttherapy Evaluation of Malignant Lymphoma. <i>Radiographics</i> , 2010, 30, 939-957.	1.4	45
1286	Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 1649-1657.	0.6	42
1287	Phase II study of autologous stem cell transplant using busulfan+melfalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 641-649.	0.6	9
1288	Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. <i>Blood</i> , 2010, 116, 5119-5125.	0.6	123

#	ARTICLE	IF	CITATIONS
1289	Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. <i>Annals of Oncology</i> , 2010, 21, 1222-1227.	0.6	40
1290	Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. <i>Leukemia and Lymphoma</i> , 2010, 51, 1523-1529.	0.6	51
1291	Pralatrexate: basic understanding and clinical development. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1705-1714.	0.9	23
1292	Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 1217-1224.	0.6	65
1293	Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 620-628.	0.6	21
1294	Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1474-1480.	0.6	32
1295	Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1222-1229.	0.6	26
1296	Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. <i>Leukemia and Lymphoma</i> , 2011, 52, 1255-1261.	0.6	44
1297	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	0.8	190
1298	Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 2082-2089.	0.6	9
1299	Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. <i>Leukemia and Lymphoma</i> , 2011, 52, 833-841.	0.6	16
1300	Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. <i>Leukemia and Lymphoma</i> , 2011, 52, 1463-1473.	0.6	37
1301	Phase II study of the tetrahydropyranil adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 629-634.	0.6	25
1302	Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjögren's Syndrome: A Retrospective Clinical Study. <i>Journal of Rheumatology</i> , 2011, 38, 2198-2208.	1.0	78
1303	Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. <i>Leukemia and Lymphoma</i> , 2011, 52, 2124-2129.	0.6	12
1304	Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2011, 4, 157-160.	0.6	11
1305	Role of Functional Imaging in the Management of Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1844-1854.	0.8	251
1306	Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. <i>Annals of Oncology</i> , 2011, 22, 664-670.	0.6	177

#	ARTICLE	IF	CITATIONS
1308	Treatment of Indolent Lymphoma in Germany - Results of a Representative Population-Based Survey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 204-211.	0.2	9
1309	90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 212-218.	0.2	52
1310	Chemoresistance As a Function of the Pretherapy Tumor Burden and the Chemotherapy Regimen Administered: Differences Observed With 2 Current Chemotherapy Regimens for Advanced Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 396-402.	0.2	11
1311	FDG-PET/CT in Lymphoma. <i>Methods in Molecular Biology</i> , 2011, 727, 1-19.	0.4	36
1312	Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma. <i>Clinical Pharmacokinetics</i> , 2011, 50, 781-791.	1.6	31
1313	Target Definitions for Hodgkin Lymphoma: The Involved Node Radiation Field Concept. , 2011, , 91-122.		0
1314	The Role of Imaging in Radiotherapy for Hodgkin Lymphoma. , 2011, , 81-89.		1
1315	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 4053-4061.	0.6	136
1316	Radiotherapy for Hodgkin Lymphoma. , 2011, , .		3
1317	The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2011, 179, 2601-2610.	1.9	57
1318	Imaging in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 165-177.	0.7	15
1319	Perspective of clinical research in follicular NHL: Interaction between science and industry. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 313-321.	0.7	1
1320	Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 412-420.	2.0	40
1321	A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Primary Refractory and Relapsed and Refractory Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 987-994.	2.0	11
1322	A Phase I Trial: Dose Escalation of Melphalan in the "BEAM" Regimen Using Amifostine Cytoprotection. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1033-1042.	2.0	7
1323	Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1051-1057.	2.0	85
1324	Long-Term Follow-Up of Tandem High-Dose Therapy with Autologous Stem Cell Support for Adults with High-Risk Age-Adjusted International Prognostic Index Aggressive non-Hodgkin Lymphomas: A GOELAMS Pilot Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 935-940.	2.0	7
1325	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1-14.	0.6	16

#	ARTICLE	IF	CITATIONS
1326	Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Human Pathology</i> , 2011, 42, 1459-1466.	1.1	44
1328	TEP/TDM au FDG et bilan initial des lymphomes: du diagnostic au pronostic. <i>Medecine Nucleaire</i> , 2011, 35, 8-20.	0.2	2
1329	Consolidation par 90Y-epratuzumab en fractionnement dans le lymphome B diffus à grandes cellules: résultats préliminaires d'une étude de phase II. <i>Medecine Nucleaire</i> , 2011, 35, 478-486.	0.2	0
1330	Évaluation de la réponse thérapeutique par tomographie par émission de positons (TEP) au 18fluoro-désoxyglucose (FDG) en oncologie-hématologie. <i>Medecine Nucleaire</i> , 2011, 35, 600-607.	0.2	5
1331	Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly. <i>Journal of Geriatric Oncology</i> , 2011, 2, 36-44.	0.5	36
1332	Treatment and outcome in non-Hodgkin's lymphoma patients with and without prevalent diabetes mellitus in a population-based cancer registry. <i>Journal of Geriatric Oncology</i> , 2011, 2, 239-245.	0.5	4
1333	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. <i>Lancet Oncology</i> , The, 2011, 12, 361-368.	5.1	151
1334	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 460-468.	5.1	420
1335	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naïve or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 773-784.	5.1	98
1336	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. <i>Lancet Oncology</i> , The, 2011, 12, 1013-1022.	5.1	633
1337	Palliation by Low-Dose Local Radiation Therapy for Indolent Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e781-e786.	0.4	46
1338	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. <i>Lancet</i> , The, 2011, 377, 42-51.	6.3	957
1339	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNHO3-2B): an open-label randomised phase 3 trial. <i>Lancet</i> , The, 2011, 378, 1858-1867.	6.3	311
1340	Treatment Outcome of Adult Burkitt Lymphoma in Japanese Patients with Modified LMB Protocol : A Single Center Retrospective Analysis. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2011, 51, 109-114.	0.3	2
1341	Romidepsin in the treatment of cutaneous T-cell lymphoma. <i>Journal of Blood Medicine</i> , 2011, 2, 37.	0.7	27
1342	Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma. <i>Journal of Korean Medical Science</i> , 2011, 26, 551.	1.1	6
1343	Neck Nodal Disease. <i>Medical Radiology</i> , 2011, , 315-340.	0.0	0
1344	Radiation Therapy for Hodgkin Lymphoma and Other Hematopoietic Disorders. <i>Medical Radiology</i> , 2011, , 1099-1140.	0.0	1

#	ARTICLE	IF	CITATIONS
1346	Fc γ RIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. <i>Neoplasma</i> , 2011, 58, 263-270.	0.7	19
1347	Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen. <i>Chinese Journal of Cancer</i> , 2011, 30, 731-738.	4.9	9
1348	Neck Lymphoma. <i>Medical Radiology</i> , 2011, , 341-361.	0.0	0
1349	Clinical Trial Risk in Non-Hodgkin's Lymphoma: Endpoint and Target Selection. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2011, 14, 227.	0.9	18
1353	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 117, 2405-2413.	0.6	30
1354	Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. <i>Blood</i> , 2011, 117, 45-52.	0.6	71
1355	Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma. <i>Blood</i> , 2011, 117, 1483-1491.	0.6	31
1356	How I treat relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 4208-4217.	0.6	126
1357	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 5827-5834.	0.6	428
1358	Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. <i>Blood</i> , 2011, 117, 5314-5320.	0.6	56
1359	90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. <i>Blood</i> , 2011, 118, 1132-1139.	0.6	62
1360	Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 6638-6649.	0.6	79
1361	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. <i>Blood</i> , 2011, 118, 4882-4889.	0.6	37
1362	Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. <i>Blood</i> , 2011, 118, 5371-5379.	0.6	66
1363	Prospective measurement of Epstein-Barr virus DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , 2011, 118, 6018-6022.	0.6	175
1364	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , 2011, 96, 1136-1143.	1.7	84
1365	Significance of aldehyde dehydrogenase 1 expression in stromal cells of diffuse large B-cell lymphoma. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 591-594.	0.8	5
1366	Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma. <i>PLoS ONE</i> , 2011, 6, e16408.	1.1	86

#	ARTICLE	IF	CITATIONS
1367	Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. <i>Haematologica</i> , 2011, 96, 1008-1014.	1.7	76
1369	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 484-560.	2.3	161
1370	Whole-Body Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Treatment Response Assessment in Patients With Diffuse Large B-Cell Lymphoma. <i>Investigative Radiology</i> , 2011, 46, 341-349.	3.5	73
1371	Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study. <i>Cancer Science</i> , 2011, 102, 414-418.	1.7	9
1372	Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. <i>Cancer Science</i> , 2011, 102, 432-438.	1.7	25
1373	Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study. <i>Cancer Science</i> , 2011, 102, 1698-1705.	1.7	21
1374	Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. <i>British Journal of Haematology</i> , 2011, 153, 191-198.	1.2	21
1375	The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. <i>British Journal of Haematology</i> , 2011, 154, 477-481.	1.2	42
1376	Vincristine induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. <i>British Journal of Haematology</i> , 2011, 155, 190-197.	1.2	48
1377	Chemotherapy only for localized Hodgkin lymphoma. <i>Journal of Internal Medicine</i> , 2011, 270, 197-205.	2.7	9
1378	Radioimmunotherapy with ¹³¹ I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 136-145.	0.7	22
1379	A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. <i>Leukemia</i> , 2011, 25, 341-347.	3.3	287
1380	Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma - EORTC lymphoma group protocol 20021 (EudraCT) Tj ETQq0 0.0 rgBT /Overlock 10		
1381	Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2011, 86, 117-123.	1.1	7
1382	Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL). <i>European Journal of Haematology</i> , 2011, 86, 246-255.	1.1	23
1383	Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. <i>European Journal of Haematology</i> , 2011, 87, 217-227.	1.1	27
1384	Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. <i>European Journal of Haematology</i> , 2011, 87, 434-440.	1.1	29
1385	Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience. <i>International Journal of Nursing Studies</i> , 2011, 48, 926-932.	2.5	39

#	ARTICLE	IF	CITATIONS
1386	Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009). <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 393-410.	2.0	33
1387	Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. <i>Annals of Oncology</i> , 2011, 22, 1839-1844.	0.6	81
1388	Early Treatment Response Evaluation in Patients with Diffuse Large B-Cell Lymphoma—A Pilot Study Comparing Volumetric MRI and PET/CT. <i>Molecular Imaging and Biology</i> , 2011, 13, 785-792.	1.3	18
1389	Renal complications of Castleman's disease: report of two cases and analysis of 75 cases. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 921-926.	0.7	22
1390	Traitement de maintenance des lymphomes malins non hodgkiniens. <i>Oncologie</i> , 2011, 13, 543-547.	0.2	0
1391	Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1064-1071.	3.3	87
1392	Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Annals of Hematology</i> , 2011, 90, 323-330.	0.8	10
1393	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	0.8	28
1394	Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Annals of Hematology</i> , 2011, 90, 409-416.	0.8	77
1395	Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. <i>Annals of Hematology</i> , 2011, 90, 539-546.	0.8	26
1396	Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with 131I-anti-CD20 antibody and stem cell rescue. <i>Annals of Hematology</i> , 2011, 90, 1307-1315.	0.8	15
1397	Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. <i>Annals of Hematology</i> , 2011, 90, 1409-1418.	0.8	7
1398	Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1439-1447.	1.1	41
1399	Prognostic significance of biochemical markers in African Burkitt's lymphoma. <i>Clinical and Translational Oncology</i> , 2011, 13, 731-736.	1.2	3
1400	Impact of FDG-PET/CT in the management of lymphoma. <i>Annals of Nuclear Medicine</i> , 2011, 25, 701-716.	1.2	39
1401	An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma. <i>International Journal of Hematology</i> , 2011, 94, 90-96.	0.7	10
1402	Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. <i>International Journal of Hematology</i> , 2011, 94, 178-184.	0.7	19
1403	Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP. <i>Pathology and Oncology Research</i> , 2011, 17, 243-247.	0.9	13

#	ARTICLE	IF	CITATIONS
1404	Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. <i>BMC Cancer</i> , 2011, 11, 87.	1.1	27
1405	Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. <i>BMC Medicine</i> , 2011, 9, 36.	2.3	78
1406	Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. <i>Journal of Hematology and Oncology</i> , 2011, 4, 34.	6.9	37
1407	Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 515-518.	2.0	1
1408	Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma: a pilot study: comparison with ² -deoxy- ² -fluoro- ¹⁸ F-glucose positron emission tomography/computed tomography. <i>NMR in Biomedicine</i> , 2011, 24, 1181-1190.	1.6	71
1409	Midtreatment ¹⁸ F-fluorodeoxyglucose positron emission tomography in aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 1010-1018.	2.0	60
1410	Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 964-973.	2.0	41
1411	Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. <i>Cancer</i> , 2011, 117, 1490-1497.	2.0	15
1412	Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. <i>Cancer</i> , 2011, 117, 2442-2451.	2.0	52
1413	Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 5067-5073.	2.0	17
1414	Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy. <i>Cancer</i> , 2011, 117, 5203-5211.	2.0	58
1415	Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. <i>Hematological Oncology</i> , 2011, 29, 5-9.	0.8	27
1416	LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. <i>Hematological Oncology</i> , 2011, 29, 75-80.	0.8	9
1417	Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after ⁹⁰ Y-ibritumomab tiuxetan. <i>Hematological Oncology</i> , 2011, 29, 131-138.	0.8	9
1418	External Beam Radiotherapy Followed by ⁹⁰ Y Ibritumomab Tiuxetan in Relapsed or Refractory Bulky Follicular Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1124-1130.	0.4	20
1419	Whole-body FSE STIR MR imaging of lymphoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2011, 42, 77-85.	0.3	1
1420	BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: A single center comparative analysis of efficacy and toxicity. <i>Leukemia Research</i> , 2011, 35, 183-187.	0.4	36
1421	Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. <i>Leukemia Research</i> , 2011, 35, 431-437.	0.4	8

#	ARTICLE	IF	CITATIONS
1422	Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. <i>Haematologica</i> , 2011, 96, 269-276.	1.7	173
1423	Predictive Value of Initial ¹⁸ F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment. <i>Journal of Nuclear Medicine</i> , 2011, 52, 690-696.	2.8	65
1424	Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma. <i>Annals of Oncology</i> , 2011, 22, 390-396.	0.6	21
1425	Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. <i>Leukemia and Lymphoma</i> , 2011, 52, 1675-1680.	0.6	38
1426	Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. <i>Bone Marrow Transplantation</i> , 2011, 46, 393-399.	1.3	24
1427	Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4410-4416.	0.8	532
1428	ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned. <i>New England Journal of Medicine</i> , 2011, 365, 203-212.	13.9	379
1429	Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. <i>Leukemia and Lymphoma</i> , 2011, 52, 597-603.	0.6	45
1430	Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1668-1674.	0.6	59
1431	Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. <i>Acta Radiologica</i> , 2011, 52, 173-180.	0.5	92
1432	Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin. <i>Clinical Cancer Research</i> , 2011, 17, 363-371.	3.2	81
1433	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2787-2794.	0.8	230
1434	Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate+Cytarabine Combination. <i>Oncologist</i> , 2011, 16, 336-341.	1.9	30
1435	Intensified alemtuzumab+CHOP therapy for peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2011, 22, 1595-1600.	0.6	69
1436	Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens. <i>Journal of Immunology</i> , 2011, 186, 6044-6055.	0.4	93
1437	Development and Measurement of Guideline-Based Indicators for Patients With Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1436-1444.	0.8	34
1438	A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). <i>Leukemia and Lymphoma</i> , 2011, 52, 394-399.	0.6	58
1439	Tissue Microarrays in Diffuse Large B-Cell Lymphomas. <i>International Journal of Surgical Pathology</i> , 2011, 19, 417-424.	0.4	1

#	ARTICLE	IF	CITATIONS
1440	Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography. <i>Advances in Hematology</i> , 2011, 2011, 1-12.	0.6	12
1441	Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas. <i>Advances in Hematology</i> , 2011, 2011, 1-6.	0.6	17
1442	Clinicopathologic Characteristics of CD99-Positive Diffuse Large B-Cell Lymphoma. <i>Acta Haematologica</i> , 2011, 125, 167-174.	0.7	14
1443	Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1182-1189.	0.8	535
1444	Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3990-3998.	0.8	59
1445	Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. <i>Journal of Clinical Oncology</i> , 2011, 29, 3194-3200.	0.8	176
1446	Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms. <i>Clinical Cancer Research</i> , 2011, 17, 3388-3397.	3.2	49
1447	Immunophenotypic characteristics and clinical relevance of CD56+ and CD56 ⁺ extranodal nasal-type natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 417-424.	0.6	25
1448	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	0.8	70
1449	The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. <i>Annals of Oncology</i> , 2011, 22, 405-410.	0.6	29
1450	Diffuse large B-cell lymphoma primary of lung. <i>Hematology</i> , 2011, 16, 110-112.	0.7	40
1451	Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. <i>Annals of Oncology</i> , 2011, 22, 671-680.	0.6	29
1452	Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. <i>Haematologica</i> , 2011, 96, 567-573.	1.7	47
1453	Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2011, 17, 2493-2501.	3.2	27
1454	Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 690-697.	0.8	300
1455	Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1509-1516.	0.6	22
1456	Computational approaches to assist in the evaluation of cancer treatment response. <i>Imaging in Medicine</i> , 2011, 3, 233-246.	0.0	3
1457	An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2011, 22, 1622-1627.	0.6	361

#	ARTICLE	IF	CITATIONS
1458	Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. <i>Annals of Oncology</i> , 2011, 22, 149-155.	0.6	82
1459	A Long-term Follow-up Study of Prospective 80%-dose CHOP Followed by Involved-field Radiotherapy in Elderly Lymphoma Patients. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 764-769.	0.6	1
1460	Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 814-824.	0.8	151
1461	Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. <i>Annals of Oncology</i> , 2011, 22, 1392-1403.	0.6	38
1462	PET imaging in a longitudinal non-Hodgkin's lymphoma study: association with tumor volume. <i>Acta Radiologica</i> , 2011, 52, 995-1002.	0.5	6
1463	Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1198-1203.	0.8	195
1464	A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. <i>Clinical Cancer Research</i> , 2011, 17, 6831-6839.	3.2	123
1465	T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab. <i>Clinical Cancer Research</i> , 2011, 17, 4136-4144.	3.2	42
1466	Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2011, 46, 827-834.	1.3	15
1467	High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2011, 46, 1339-1344.	1.3	34
1468	Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. <i>Leukemia and Lymphoma</i> , 2011, 52, 2270-2275.	0.6	32
1469	Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3396-3401.	0.8	33
1470	Usefulness of semi-automatic volumetry compared to established linear measurements in predicting lymph node metastases in MSCT. <i>Acta Radiologica</i> , 2011, 52, 540-546.	0.5	8
1471	Usefulness of Flow Cytometric Immunophenotyping for Bone Marrow Staging in Patients With Mantle Cell Lymphoma After Therapy. <i>American Journal of Clinical Pathology</i> , 2012, 137, 634-640.	0.4	6
1472	Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012, 104, 18-28.	3.0	74
1473	Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. <i>Annals of Oncology</i> , 2012, 23, 1555-1561.	0.6	39
1474	Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. <i>Annals of Oncology</i> , 2012, 23, 2356-2362.	0.6	59
1475	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90â€”Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126.	0.8	86

#	ARTICLE	IF	CITATIONS
1476	Should Patients With Aggressive Peripheral T-Cell Lymphoma All Be Treated the Same?. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 445-449.	1.0	6
1477	A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 4830-4840.	3.2	128
1478	Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2012, 97, 310-317.	1.7	194
1479	Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 631-636.	0.8	571
1480	Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2012, 17, 838-846.	1.9	114
1481	Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγR1/3a-Genotyped Patients with Previously Treated Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 1395-1403.	3.2	61
1482	A phase II study of rituximab combined with pirarubicin, cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 247-253.	0.6	2
1483	The extent of cutaneous lesions predicts outcome in extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract with secondary cutaneous involvement. <i>Leukemia and Lymphoma</i> , 2012, 53, 855-861.	0.6	12
1484	Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. <i>Leukemia and Lymphoma</i> , 2012, 53, 1494-1500.	0.6	22
1485	Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1859-1866.	0.6	1
1486	Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2012, 47, 82-87.	1.3	8
1487	Interim [¹⁸ F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. <i>Leukemia and Lymphoma</i> , 2012, 53, 2143-2150.	0.6	54
1488	Pediatric Nonlymphoblastic Non-Hodgkin Lymphoma: Baseline, Interim, and Posttreatment PET/CT versus Contrast-enhanced CT for Evaluation—A Prospective Study. <i>Radiology</i> , 2012, 262, 956-968.	3.6	51
1489	The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant. <i>Expert Review of Hematology</i> , 2012, 5, 483-486.	1.0	6
1490	Rituximab in treatment of primary gastric diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 2175-2181.	0.6	10
1491	High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1306-1310.	0.6	12
1492	Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d'Étude des Lymphomes de l'Adulte Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 3939-3946.	0.8	162
1493	Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma. <i>Leukemia</i> , 2012, 26, 1046-1052.	3.3	20

#	ARTICLE	IF	CITATIONS
1494	Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. <i>Leukemia</i> , 2012, 26, 520-526.	3.3	129
1495	How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?. <i>Blood Cancer Journal</i> , 2012, 2, e93-e93.	2.8	14
1496	A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. <i>Leukemia and Lymphoma</i> , 2012, 53, 259-262.	0.6	69
1497	Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. <i>Journal of Clinical Oncology</i> , 2012, 30, 3093-3099.	0.8	490
1498	Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1143-1145.	0.6	22
1499	Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. <i>Leukemia and Lymphoma</i> , 2012, 53, 57-63.	0.6	20
1500	Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. <i>Oncologist</i> , 2012, 17, 663-672.	1.9	52
1501	Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. <i>Leukemia and Lymphoma</i> , 2012, 53, 836-841.	0.6	34
1502	A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 254-258.	0.6	27
1503	Clinical Significance of Alk-1 Gene Abnormalities in Diffuse Large Cell Lymphoma. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S9920.	0.6	2
1504	18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma. <i>ISRN Hematology</i> , 2012, 2012, 1-9.	1.6	3
1505	Clinical Trials and Treatment of ATL. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-12.	2.0	29
1506	HTLV-1 Infection and Its Associated Diseases. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-1.	2.0	12
1507	Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma. <i>Cancer Imaging</i> , 2012, 12, 403-408.	1.2	35
1508	Frequency and Clinical Relevance of Multidrug Resistance Protein Expressions in Lymphomas. <i>Turkish Journal of Haematology</i> , 2012, 29, 120-125.	0.2	2
1509	Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin's lymphoma in a developing country?. <i>Hematology</i> , 2012, 17, 193-197.	0.7	6
1510	Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST. <i>American Journal of Roentgenology</i> , 2012, 198, 737-745.	1.0	169
1511	Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients?. <i>Transplantation</i> , 2012, 94, 295-301.	0.5	12

#	ARTICLE	IF	CITATIONS
1512	Primary Bone Marrow Lymphoma. American Journal of Surgical Pathology, 2012, 36, 296-304.	2.1	59
1513	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 2012, 97, 1085-1091.	1.7	94
1514	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica, 2012, 97, 1431-1438.	1.7	96
1515	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood, 2012, 119, 3698-3704.	0.6	125
1516	Nonmyeloablative allogeneic transplantation with or without ⁹⁰ yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood, 2012, 119, 6373-6378.	0.6	97
1517	A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood, 2012, 120, 1210-1217.	0.6	58
1518	Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood, 2012, 119, 2171-2172.	0.6	64
1519	Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood, 2012, 119, 6072-6079.	0.6	23
1520	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood, 2012, 119, 5126-5132.	0.6	175
1521	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood, 2012, 119, 5118-5125.	0.6	145
1522	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood, 2012, 120, 2650-2657.	0.6	56
1523	Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood, 2012, 120, 2003-2010.	0.6	93
1524	Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood, 2012, 120, 3858-3860.	0.6	58
1525	Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica, 2012, 97, 1594-1602.	1.7	76
1526	Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20 ⁺ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. Journal of Clinical Oncology, 2012, 30, 4462-4469.	0.8	248
1527	HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. Journal of Clinical Oncology, 2012, 30, 4111-4116.	0.8	145
1528	A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma. European Journal of Haematology, 2012, 89, 385-394.	1.1	19
1529	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research, 2012, 18, 3396-3406.	3.2	188

#	ARTICLE	IF	CITATIONS
1530	Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a <sc>UK</sc> phase II study suggest activity and possible gender differences. <i>British Journal of Haematology</i> , 2012, 159, 154-163.	1.2	85
1531	Therapy-related classical <sc>H</sc>odgkin lymphoma after a primary haematological malignancy: a report on 13 cases. <i>British Journal of Haematology</i> , 2012, 158, 644-648.	1.2	4
1532	Treatment of Older Patients with Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2012, 367, 520-531.	13.9	465
1533	Impact of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. <i>Journal of Clinical Oncology</i> , 2012, 30, 4317-4322.	0.8	168
1534	Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432. <i>Clinical Cancer Research</i> , 2012, 18, 2954-2963.	3.2	68
1535	Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). <i>Lancet Oncology</i> , The, 2012, 13, 1250-1259.	5.1	217
1536	<i>Chlamydia Psittaci</i> Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2988-2994.	0.8	167
1537	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. <i>Lancet Oncology</i> , The, 2012, 13, 716-723.	5.1	274
1538	Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 696-706.	5.1	109
1539	Enfermedad o linfoma de Hodgkin. <i>EMC - Tratado De Medicina</i> , 2012, 16, 1-5.	0.0	0
1540	Linfomas no Hodgkin: diagnóstico y tratamiento. <i>EMC - Tratado De Medicina</i> , 2012, 16, 1-6.	0.0	0
1541	Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2367-2373.	2.0	7
1543	Dosimetric and Clinical Outcomes of Involved-Field Intensity-Modulated Radiotherapy After Chemotherapy for Early-Stage Hodgkin's Lymphoma With Mediastinal Involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 210-216.	0.4	23
1544	Role of Salvage Radiation Therapy for Patients With Relapsed or Refractory Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e329-e335.	0.4	35
1545	Pralatrexate: A novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 275-283.	0.5	8
1546	FDG-PET in Lymphoma: Nuclear Medicine Perspective. <i>PET Clinics</i> , 2012, 7, 21-33.	1.5	0
1547	The Evolving Role of Medical Imaging in Lymphoma Management: The Clinician's Perspective. <i>PET Clinics</i> , 2012, 7, 35-46.	1.5	1
1548	Role of Positron Emission Tomography with Fluorodeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma. <i>PET Clinics</i> , 2012, 7, 57-65.	1.5	2

#	ARTICLE	IF	CITATIONS
1549	Pharmacokinetic-Directed High-Dose Busulfan Combined with Cyclophosphamide and Etoposide Results in Predictable Drug Levels and Durable Long-Term Survival in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1287-1294.	2.0	31
1550	Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 725-727.	0.6	3
1551	Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. <i>Leukemia and Lymphoma</i> , 2012, 53, 43-49.	0.6	36
1552	Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1882-1888.	0.6	43
1553	Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia. <i>Annals of Oncology</i> , 2012, 23, 2386-2390.	0.6	11
1554	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	0.6	301
1555	Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 1945-1948.	0.6	12
1556	Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. <i>Blood</i> , 2012, 119, 4597-4607.	0.6	278
1557	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. <i>Haematologica</i> , 2012, 97, 758-765.	1.7	153
1558	Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2776-2782.	0.8	162
1559	Head and Neck Cancer Imaging. <i>Medical Radiology</i> , 2012, , .	0.0	17
1560	Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. <i>Leukemia and Lymphoma</i> , 2012, 53, 394-399.	0.6	22
1561	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Leukemia</i> , 2012, 26, 2103-2113.	3.3	301
1562	R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. <i>Annals of Oncology</i> , 2012, 23, 147-153.	0.6	60
1563	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. <i>Annals of Oncology</i> , 2012, 23, 2380-2385.	0.6	48
1564	A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders. <i>Clinical Cancer Research</i> , 2012, 18, 5752-5760.	3.2	64
1565	Matched-Cohort Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy versus Total Body Irradiation-Based Conditioning for Poor-Risk Diffuse Large Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 441-450.	2.0	34
1566	Tandem Autologous Allogeneic Nonmyeloablative Sibling Transplantation in Relapsed Follicular Lymphoma Leads to Impressive Progression-Free Survival with Minimal Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 951-957.	2.0	23

#	ARTICLE	IF	CITATIONS
1567	18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: A systematic review and meta-analysis. <i>European Journal of Radiology</i> , 2012, 81, 303-311.	1.2	62
1568	Targeting the B cell receptor pathway in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2362-2370.	0.6	71
1569	Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). <i>Journal of Hematology and Oncology</i> , 2012, 5, 49.	6.9	83
1570	Homozygous A polymorphism of the complement C1qA 276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. <i>Journal of Hematology and Oncology</i> , 2012, 5, 51.	6.9	25
1571	Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. <i>Journal of Hematology and Oncology</i> , 2012, 5, 67.	6.9	16
1572	Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. <i>British Journal of Haematology</i> , 2012, 158, 608-614.	1.2	31
1573	Residual Disease Assessment and Its Role in Monitoring Lymphoid and Plasma Cell Neoplasms. , 2012, , 83-95.		0
1574	PET for Measuring Therapy Response After Radionuclide Therapy. <i>Medical Radiology</i> , 2012, , 917-929.	0.0	0
1575	Bendamustine. <i>Drugs</i> , 2012, 72, 1929-1950.	4.9	18
1576	Bortezomib (Velcade), Rituximab, Cyclophosphamide, and Dexamethasone Combination Regimen Is Active as Front-Line Therapy of Low-Grade Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 26-31.	0.2	11
1577	Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 106-112.	0.2	13
1578	Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 238-243.	0.2	50
1579	Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. <i>European Journal of Cancer</i> , 2012, 48, 3223-3231.	1.3	99
1580	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> . 2012, 53, 581-588.	0.6	74
1581	Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2012, 91, 1757-1763.	0.8	5
1583	A novel prognostic model for extranodal natural killer/T-cell lymphoma. <i>Medical Oncology</i> , 2012, 29, 2183-2190.	1.2	23
1584	Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. <i>Medical Oncology</i> , 2012, 29, 2153-2158.	1.2	14
1585	Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). <i>Medical Oncology</i> , 2012, 29, 3515-3521.	1.2	11

#	ARTICLE	IF	CITATIONS
1586	Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. <i>Medical Oncology</i> , 2012, 29, 3535-3539.	1.2	7
1587	Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. <i>International Journal of Hematology</i> , 2012, 96, 617-623.	0.7	43
1588	Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2012, 96, 241-246.	0.7	2
1589	Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation. <i>Annals of Hematology</i> , 2012, 91, 1907-1915.	0.8	6
1590	Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases. <i>Annals of Hematology</i> , 2012, 91, 1721-1729.	0.8	16
1591	Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. <i>Annals of Hematology</i> , 2012, 91, 1741-1745.	0.8	34
1592	The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 1383-1391.	0.8	39
1593	Hematologic Malignancy. , 2012, , 531-553.		1
1594	Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. <i>Blood</i> , 2012, 119, 2956-2959.	0.6	17
1595	Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 242-246.	0.6	14
1596	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. <i>Leukemia and Lymphoma</i> , 2012, 53, 1743-1748.	0.6	16
1597	The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. <i>Radiology and Oncology</i> , 2012, 46, 153-9.	0.6	8
1598	Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. <i>Haematologica</i> , 2012, 97, 751-757.	1.7	23
1599	Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. <i>The Korean Journal of Hematology</i> , 2012, 47, 119.	0.7	10
1600	A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. <i>The Korean Journal of Hematology</i> , 2012, 47, 53.	0.7	12
1601	Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt?. <i>Haematologica</i> , 2012, 97, 797-799.	1.7	16
1602	Early Relapse is Associated with the High Serum Soluble Interleukin-2 Receptor Level after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma. <i>Annals of Oncology</i> , 2012, 23, xi143.	0.6	0
1603	State of the Art Therapy of Advanced Hodgkin Lymphoma. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
1605	Treatment of Early Stage Hodgkin Lymphoma. , 2012, , .		0
1606	Diagnostic Value of Software-Based Image Fusion of Computed Tomography and F18-FDG PET Scans in Patients with Malignant Lymphoma. Scientific World Journal, The, 2012, 2012, 1-9.	0.8	1
1607	Clinical characteristics and outcomes of primary bone lymphoma in Korea. The Korean Journal of Hematology, 2012, 47, 213.	0.7	12
1608	Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study. Experimental and Therapeutic Medicine, 2012, 4, 475-480.	0.8	12
1609	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkinâ€™s lymphoma patients. Annals of Hematology, 2012, 91, 1013-1022.	0.8	36
1610	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood, 2012, 119, 4123-4128.	0.6	70
1611	Repeated transfusions of autologous cytokineâ€induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematological Oncology, 2012, 30, 115-122.	0.8	26
1612	Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large Bâ€™cell lymphoma associated with follicular lymphoma, or <i>de novo</i> diffuse large Bâ€™cell lymphoma. American Journal of Hematology, 2012, 87, 770-775.	2.0	13
1613	Phase 2 trial of â€œSandwichâ€â€™ asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/Tâ€™cell lymphoma. Cancer, 2012, 118, 3294-3301.	2.0	114
1614	Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent Bâ€™cell nonfollicular lymphomas. Cancer, 2012, 118, 3954-3961.	2.0	21
1615	Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIVâ€™associated nonâ€™Hodgkin lymphoma. Cancer, 2012, 118, 3977-3983.	2.0	81
1616	High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score. International Journal of Hematology, 2012, 96, 58-64.	0.7	5
1619	Clinical characteristics and prognostic factors in Chinese patients with Hodgkinâ€™s lymphoma. Medical Oncology, 2012, 29, 1127-1133.	1.2	9
1620	Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination. Annals of Nuclear Medicine, 2012, 26, 248-252.	1.2	114
1621	FDG PET/CT predictive role in follicular lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 864-871.	3.3	32
1622	Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Annals of Hematology, 2012, 91, 687-695.	0.8	85
1623	Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Annals of Hematology, 2012, 91, 705-714.	0.8	58
1624	Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL. Annals of Hematology, 2012, 91, 997-1005.	0.8	24

#	ARTICLE	IF	CITATIONS
1625	Serum beta2-microglobulin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 1265-1270.	0.8	25
1626	Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy. <i>British Journal of Haematology</i> , 2012, 156, 142-143.	1.2	9
1627	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012, 156, 346-353.	1.2	122
1628	Burkitt lymphoma: staging and response evaluation. <i>British Journal of Haematology</i> , 2012, 156, 761-765.	1.2	30
1629	Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. <i>Histopathology</i> , 2012, 60, 313-319.	1.6	89
1630	Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group. <i>Histopathology</i> , 2012, 60, 924-932.	1.6	13
1631	A real-time (PCR) for a real life? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice. <i>Experimental Hematology</i> , 2012, 40, 528-539.e4.	0.2	3
1632	Primary Testicular Lymphoma. <i>Clinical Oncology</i> , 2012, 24, 358-365.	0.6	66
1633	Apheresis-related enrichment of CD26++ T lymphocytes: phenotypic characterization and correlation with unfavorable outcome in autologous hematopoietic progenitor cell transplantation. <i>Transfusion</i> , 2012, 52, 765-776.	0.8	4
1634	High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. <i>European Journal of Haematology</i> , 2012, 88, 510-517.	1.1	39
1635	Double-hit BCL2/ MYC translocations in a consecutive cohort of patients with large B-cell lymphoma: a single centre's experience. <i>European Journal of Haematology</i> , 2012, 89, 63-71.	1.1	92
1636	Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). <i>Leukemia Research</i> , 2012, 36, 857-861.	0.4	19
1637	Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Cancer Science</i> , 2012, 103, 933-938.	1.7	61
1638	Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T-natural killer cell malignancies. <i>Cancer Science</i> , 2012, 103, 1290-1295.	1.7	18
1639	Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions. <i>British Journal of Dermatology</i> , 2012, 167, 194-197.	1.4	29
1640	Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. <i>British Journal of Haematology</i> , 2012, 157, 438-445.	1.2	53
1641	T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies. <i>British Journal of Haematology</i> , 2012, 157, 580-585.	1.2	7
1642	Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC: autologous stem cell support: still very long survival but late relapses do occur. <i>British Journal of Haematology</i> , 2012, 158, 355-362.	1.2	241

#	ARTICLE	IF	CITATIONS
1643	Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma. <i>Cancer</i> , 2012, 118, 1593-1598.	2.0	20
1644	ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin. <i>American Journal of Hematology</i> , 2012, 87, 116-119.	2.0	12
1645	Cyclic thrombocytopenia associated with marked rebound thrombocytosis and fluctuating levels of endogenous thrombopoietin and reticulated platelets: A case report. <i>American Journal of Hematology</i> , 2012, 87, 120-122.	2.0	10
1646	Is HbA2 level a reliable diagnostic measurement for β^2 -thalassemia trait in people with iron deficiency?. <i>American Journal of Hematology</i> , 2012, 87, 114-116.	2.0	26
1647	Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. <i>American Journal of Hematology</i> , 2012, 87, 22-25.	2.0	27
1648	Unintended benefit of anabolic steroid use in hemophilia B leiden. <i>American Journal of Hematology</i> , 2012, 87, 122-123.	2.0	4
1649	Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2012, 87, 129-130.	2.0	1
1650	Experience with use of Zostavax® in patients with hematologic malignancy and hematopoietic cell transplant recipients. <i>American Journal of Hematology</i> , 2012, 87, 123-125.	2.0	44
1651	Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2012, 87, 127-129.	2.0	25
1652	Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2012, 87, 126-127.	2.0	2
1653	The potential role of pre-transplant HBcIgG seropositivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network. <i>American Journal of Hematology</i> , 2012, 87, 213-217.	2.0	14
1654	A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 111-114.	2.0	26
1655	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. <i>American Journal of Hematology</i> , 2012, 87, 203-204.	2.0	29
1656	Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Cell Biochemistry and Biophysics</i> , 2012, 62, 257-265.	0.9	32
1658	Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 4-12.	3.3	119
1659	Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2012, 91, 73-82.	0.8	36
1660	Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors. <i>Annals of Hematology</i> , 2012, 91, 391-397.	0.8	25
1661	Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Annals of Hematology</i> , 2012, 91, 543-551.	0.8	50

#	ARTICLE	IF	CITATIONS
1662	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. <i>Investigational New Drugs</i> , 2012, 30, 368-375.	1.2	17
1663	How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 125-132.	1.2	21
1664	High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. <i>Hematological Oncology</i> , 2013, 31, 34-40.	0.8	20
1665	Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma. <i>Cancer</i> , 2013, 119, 99-106.	2.0	41
1666	Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2013, 119, 371-379.	2.0	74
1667	First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIIE extranodal natural killer/T-cell lymphoma. <i>Cancer</i> , 2013, 119, 348-355.	2.0	182
1668	A phase II study of sorafenib (BAY 439006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). <i>Journal of Hematology and Oncology</i> , 2013, 6, 46.	6.9	10
1669	Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 1684-1690.	0.6	23
1670	A Radiologist's Guide to Treatment Response Criteria in Oncologic Imaging: Functional, Molecular, and Disease-Specific Imaging Biomarkers. <i>American Journal of Roentgenology</i> , 2013, 201, 246-256.	1.0	17
1671	Adults with Palpable Neck Mass: Evidence-Based Neuroimaging. , 2013, , 641-677.		2
1672	A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial. <i>BMC Cancer</i> , 2013, 13, 308.	1.1	19
1673	Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma. <i>Cancer Cell International</i> , 2013, 13, 58.	1.8	12
1674	The recipient CXCL10 +1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation. <i>Clinical Immunology</i> , 2013, 146, 104-111.	1.4	14
1675	A Retrospective Analysis of Clinicopathological Characteristics, Treatment, and Outcome of 27 Patients of Primary Intestinal Lymphomas. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 417-421.	0.6	12
1676	Combined therapy in untreated patients improves outcome in Nasal NK/T lymphoma: results of a clinical trial. <i>Medical Oncology</i> , 2013, 30, 637.	1.2	24
1677	Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience. <i>Medical Oncology</i> , 2013, 30, 611.	1.2	19
1678	Treatment of peripheral T Cell Lymphoma with an intensive protocol ACEP (Adriamycin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 107 Td (C overall survival rates. <i>Medical Oncology</i> , 2013, 30, 554.	1.2	1
1679	Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods. <i>Medical Oncology</i> , 2013, 30, 528.	1.2	16

#	ARTICLE	IF	CITATIONS
1680	Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2013, 61, 165-174.	1.0	2
1681	A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group. <i>International Journal of Hematology</i> , 2013, 98, 171-178.	0.7	7
1682	Clinical significance of jejunoileal involvement of non-Hodgkin's lymphoma detected by double-balloon enteroscopy. <i>International Journal of Hematology</i> , 2013, 97, 369-381.	0.7	2
1683	A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 974-985.	1.2	28
1684	Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2013, 92, 1359-1367.	0.8	15
1685	Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. <i>Annals of Hematology</i> , 2013, 92, 1351-1358.	0.8	51
1686	DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. <i>Annals of Hematology</i> , 2013, 92, 1041-1048.	0.8	15
1687	Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis. <i>Annals of Hematology</i> , 2013, 92, 925-933.	0.8	9
1688	A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components. <i>Annals of Hematology</i> , 2013, 92, 807-815.	0.8	14
1689	Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2013, 92, 325-332.	0.8	8
1690	Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 945-953.	1.1	33
1691	Risk factors of central nervous system relapse in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1908-1914.	0.6	38
1692	Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. <i>Leukemia</i> , 2013, 27, 1902-1909.	3.3	197
1694	Bilan d'extension et suivi dans le traitement des lymphomes. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 150-163.	0.0	0
1695	The role of FDG-PET scanning in assessing lymphoma in 2012. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 158-168.	1.8	13
1696	c-FLIP does not correlate with response to immunochemotherapy treatment and outcome of patients with nodal diffuse large B-cell lymphoma. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 445-449.	2.5	1
1697	A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. <i>European Journal of Cancer</i> , 2013, 49, 2869-2876.	1.3	114
1698	High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 991-994.	2.0	36

#	ARTICLE	IF	CITATIONS
1699	Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 611-620.	1.2	23
1700	An Update on Criteria for Assessing Tumor Response to Treatment. <i>Current Problems in Diagnostic Radiology</i> , 2013, 42, 209-219.	0.6	1
1701	Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2920-2926.	0.8	137
1702	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 525-533.	5.1	257
1703	Vinorelbine, Paclitaxel, Etoposide, Cisplatin, and Cytarabine (VTEPA) Is an Effective Second Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 657-663.	0.2	12
1704	Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients. <i>EJNMMI Research</i> , 2013, 3, 71.	1.1	9
1705	Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNHO3-1B). <i>Annals of Oncology</i> , 2013, 24, 1032-1037.	0.6	31
1706	The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. <i>American Journal of Hematology</i> , 2013, 88, 394-399.	2.0	38
1707	Anthracycline-containing regimens for treatment of follicular lymphoma in adults. <i>The Cochrane Library</i> , 2013, , CD008909.	1.5	4
1708	Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. <i>Leukemia</i> , 2013, 27, 1628-1636.	3.3	123
1709	CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. <i>Annals of Hematology</i> , 2013, 92, 1521-1528.	0.8	26
1710	Clinical and epidemiologic characteristics of non Hodgkin's lymphoma in Bedouins in the south of Israel. <i>SpringerPlus</i> , 2013, 2, 672.	1.2	2
1711	¹⁸ F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma Kinase. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 249-256.	0.6	10
1712	High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL). <i>Medical Oncology</i> , 2013, 30, 690.	1.2	8
1713	Clinical significance of serum soluble interleukin-2 receptor- β in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. <i>Medical Oncology</i> , 2013, 30, 723.	1.2	18
1714	Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability. <i>Leukemia and Lymphoma</i> , 2013, 54, 83-89.	0.6	10
1715	Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2627-2630.	0.6	5
1716	A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. <i>Leukemia and Lymphoma</i> , 2013, 54, 1373-1379.	0.6	65

#	ARTICLE	IF	CITATIONS
1717	Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 1928-1933.	0.6	9
1718	Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. <i>Leukemia and Lymphoma</i> , 2013, 54, 2412-2417.	0.6	6
1719	Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. <i>European Journal of Haematology</i> , 2013, 91, 20-28.	1.1	222
1720	Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study. <i>Cancer</i> , 2013, 119, 4129-4136.	2.0	18
1721	A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. <i>Cancer</i> , 2013, 119, 1683-1689.	2.0	8
1722	Phase I Study of a Modified Regimen of ⁹⁰ Yttrium-Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 370-379.	0.7	2
1723	Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-E regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. <i>Hematological Oncology</i> , 2013, 31, 143-150.	0.8	66
1724	Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. <i>Haematologica</i> , 2013, 98, 364-370.	1.7	117
1725	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus ¹³¹ Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013, 31, 314-320.	0.8	152
1726	Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 565-572.	0.8	198
1727	Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2645-2653.	0.6	12
1728	Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. <i>Leukemia and Lymphoma</i> , 2013, 54, 1915-1920.	0.6	12
1729	Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2441-2447.	0.6	25
1730	Three prognostic factors influence clinical outcomes of primary testicular lymphoma. <i>Tumor Biology</i> , 2013, 34, 55-63.	0.8	24
1731	⁹⁰ Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 308-313.	0.8	110
1732	NCCN, NCCN, NCCN revised guidelines for the management of follicular lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 185-192.	2.0	32
1733	Prognostic Value of C-reactive Protein, Lactate Dehydrogenase and Anemia in Recurrent or Refractory Aggressive Lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 37-44.	0.6	9
1734	Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 216-237.	2.0	93

#	ARTICLE	IF	CITATIONS
1735	Staging and monitoring in the treatment of lymphomas. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 145-157.	1.8	10
1736	Expression of DBC1 and Androgen Receptor Predict Poor Prognosis in Diffuse Large B Cell Lymphoma. <i>Translational Oncology</i> , 2013, 6, 370-381.	1.7	27
1737	Early-stage splenic diffuse large B-cell lymphoma is highly associated with hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 150-156.	0.8	13
1738	Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 82-86.	2.0	6
1740	Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 602-606.	2.0	87
1741	¿Está siempre indicada la biopsia de médula ósea en los pacientes con linfoma primario cutáneo de células B de la zona marginal?. <i>Actas Dermo-sifilográficas</i> , 2013, 104, 667-671.	0.2	2
1742	High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2013, 97, 256-262.	0.7	0
1743	Does Functional Imaging Distinguish Nodular Lymphocyte-Predominant Hodgkin Lymphoma From T-Cell/Histiocyte-Rich Large B-Cell Lymphoma?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 392-397.	0.2	8
1744	Is Bone Marrow Biopsy Always Indicated in Patients With Primary Cutaneous Marginal Zone B-Cell Lymphoma?. <i>Actas Dermo-sifilográficas</i> , 2013, 104, 667-671.	0.2	1
1745	Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-line Chemotherapy in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma. <i>Academic Radiology</i> , 2013, 20, 1122-1129.	1.3	9
1746	Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. <i>European Journal of Cancer</i> , 2013, 49, 386-394.	1.3	124
1747	Non-Hodgkin Lymphomas Presenting as Soft Tissue Masses: A Single Center Experience and Meta-Analysis of the Published Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 258-265.	0.2	21
1748	Les lymphomes: quelques notions de base que le radiologue doit connaître. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 135-149.	0.0	0
1749	High-Dose and Extended-Field Intensity Modulated Radiation Therapy for Early-Stage NK/T-Cell Lymphoma of Waldeyer's Ring: Dosimetric Analysis and Clinical Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 1086-1093.	0.4	51
1750	A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: Clinical significance of treatment intensity and comprehensive geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2013, 4, 242-248.	0.5	32
1751	Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d'Étude des Lymphomes de l'Adulte (GELA). <i>European Journal of Cancer</i> , 2013, 49, 904-910.	1.3	18
1752	Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 385-391.	0.2	35
1753	Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 568-574.	0.2	72

#	ARTICLE	IF	CITATIONS
1754	Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 123-128.	2.0	19
1755	Dosimetric Evaluation and Treatment Outcome of Intensity Modulated Radiation Therapy After Doxorubicin-Based Chemotherapy for Primary Mediastinal Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1289-1295.	0.4	17
1756	La place de la TEP au FDG dans l'évaluation des lymphomes en 2012. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 164-174.	0.0	0
1757	Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin's lymphoma with prior rituximab exposure. <i>Journal of the Chinese Medical Association</i> , 2013, 76, 195-200.	0.6	3
1758	Snake model-based lymphoma segmentation for sequential CT images. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 111, 366-375.	2.6	12
1759	Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. <i>Medical Oncology</i> , 2013, 30, 351.	1.2	31
1760	Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma. <i>Medical Oncology</i> , 2013, 30, 441.	1.2	18
1761	Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Cancer Science</i> , 2013, 104, 105-110.	1.7	31
1762	[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 34-43.	3.3	35
1763	Lymphomas: Basic points that radiologists should know. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 131-144.	1.8	32
1764	Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. , 2013, , 1027-1047.		0
1765	R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 161, 383-388.	1.2	23
1766	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet, The</i> , 2013, 381, 1817-1826.	6.3	450
1767	Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 973-978.	0.6	5
1768	Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. <i>Leukemia and Lymphoma</i> , 2013, 54, 2399-2404.	0.6	25
1769	Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. <i>Leukemia and Lymphoma</i> , 2013, 54, 261-267.	0.6	35
1770	High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. <i>British Journal of Haematology</i> , 2013, 162, 240-249.	1.2	12
1771	Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. <i>Hematological Oncology</i> , 2013, 31, 179-182.	0.8	20

#	ARTICLE	IF	CITATIONS
1772	Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease—added value of low-dose CT. <i>Pediatric Radiology</i> , 2013, 43, 86-92.	1.1	19
1773	Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma. <i>Leukemia Research</i> , 2013, 37, 58-63.	0.4	21
1774	End-Therapy Positron Emission Tomography for Treatment Response Assessment in Follicular Lymphoma: A Systematic Review and Meta-analysis. <i>Clinical Cancer Research</i> , 2013, 19, 6566-6577.	3.2	21
1775	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	0.8	223
1776	Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma. <i>International Journal of Hematology</i> , 2013, 98, 543-548.	0.7	2
1777	Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. <i>Leukemia and Lymphoma</i> , 2013, 54, 1640-1646.	0.6	15
1778	Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 3351-3359.	0.8	54
1779	Rituximab Maintenance Therapy Until Progression After Rituximab and Chemotherapy Induction in Patients With Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 253-257.	0.2	8
1780	Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. <i>British Journal of Haematology</i> , 2013, 162, 639-647.	1.2	35
1781	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. <i>Blood</i> , 2013, 121, 48-53.	0.6	243
1783	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. <i>Annals of Oncology</i> , 2013, 24, 1385-1392.	0.6	99
1785	Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 483-490.	0.6	13
1786	Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1530-1536.	1.3	46
1787	Pre-transplant 18F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 551-556.	1.3	11
1788	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. <i>Haematologica</i> , 2013, 98, 1726-1731.	1.7	131
1789	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013, 24, 2108-2112.	0.6	124
1790	99mTc Sestamibi as a Prognostic Factor of Response to First-Line Therapy and Outcome in Patients With Malignant Lymphoma. <i>Clinical Nuclear Medicine</i> , 2013, 38, 847-854.	0.7	2
1791	A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination With Rituximab in Patients With Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2013, 36, 331-341.	1.2	30

#	ARTICLE	IF	CITATIONS
1792	Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomibâ€“Rituximab Versus Rituximab. <i>Clinical Cancer Research</i> , 2013, 19, 2551-2561.	3.2	16
1793	Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated WaldenstrÃ¶m Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 301-307.	0.8	146
1794	Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 104-110.	0.8	134
1795	Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 466-475.	0.6	10
1796	⁹⁰ Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1977-1983.	0.8	192
1797	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 4262-4272.	3.2	92
1798	Primary Bone Lymphoma: A Retrospective Analysis of 22 Patients Treated in a Single Tertiary Center. <i>Acta Haematologica</i> , 2013, 130, 291-296.	0.7	14
1799	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1442-1449.	0.8	167
1800	Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. <i>Haematologica</i> , 2013, 98, 620-625.	1.7	12
1801	Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells. <i>Acta Haematologica</i> , 2013, 130, 230-237.	0.7	15
1802	Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2013, 24, 1603-1609.	0.6	28
1803	A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. <i>British Journal of Haematology</i> , 2013, 161, 183-191.	1.2	35
1804	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 1164-1171.	0.8	92
1805	Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. <i>Annals of Oncology</i> , 2013, 24, 2892-2897.	0.6	105
1806	Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma. <i>European Journal of Haematology</i> , 2013, 90, 195-201.	1.1	18
1807	Fludarabineâ€“mitoxantroneâ€“rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: Experience on 142 patients. <i>American Journal of Hematology</i> , 2013, 88, E273-6.	2.0	9
1808	The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. <i>American Journal of Hematology</i> , 2013, 88, 1062-1067.	2.0	54
1809	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and ⁹⁰ yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 589-593.	2.0	33

#	ARTICLE	IF	CITATIONS
1810	Should children with non-Hodgkin lymphoma be treated with different protocols according to histopathologic subtype?. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1842-1847.	0.8	6
1811	Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen. <i>European Journal of Haematology</i> , 2013, 91, 322-331.	1.1	15
1812	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. <i>Cancer</i> , 2013, 119, 3797-3804.	2.0	47
1813	Advanced MR techniques in multicenter clinical trials. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 761-769.	1.9	12
1814	Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature. <i>International Journal of Dermatology</i> , 2013, 52, 1308-1318.	0.5	35
1815	A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , 2013, 163, 55-61.	1.2	39
1816	The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. <i>Leukemia and Lymphoma</i> , 2013, 54, 708-713.	0.6	22
1817	Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2013, 88, 400-405.	2.0	78
1818	Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. <i>Hematological Oncology</i> , 2013, 31, 183-188.	0.8	27
1819	Cytarabine, Ki67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. <i>Cancer</i> , 2013, 119, 3318-3325.	2.0	5
1820	Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up. <i>Hematological Oncology</i> , 2013, 31, 213-217.	0.8	10
1821	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine-Tositumomab. <i>Clinical Cancer Research</i> , 2013, 19, 6624-6632.	3.2	32
1822	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. <i>Journal of Clinical Oncology</i> , 2013, 31, 573-583.	0.8	142
1823	Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2912-2919.	0.8	185
1824	A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. <i>Clinical Cancer Research</i> , 2013, 19, 3659-3670.	3.2	180
1825	Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. <i>British Journal of Cancer</i> , 2013, 108, 380-386.	2.9	20
1826	Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 515-523.	0.9	10
1827	Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3688-3695.	0.8	320

#	ARTICLE	IF	CITATIONS
1828	Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 731-742.	3.2	91
1829	Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2013, 121, 2864-2874.	0.6	31
1830	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013, 122, 3759-3766.	0.6	82
1831	Safety and Efficacy of Chop for Treatment of Diffuse Large B-Cell Lymphoma with Different Combination Antiretroviral Therapy Regimens: Sculpt Study. <i>Antiviral Therapy</i> , 2013, 18, 699-707.	0.6	6
1832	First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. <i>Haematologica</i> , 2013, 98, 1563-1570.	1.7	25
1833	Treatment Outcomes in AIDS-Related Diffuse Large B-cell Lymphoma in the Setting Roll Out of Combination Antiretroviral Therapy in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 66-73.	0.9	28
1834	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. <i>Haematologica</i> , 2013, 98, 357-363.	1.7	51
1835	Potential of compressed sensing in quantitative MR imaging of cancer. <i>Cancer Imaging</i> , 2013, 13, 633-644.	1.2	16
1836	The Metabolic Signature of Tumors as an Imaging Biomarker in Staging, Restaging and Therapy Response on FDG PET. <i>OMICS Journal of Radiology</i> , 2013, 02, .	0.0	0
1837	Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas. <i>Oncology Reports</i> , 2013, 29, 805-811.	1.2	6
1838	Primary breast lymphoma: a single institution's experience. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2013, 84, 267.	1.1	11
1839	Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. <i>Blood Research</i> , 2013, 48, 115.	0.5	5
1840	Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma – characteristics and risk factors analysis. <i>Wspolczesna Onkologia</i> , 2013, 2, 200-204.	0.7	5
1841	Prognostic Importance of the Soluble Form of IL-2 Receptor ^α (sIL-2R ^α) and its Relationship with Surface Expression of IL-2R ^α (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases. <i>Journal of Clinical and Experimental Hematopathology: ICEH</i> , 2013, 53, 197-205.	0.3	14
1842	Positron emission tomography/CT in the management of lymphoma. <i>Imaging</i> , 2013, 22, 20110086.	0.0	2
1843	Serum C-Reactive Protein (CRP) as a Simple and Independent Prognostic Factor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. <i>PLoS ONE</i> , 2013, 8, e64158.	1.1	37
1844	Early Stage W.H.O. Grade I and II Follicular Lymphoma Treated with Radiation Therapy Alone. <i>PLoS ONE</i> , 2013, 8, e65156.	1.1	16
1845	PET – Assessment of Oncologic Treatment Response. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1846	The Effect of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients with Ocular Adnexal Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1157.	0.0	2
1847	The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen. <i>Yonsei Medical Journal</i> , 2014, 55, 1568.	0.9	21
1848	Gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. <i>OncoTargets and Therapy</i> , 2014, 7, 2093.	1.0	23
1849	Dynamic Metabolic Changes during the First 3 Months after ⁹⁰ Y-ibritumomab Tiuxetan Radioimmunotherapy. <i>Scientific World Journal</i> , The, 2014, 2014, 1-6.	0.8	2
1850	Treatment modalities in primary gastric lymphoma: effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology. <i>Wspolczesna Onkologia</i> , 2014, 4, 273-278.	0.7	8
1851	Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. <i>OncoTargets and Therapy</i> , 2014, 7, 865.	1.0	17
1852	Clinical Features and Outcomes of 9 Patients with Immunodeficiency-Associated Lymphoproliferative Disorders Treated at a Single Institution. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2014, 54, 187-196.	0.3	5
1853	Advances in Nanomaterials for Diagnosis and Therapy of Leukemia. <i>Recent Patents on Nanomedicine</i> , 2014, 3, 99-104.	0.5	0
1854	Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2014, 54, 117-127.	0.3	4
1855	High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2014, 55, 2319-2327.	0.6	9
1856	Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL. <i>Medical Oncology</i> , 2014, 31, 244.	1.2	1
1857	Lymphoma: Management Using PET/CT. , 2014, , 257-260.		0
1858	Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 4127-4133.	0.8	79
1859	Hematologic findings predictive of bone marrow disease in dogs with multicentric largeâ€œcell lymphoma. <i>Veterinary Clinical Pathology</i> , 2014, 43, 505-512.	0.3	11
1860	The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy. <i>Cancer Imaging</i> , 2014, 14, 34.	1.2	19
1861	Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study). <i>Oncologist</i> , 2014, 19, 291-298.	1.9	70
1862	Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). <i>Leukemia and Lymphoma</i> , 2014, 55, 768-772.	0.6	42
1863	Clinical impact of contrast-enhanced computed tomography combined with low-dose ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management. <i>Leukemia and Lymphoma</i> , 2014, 55, 2887-2892.	0.6	29

#	ARTICLE	IF	CITATIONS
1864	Validity of reduced radiation dose for localized diffuse large B-cell lymphoma showing a good response to chemotherapy. <i>Journal of Radiation Research</i> , 2014, 55, 359-363.	0.8	1
1865	Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2014, 55, 51-55.	0.6	21
1866	A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2014, 55, 2739-2747.	0.6	9
1867	Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2071-2078.	0.6	7
1868	Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2312-2318.	0.6	19
1869	Positron Emission Tomography (PET) in Oncology. <i>Cancers</i> , 2014, 6, 1821-1889.	1.7	231
1870	Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma. <i>Molecular and Clinical Oncology</i> , 2014, 2, 1172-1176.	0.4	14
1871	Surgical resection followed by chemotherapy may be an effective treatment strategy for primary gastrointestinal natural killer/T-cell lymphoma: a single center experience. <i>Leukemia and Lymphoma</i> , 2014, 55, 2649-2651.	0.6	4
1872	Functional Imaging in Lymphoma. , 2014, , 1311-1334.		0
1873	The role of contrast-enhanced ultrasound (CEUS) in the early assessment of microvascularization in patients with aggressive B-cell lymphoma treated by rituximab-CHOP: A preliminary study. <i>Clinical Hemorheology and Microcirculation</i> , 2014, 58, 363-376.	0.9	10
1874	COMPARATIVE EVALUATION OF BONE MARROW ASPIRATE WITH TREPHINE BIOPSY IN HEMATOLOGICAL DISORDERS AND DETERMINATION OF OPTIMUM TREPHINE LENGTH IN LYMPHOMA INFILTRATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014002.	0.5	19
1875	Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-9.	1.4	83
1876	Clinical Characteristics and Treatment Outcome in a Taiwanese Population of Patients with Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1164-1171.	0.6	14
1877	Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2014, 55, 781-785.	0.6	8
1878	Chemoimmunotherapy with fludarabine, cytoxan and rituximab regimen: to use, not to use, or give it as "FCR-LITE". <i>Leukemia and Lymphoma</i> , 2014, 55, 733-734.	0.6	2
1879	Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine ¹³¹ -tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2754-2760.	0.6	7
1880	Sequential single-agent obatoclox mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2932-2934.	0.6	9
1881	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , 2014, 99, 1107-1113.	1.7	225

#	ARTICLE	IF	CITATIONS
1882	Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. <i>Haematologica</i> , 2014, 99, 1817-1825.	1.7	44
1883	FCGR3A158V/F Polymorphism and Response to Frontline R-CHOP Therapy in Diffuse Large B-Cell Lymphoma. <i>DNA and Cell Biology</i> , 2014, 33, 616-623.	0.9	15
1884	Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. <i>American Journal of Hematology</i> , 2014, 89, E239-43.	2.0	81
1885	Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 19-24.	2.0	26
1886	A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 768-776.	1.2	104
1887	First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2014, 1, e104-e111.	2.2	77
1888	Safety and efficacy of 90Y-rituximab + rituximab + tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. <i>British Journal of Haematology</i> , 2014, 164, 710-716.	1.2	31
1889	A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2014, 165, 358-363.	1.2	91
1890	90Y-rituximab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. <i>British Journal of Haematology</i> , 2014, 167, 207-213.	1.2	27
1891	Clinical Outcomes of AIDS-related Burkitt Lymphoma: A Multi-institution Retrospective Survey in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 318-323.	0.6	7
1892	Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma. <i>British Journal of Haematology</i> , 2014, 166, 91-97.	1.2	14
1893	R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2014, 93, 70-76.	1.1	12
1894	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.	0.6	67
1895	High-dose therapy and autologous hematopoietic stem cell transplant in T-cell lymphoma: a single center experience. <i>Leukemia and Lymphoma</i> , 2014, 55, 1827-1831.	0.6	2
1896	A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. <i>American Journal of Hematology</i> , 2014, 89, 536-541.	2.0	8
1897	Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. <i>Journal of Clinical Oncology</i> , 2014, 32, 3096-3102.	0.8	159
1898	Imaging Biomarkers and Surrogate Endpoints in Oncology Clinical Trials. , 2014, , 29-42.		1
1900	Whole-body DWI in patients with lymphoma: imaging findings, pitfalls, and limitations. <i>Cancer Imaging</i> , 2014, 14, .	1.2	0

#	ARTICLE	IF	CITATIONS
1901	CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. <i>BMC Cancer</i> , 2014, 14, 890.	1.1	25
1902	Clinical Disparity and Favorable Prognoses for Patients With Waldeyer Ring Extranodal Nasal-type NK/T-cell Lymphoma and Diffuse Large B-cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 41-46.	0.6	12
1903	Comparison of Therapeutic Outcomes Between Surgical Resection Followed By R-CHOP and R-CHOP Alone for Localized Primary Intestinal Diffuse Large B-cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 182-187.	0.6	24
1904	Clinical Significance of MYC Expression and/or "High-grade" Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 494-501.	2.1	43
1905	Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. <i>Annals of Oncology</i> , 2014, 25, 1800-1806.	0.6	60
1906	Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 3-12.	1.1	17
1907	SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014003.	0.5	22
1908	Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival. <i>International Journal of Hematology</i> , 2014, 100, 370-378.	0.7	7
1909	Hypermethylation of <i>p15</i> Gene in Diffuse "Large B" Cell Lymphoma: Association with Less Aggressiveness of the Disease. <i>Clinical and Translational Science</i> , 2014, 7, 384-390.	1.5	12
1910	A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2761-2768.	0.6	40
1911	Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group. <i>International Journal of Hematology</i> , 2014, 100, 281-289.	0.7	8
1912	Management of relapsed-refractory diffuse large B cell lymphoma. <i>South Asian Journal of Cancer</i> , 2014, 03, 066-070.	0.2	53
1913	Clinical Features of Testicular Lymphoma. <i>Acta Haematologica</i> , 2014, 131, 187-192.	0.7	3
1914	Autologous Stem Cell Transplantation as the First-Line Treatment for Peripheral T Cell Lymphoma: Results of a Comprehensive Meta-Analysis. <i>Acta Haematologica</i> , 2014, 131, 114-125.	0.7	24
1915	Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. <i>Journal of Hematology and Oncology</i> , 2014, 7, 11.	6.9	176
1916	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 44.	6.9	76
1917	Phase I Trial of Bortezomib (PS-341; NSC 681239) and "Nonhybrid" (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. <i>Clinical Cancer Research</i> , 2014, 20, 5652-5662.	3.2	26
1918	Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2490-2496.	0.6	9

#	ARTICLE	IF	CITATIONS
1919	Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. <i>Hepatology</i> , 2014, 59, 2092-2100.	3.6	235
1920	PET-CT and diagnostic CT: The synergy of metabolic and morphological data in onco-haematology. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 55-62.	1.8	8
1921	Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years with B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 770-775.	2.0	21
1922	R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Transfusion and Apheresis Science</i> , 2014, 50, 411-414.	0.5	2
1923	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community. <i>European Journal of Cancer</i> , 2014, 50, 260-266.	1.3	34
1924	Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 424-435.	5.1	304
1925	A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B-Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 354-360.	2.0	35
1926	Pretransplantation Fluorine-18-Deoxyglucose ⁺ Positron Emission Tomography Scan Lacks Prognostic Value in Chemosensitive B Cell Non-Hodgkin Lymphoma Patients Undergoing Nonmyeloablative Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 881-884.	2.0	28
1927	What Determines Therapeutic Choices for Elderly Patients With DLBCL? Clinical Findings of a Multicenter Study in Portugal. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 370-379.	0.2	7
1928	Modified Irinotecan Plus Cisplatin and Dexamethasone (ICD) Combination Chemotherapy as Salvage Chemotherapy for Patients with Relapsed/Refractory Diffuse Large Cell Lymphoma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 265-268.	0.3	0
1929	Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. <i>SpringerPlus</i> , 2014, 3, 5.	1.2	7
1930	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18-year follow-up of 488 patients (IELSG 23 study). <i>Annals of Hematology</i> , 2014, 93, 221-231.	0.8	36
1931	Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse. <i>Annals of Hematology</i> , 2014, 93, 1001-1005.	0.8	18
1932	Association of interleukin-10, tumor necrosis factor- α and transforming growth factor- β gene polymorphisms with the outcome of diffuse large B-cell lymphomas. <i>International Journal of Clinical Oncology</i> , 2014, 19, 186-192.	1.0	12
1933	Current role of FDG PET/CT in lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1004-1027.	3.3	63
1934	Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. <i>Annals of Hematology</i> , 2014, 93, 437-447.	0.8	19
1935	Epstein-Barr Viral Load is Associated to Response in AIDS-Related Lymphomas. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 191-4.	0.3	3
1936	Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma. <i>Cancer Cell International</i> , 2014, 14, 5.	1.8	5

#	ARTICLE	IF	CITATIONS
1937	GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. <i>Annals of Hematology</i> , 2014, 93, 827-834.	0.8	8
1938	Medical Imaging in Clinical Trials. , 2014, , .		19
1939	Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 343-355.e6.	0.2	15
1940	<sc>R</sc>â€<sc>CHOP</sc> with iodineâ€131 tositumomab consolidation for advanced stage diffuse large <sc>B</sc>â€cell lymphoma (<sc>DLBCL</sc>): <sc>SWOG S</sc>0433. <i>British Journal of Haematology</i> , 2014, 166, 382-389.	1.2	33
1941	Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 253-264.	3.2	117
1942	Imaging in Clinical Oncology. , 2014, , .		2
1943	High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis. <i>International Journal of Hematology</i> , 2014, 99, 69-78.	0.7	21
1944	Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. <i>Journal of Clinical Oncology</i> , 2014, 32, 3490-3496.	0.8	358
1945	Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. <i>British Journal of Haematology</i> , 2014, 165, 510-518.	1.2	34
1946	ABVD (8 cycles) versus BEACOPP (4 escalated cycles â‰¥4 baseline): final results in stage IIIâ€IV low-risk Hodgkin lymphoma (IPS 0â€2) of the LYSA H34 randomized trial. <i>Annals of Oncology</i> , 2014, 25, 1622-1628.	0.6	91
1947	Impact of prior rituximab on outcomes of autologous stemâ€cell transplantation in patients with relapsed or refractory aggressive Bâ€cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. <i>British Journal of Haematology</i> , 2014, 164, 668-674.	1.2	14
1948	Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. <i>British Journal of Haematology</i> , 2014, 164, 659-667.	1.2	31
1949	Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1905-1911.	2.0	12
1950	Autologous Transplantation for Transformed Non-Hodgkin Lymphoma Using an Yttrium-90 Ibritumomab Tiuxetan Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2072-2075.	2.0	15
1951	Advanced-stage Hodgkin Lymphoma: US/Chest Radiography for Detection of Relapse in Patients in First Complete Remissionâ€A Randomized Trial of Routine Surveillance Imaging Procedures. <i>Radiology</i> , 2014, 272, 262-274.	3.6	37
1952	Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large <sc>B</sc>â€cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2014, 92, 204-210.	1.1	55
1953	Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2014, 49, 671-678.	1.3	18
1954	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1311-1318.	5.1	239

#	ARTICLE	IF	CITATIONS
1955	PET-CT restaging: a surrogate for follicular lymphoma?. <i>Lancet Haematology</i> , 2014, 1, e2-e3.	2.2	2
1956	Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. <i>Lancet Haematology</i> , 2014, 1, e17-e27.	2.2	138
1957	Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma. <i>Clinical Neurology and Neurosurgery</i> , 2014, 127, 106-111.	0.6	12
1958	Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1813-1818.	2.0	16
1959	Early Determination of Prognosis by Interim 18 F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 216-222.	2.8	27
1960	British HIV Association guidelines for HIV-associated malignancies 2014. <i>HIV Medicine</i> , 2014, 15, 1-92.	1.0	67
1962	Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. <i>Journal of Clinical Oncology</i> , 2014, 32, 3059-3067.	0.8	3,729
1963	Double hit lymphoma: the MD Anderson Cancer Center clinical experience. <i>British Journal of Haematology</i> , 2014, 166, 891-901.	1.2	310
1964	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. <i>British Journal of Haematology</i> , 2014, 166, 514-520.	1.2	17
1965	Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1112-1118.	0.8	201
1966	Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. <i>Leukemia</i> , 2014, 28, 1885-1891.	3.3	83
1967	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1797-1803.	0.8	75
1968	De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituximab, Cyclophosphamide, Vincristine, Gemcitabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom National Cancer Research Institute Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 282-287.	0.8	82
1969	Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1047-1052.	0.4	41
1970	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. <i>Clinical Immunology</i> , 2014, 154, 37-46.	1.4	25
1973	Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type. <i>Medical Oncology</i> , 2014, 31, 149.	1.2	15
1974	Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab. <i>Medical Oncology</i> , 2014, 31, 206.	1.2	4
1975	Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type. <i>Medical Oncology</i> , 2014, 31, 218.	1.2	19

#	ARTICLE	IF	CITATIONS
1976	Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-â€Predominant Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 912-918.	0.8	96
1977	Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. <i>International Journal of Cancer</i> , 2014, 135, 2834-2846.	2.3	31
1978	Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17-â€years-â€ experience in a single centre. <i>Annals of Hematology</i> , 2014, 93, 147-156.	0.8	6
1979	The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1297-1304.	0.8	53
1980	Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-â€Japan collaborative study. <i>Annals of Hematology</i> , 2014, 93, 1345-1351.	0.8	11
1981	New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2014, 93, 1541-1549.	0.8	22
1982	Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. <i>Annals of Hematology</i> , 2014, 93, 1717-1724.	0.8	28
1983	Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. <i>Annals of Hematology</i> , 2014, 93, 1853-1857.	0.8	14
1984	Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. <i>Annals of Hematology</i> , 2014, 93, 1879-1887.	0.8	59
1985	Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. <i>Annals of Hematology</i> , 2014, 93, 1895-1901.	0.8	115
1986	Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen. <i>Supportive Care in Cancer</i> , 2014, 22, 2557-2561.	1.0	3
1987	High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 684-689.	2.0	45
1988	Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. <i>British Journal of Haematology</i> , 2014, 165, 334-340.	1.2	28
1989	Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. <i>Cancer</i> , 2014, 120, 222-228.	2.0	45
1990	Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin-â€s lymphoma: A retrospective analysis. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2014, 34, 260-264.	1.0	2
1991	Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. <i>Tumor Biology</i> , 2014, 35, 2141-2149.	0.8	24
1992	CD30 as a Therapeutic Target for Lymphoma. <i>BioDrugs</i> , 2014, 28, 181-209.	2.2	32
1993	Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. <i>BMC Gastroenterology</i> , 2014, 14, 31.	0.8	24

#	ARTICLE	IF	CITATIONS
1994	Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2014, 14, 341.	1.1	33
1995	Mesenchymal Stem Cells versus Mesenchymal Stem Cells Combined with Cord Blood for Engraftment Failure after Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective, Open-Label, Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 236-242.	2.0	26
1996	Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 375-381.	1.2	73
1997	Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2014, 32, 1338-1346.	0.8	137
1998	R-CHOP versus R-COMP: Are They Really Equally Effective?. <i>Clinical Oncology</i> , 2014, 26, 648-652.	0.6	12
1999	Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1157-1163.	0.8	309
2000	Comparison of manual and semi-automatic measuring techniques in MSCT scans of patients with lymphoma: a multicentre study. <i>European Radiology</i> , 2014, 24, 2709-2718.	2.3	7
2001	Fractionated ⁹⁰ Y-ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. <i>Journal of Clinical Oncology</i> , 2014, 32, 212-218.	0.8	57
2002	Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 167, 177-184.	1.2	14
2003	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. <i>Human Pathology</i> , 2014, 45, 2085-2093.	1.1	23
2004	Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience. <i>Annals of Hematology</i> , 2014, 93, 1551-1558.	0.8	12
2005	Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 757-766.	5.1	95
2006	The spectrum of primary mucosal CD30-positive T-cell lymphoproliferative disorders of the head and neck. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 117, 96-104.	0.2	19
2007	Prognostic value of FOXP3 and TGF- β 2 expression in both peripheral blood and lymph nodes in patients with B-Non Hodgkin's lymphoma. <i>Alexandria Journal of Medicine</i> , 2014, 50, 253-265.	0.4	2
2008	Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 107-113.	0.2	14
2010	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 951-959.	2.0	37
2011	Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. <i>Lancet Oncology</i> , The, 2014, 15, 343-352.	5.1	100
2012	EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. <i>Bone Marrow Transplantation</i> , 2014, 49, 280-286.	1.3	86

#	ARTICLE	IF	CITATIONS
2013	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014, 93, 233-242.	0.8	17
2014	Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 1849-1853.	0.6	6
2015	A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 213-220.	3.2	105
2016	Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 689-703.	1.8	52
2017	Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy. <i>Frontiers in Medicine</i> , 2014, 1, 54.	1.2	17
2018	Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma. <i>Molecular and Clinical Oncology</i> , 2014, 2, 773-782.	0.4	8
2019	Clinicopathological analysis and prognostic factors of 11 patients with primary non-Hodgkin lymphoma of the small intestine in a single institute. <i>Oncology Letters</i> , 2014, 8, 876-880.	0.8	6
2020	Midtreatment Evaluation of Lymphoma Response to Chemotherapy by Volume Perfusion Computed Tomography. <i>Journal of Computer Assisted Tomography</i> , 2014, 38, 123-130.	0.5	6
2021	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014, 123, 2953-2959.	0.6	90
2022	Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. <i>Blood</i> , 2014, 124, 3870-3879.	0.6	236
2023	HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. <i>Aids</i> , 2014, 28, 689-697.	1.0	53
2024	Autologous stem cell transplantation with <i>in vivo</i> purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 230-234.	2.0	9
2025	Updated survival analysis of two sequential prospective trials of R-CHOP followed by maintenance for newly diagnosed mantle cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, E111-6.	2.0	6
2026	Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review. <i>Cancer Medicine</i> , 2015, 4, 1817-1827.	1.3	2
2027	Phase I study of OPB1602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. <i>Cancer Science</i> , 2015, 106, 896-901.	1.7	83
2028	Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab. <i>Oncology Letters</i> , 2015, 9, 2307-2312.	0.8	17
2029	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. <i>Blood</i> , 2015, 125, 2669-2677.	0.6	44
2030	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> , 2015, 125, 82-89.	0.6	45

#	ARTICLE	IF	CITATIONS
2031	Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. <i>Blood</i> , 2015, 126, 1407-1414.	0.6	28
2032	Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e454-e457.	1.7	7
2033	Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. <i>Haematologica</i> , 2015, 100, 1199-1206.	1.7	30
2034	Hodgkin Lymphoma, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 554-586.	2.3	37
2035	Primary sternum diffuse large B-cell lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , 2015, 9, 2623-2628.	0.8	5
2036	Human leukocyte antigen G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 185-193.	1.5	18
2037	Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients. <i>Hematological Oncology</i> , 2015, 33, 9-14.	0.8	12
2038	A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I-II) diffuse large B-cell non-Hodgkin lymphoma: ECOG 3402. <i>British Journal of Haematology</i> , 2015, 170, 679-686.	1.2	19
2039	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 539-546.	1.2	12
2040	Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 522-30.	4.9	7
2041	Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. <i>British Journal of Haematology</i> , 2015, 171, 710-719.	1.2	30
2042	Changed expression and function of P-gp in peripheral blood CD56 + cells predicting chemoresistance in non-Hodgkin lymphoma patients. <i>Cancer Biomarkers</i> , 2015, 15, 289-297.	0.8	5
2043	Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. <i>Aids</i> , 2015, 29, 903-910.	1.0	29
2044	Longer-term follow-up and outcome by tumour cell proliferation rate (Ki67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL001 (EMERGE) pivotal trial. <i>British Journal of Haematology</i> , 2015, 170, 496-503.	1.2	34
2045	Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan. <i>British Journal of Haematology</i> , 2015, 170, 657-668.	1.2	20
2046	Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. <i>British Journal of Haematology</i> , 2015, 169, 814-823.	1.2	5
2047	Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 509-516.	1.2	15
2048	Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis. <i>Internal Medicine Journal</i> , 2015, 45, 1147-1153.	0.5	6

#	ARTICLE	IF	CITATIONS
2049	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015, 121, 3709-3716.	2.0	27
2050	Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up. <i>Hematological Oncology</i> , 2015, 33, 1-8.	0.8	11
2051	Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. <i>British Journal of Haematology</i> , 2015, 170, 96-109.	1.2	51
2052	The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, 767-773.	0.7	25
2053	Conversion Rate to Resectability in Colorectal Cancer Liver Metastases: Need for Criteria Adapted to Current Therapy. <i>Jurnalul De Chirurgie</i> , 2015, 11, .	0.0	0
2054	Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma. <i>Chonnam Medical Journal</i> , 2015, 51, 109.	0.5	1
2055	Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas. <i>Chinese Medical Journal</i> , 2015, 128, 2498-2504.	0.9	4
2056	Development and Blind Clinical Validation of a MicroRNA Based Predictor of Response to Treatment with R-CHO(E)P in DLBCL. <i>PLoS ONE</i> , 2015, 10, e0115538.	1.1	19
2057	Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14. <i>PLoS ONE</i> , 2015, 10, e0123978.	1.1	21
2058	Î³-Herpesvirus Load as Surrogate Marker of Early Death in HIV-1 Lymphoma Patients Submitted to High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation. <i>PLoS ONE</i> , 2015, 10, e0116887.	1.1	5
2059	Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. <i>PLoS ONE</i> , 2015, 10, e0131158.	1.1	22
2060	Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy. <i>OncoTargets and Therapy</i> , 2015, 8, 2589.	1.0	15
2061	Staging of Primary Abdominal Lymphomas: Comparison of Whole-Body MRI with Diffusion-Weighted Imaging and ¹⁸ F-FDG-PET/CT. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-8.	0.7	11
2062	Favorable Event Free-Survival of High-Dose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission. <i>Hematology Reports</i> , 2015, 7, 5812.	0.3	8
2063	Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110Î±, for treating relapsed or refractory non-Hodgkin's lymphoma. <i>Oncotarget</i> , 2015, 6, 44049-44056.	0.8	3
2064	Rethinking Clinical Response and Outcome Assessment in a Biologic Age. <i>Current Oncology Reports</i> , 2015, 17, 27.	1.8	3
2065	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	0.6	92
2066	Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer: results of a first-in-man dose-escalation study with a fixed-dose extension phase. <i>Annals of Oncology</i> , 2015, 26, 1005-1011.	0.6	25

#	ARTICLE	IF	CITATIONS
2067	The extent of local tumor invasion predicts prognosis in stage IE nasal natural killer/T-cell lymphoma: a novel T staging system for risk stratification. <i>Annals of Hematology</i> , 2015, 94, 1515-1524.	0.8	9
2068	High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2015, 94, 1535-1544.	0.8	21
2069	Clinical Development of Siltuximab. <i>Current Oncology Reports</i> , 2015, 17, 29.	1.8	11
2070	CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis. <i>Tumor Biology</i> , 2015, 36, 7717-7723.	0.8	17
2071	Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2986-2988.	0.6	20
2072	Serum Lactate Dehydrogenase with a Systemic Inflammation Score Is Useful for Predicting Response and Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Acta Haematologica</i> , 2015, 133, 10-17.	0.7	26
2073	Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Journal of Clinical Pathology</i> , 2015, 68, 733-738.	1.0	14
2074	Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2015, 125, 2579-2581.	0.6	111
2075	Stage III follicular lymphoma: an endangered species?. <i>Leukemia and Lymphoma</i> , 2015, 56, 2229-2230.	0.6	0
2076	Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 544-547.	0.1	1
2077	Rituximab combined with Dexamethasone-rituximab-CHOP followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. <i>British Journal of Haematology</i> , 2015, 168, 824-834.	1.2	12
2078	A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 811-819.	1.2	172
2079	CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. <i>Leukemia and Lymphoma</i> , 2015, 56, 332-341.	0.6	32
2080	Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2039-2046.	0.6	12
2081	Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients. <i>Annals of Hematology</i> , 2015, 94, 239-247.	0.8	28
2082	High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma. <i>Annals of Hematology</i> , 2015, 94, 79-88.	0.8	10
2083	Trial of LVDP regimen (l-asparaginase, etoposide, dexamethasone, and cisplatin, followed by) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 107 T lymphoma. <i>Medical Oncology</i> , 2015, 32, 435.	1.2	15
2084	Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. <i>Lancet Haematology</i> , 2015, 2, e66-e74.	2.2	85

#	ARTICLE	IF	CITATIONS
2085	Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM)â€™Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin Lymphoma: An Analysis of Outcomes from the British Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 483-488.	2.0	5
2086	Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. <i>PET Clinics</i> , 2015, 10, 207-225.	1.5	11
2087	High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2379-2387.	0.6	19
2088	Primary and secondary bone lymphomas. <i>Cancer Treatment Reviews</i> , 2015, 41, 235-246.	3.4	101
2089	Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy. <i>Annals of Hematology</i> , 2015, 94, 1175-1184.	0.8	31
2090	Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 431-436.	0.8	23
2091	Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 855-859.	2.0	36
2093	Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma. <i>International Journal of Hematology</i> , 2015, 101, 46-51.	0.7	24
2094	High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy. <i>International Journal of Hematology</i> , 2015, 101, 140-147.	0.7	14
2095	Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus l-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). <i>Annals of Hematology</i> , 2015, 94, 437-444.	0.8	32
2096	Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Treatment for Relapsed or Refractory Lymphoma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2015, 31, 426-433.	0.3	0
2097	Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review. <i>Oncologist</i> , 2015, 20, 210-223.	1.9	91
2098	Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies. <i>Cancer Treatment and Research</i> , 2015, 165, 125-146.	0.2	12
2099	90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. <i>Annals of Oncology</i> , 2015, 26, 193-198.	0.6	9
2100	Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma. <i>Archives of Medical Research</i> , 2015, 46, 454-461.	1.5	14
2101	Radiation Therapy Overcomes Adverse Prognostic Role of Cyclooxygenase-2 Expression on Reed-Sternberg Cells in Early Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 84-90.	0.4	3
2102	Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 677-683.	0.4	28
2103	Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 458-463.	0.2	16

#	ARTICLE	IF	CITATIONS
2104	Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with Tâ€cell lymphoma. <i>Cancer</i> , 2015, 121, 716-723.	2.0	84
2105	Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2015, 26, 774-779.	0.6	17
2106	Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2015, 26, 1766-1771.	0.6	257
2107	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica</i> , 2015, 100, 955-963.	1.7	75
2108	Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified. <i>Annals of Hematology</i> , 2015, 94, 1655-1665.	0.8	19
2109	Additional Survival Benefit of Involved-Lesion Radiation Therapy After R-CHOP Chemotherapy in Limited Stage Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 91-98.	0.4	22
2110	Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 3071-3081.	0.6	16
2111	Primary Bone Lymphoma: A Clinical Analysis of 17 Patients in a Single Institution. <i>Acta Haematologica</i> , 2015, 134, 80-85.	0.7	19
2112	Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1645-1654.	0.8	10
2113	PET/CT, MR, and PET/MR in Lymphoma and Melanoma. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 322-331.	2.5	32
2114	Predicting the Outcome of Sjogrenâ€™s Syndrome-Associated Non-Hodgkinâ€™s Lymphoma Patients. <i>PLoS ONE</i> , 2015, 10, e0116189.	1.1	77
2115	Prognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: A single institution analysis. <i>Oncology Letters</i> , 2015, 9, 851-856.	0.8	8
2116	A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. <i>Acta Oncologica</i> , 2015, 54, 933-938.	0.8	11
2117	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. <i>Current Medical Research and Opinion</i> , 2015, 31, 993-1001.	0.9	17
2118	Frontâ€line, doseâ€escalated immunochemotherapy is associated with a significant progressionâ€free survival advantage in patients with doubleâ€hit lymphomas: a systematic review and metaâ€analysis. <i>British Journal of Haematology</i> , 2015, 170, 504-514.	1.2	140
2119	Outcome of patients older than 60â€years with classical Hodgkin lymphoma treated with front line <sc>ABVD</sc> chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. <i>British Journal of Haematology</i> , 2015, 170, 179-184.	1.2	69
2120	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1.	0.2	19
2121	Clinicopathological implications of nuclear factor ðB signal pathway activation in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2015, 46, 524-531.	1.1	9

#	ARTICLE	IF	CITATIONS
2122	Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. <i>Lancet Haematology</i> , 2015, 2, e166-e174.	2.2	36
2123	Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. <i>Journal of Clinical Oncology</i> , 2015, 33, 1482-1490.	0.8	60
2124	Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis. <i>Annals of Hematology</i> , 2015, 94, 989-994.	0.8	14
2125	CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2015, 94, 1381-1388.	0.8	75
2126	The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2015, 94, 1389-1400.	0.8	32
2127	Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma. <i>Medical Oncology</i> , 2015, 32, 370.	1.2	10
2128	Assessment of the prognostic capacity of pretreatment, interim, and post-therapy 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type. <i>Annals of Nuclear Medicine</i> , 2015, 29, 442-451.	1.2	24
2129	A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. <i>International Journal of Hematology</i> , 2015, 101, 554-562.	0.7	17
2130	Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2015, 101, 585-593.	0.7	12
2131	Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 569-578.	1.1	12
2132	Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. <i>Cancer Epidemiology</i> , 2015, 39, 382-387.	0.8	7
2133	Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin lymphoma. <i>EJNMMI Research</i> , 2015, 5, 10.	1.1	31
2134	Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity Fcγ3R11a Patients with Previously Treated Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 42-48.	0.6	29
2135	Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1525-1533.	0.8	39
2136	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20 ⁺ lymphoid malignancies. <i>British Journal of Haematology</i> , 2015, 170, 669-678.	1.2	80
2137	High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. <i>Annals of Oncology</i> , 2015, 26, 1760-1765.	0.6	43
2138	International Pediatric Non-Hodgkin Lymphoma Response Criteria. <i>Journal of Clinical Oncology</i> , 2015, 33, 2106-2111.	0.8	64
2139	Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 400-407.	0.6	2

#	ARTICLE	IF	CITATIONS
2140	Response criteria for malignant lymphoma. <i>Nuclear Medicine Communications</i> , 2015, 36, 398-405.	0.5	1
2141	The prognostic value of positron emission tomography performed after two courses (<sc>INTERIM&PET</sc>) of standard therapy on treatment outcome in early stage <sc>H</sc>odgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503.	2.0	49
2142	Prognostic value of complete remission status at end-of-treatment FDG&PET in R&CHOP&treated diffuse large B&cell lymphoma: systematic review and meta&analysis. <i>British Journal of Haematology</i> , 2015, 170, 185-191.	1.2	57
2143	Response&adapted therapy for aggressive non&Hodgkin's lymphomas based on early [18F] FDG&PET scanning: ECO&ACRIN Cancer Research Group study (E3404). <i>British Journal of Haematology</i> , 2015, 170, 56-65.	1.2	50
2144	Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: Significance of hepatitis B core antibodies screening. <i>Journal of the Egyptian National Cancer Institute</i> , 2015, 27, 11-18.	0.6	13
2145	Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Radiographics</i> , 2015, 35, 747-764.	1.4	50
2146	Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma. <i>International Journal of Hematology</i> , 2015, 101, 536-542.	0.7	16
2147	Efficacy and Tolerability of Anthracycline-Based Therapy in Elderly Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 270-277.	0.2	10
2148	Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. <i>Lancet Oncology</i> , The, 2015, 16, 541-549.	5.1	346
2149	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, 357-362.	1.7	66
2150	Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. <i>Cell Cycle</i> , 2015, 14, 3434-3440.	1.3	6
2151	Decisional Early Interim 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography after Two Cycles of Chemotherapy in de novo Hodgkin Lymphoma. <i>Acta Haematologica</i> , 2015, 133, 172-178.	0.7	4
2152	Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. <i>Leukemia and Lymphoma</i> , 2015, 56, 92-96.	0.6	5
2153	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>European Journal of Cancer</i> , 2015, 51, 2386-2395.	1.3	32
2154	Imaging for Staging and Response Assessment in Lymphoma. <i>Radiology</i> , 2015, 276, 323-338.	3.6	139
2155	Predictive role of levels of soluble interleukin-2 receptor and C-reactive protein in selecting autologous PBSC transplantation for lymphoma. <i>Bone Marrow Transplantation</i> , 2015, 50, 301-303.	1.3	2
2156	Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2015, 26, 393-399.	0.6	39
2157	Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant. <i>Acta Haematologica</i> , 2015, 133, 347-353.	0.7	7

#	ARTICLE	IF	CITATIONS
2158	Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. <i>Annals of Oncology</i> , 2015, 26, 2323-2328.	0.6	30
2159	Outcome prediction by extranodal involvement, IPI, R _i -IPI, and NCCN _i -IPI in the PET/CT and rituximab era: A Canadian study of 443 patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1041-1046.	2.0	71
2160	Involved-field radiotherapy for patients with mantle cell lymphoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 631-639.	0.9	5
2161	Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 939-948.	1.1	7
2162	Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13045-13050.	3.3	44
2163	Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. <i>Medical Oncology</i> , 2015, 32, 232.	1.2	0
2164	Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. <i>Clinical Cancer Research</i> , 2015, 21, 4294-4304.	3.2	75
2165	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3993-3998.	0.8	74
2166	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3635-3640.	0.8	163
2167	Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	2.9	17
2168	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20 ⁺ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3467-3474.	0.8	149
2169	FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 271-281.	1.1	2
2170	Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab. <i>Leukemia and Lymphoma</i> , 2015, 56, 779-781.	0.6	14
2171	Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2015, 50, 1299-1305.	1.3	7
2172	Quantitative Radiology Reporting in Oncology: Survey of Oncologists and Radiologists. <i>American Journal of Roentgenology</i> , 2015, 205, W233-W243.	1.0	29
2173	Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Annals of Hematology</i> , 2015, 94, 1865-1873.	0.8	14
2174	A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma. <i>Tumor Microenvironment and Therapy</i> , 2015, 2, 14-18.	1.2	3
2175	Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. <i>Clinical Cancer Research</i> , 2015, 21, 1835-1842.	3.2	58

#	ARTICLE	IF	CITATIONS
2176	Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 184-189.	0.7	5
2177	Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. <i>Leukemia and Lymphoma</i> , 2015, 56, 3045-3051.	0.6	77
2178	PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 215-221.	3.3	24
2179	Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 57-64.	0.6	2
2180	Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 575-581.	0.8	55
2181	Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 152-158.	0.2	34
2182	Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. <i>British Journal of Haematology</i> , 2015, 169, 188-198.	1.2	49
2183	Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients. <i>Hematological Oncology</i> , 2015, 33, 141-146.	0.8	13
2185	Whole-body diffusion-weighted MRI for staging lymphoma at 3.0T: comparative study with MR imaging at 1.5T. <i>Clinical Imaging</i> , 2015, 39, 104-109.	0.8	18
2186	Lymphopenia during routine follow-up may predict relapse in patients with extranodal NK/T cell lymphoma. <i>Tumor Biology</i> , 2015, 36, 1747-1753.	0.8	5
2187	Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2015, 168, 654-662.	1.2	90
2188	Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. <i>Annals of Oncology</i> , 2015, 26, 386-392.	0.6	44
2189	Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. <i>Annals of Hematology</i> , 2015, 94, 593-601.	0.8	6
2190	Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 1-12.e7.	0.2	13
2192	Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study. <i>Hematological Oncology</i> , 2015, 33, 129-135.	0.8	11
2193	The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma. <i>Targeted Oncology</i> , 2015, 10, 15-26.	1.7	18
2194	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. <i>Oncotarget</i> , 2016, 7, 85573-85583.	0.8	13
2195	Decreased apolipoprotein A-I level indicates poor prognosis in extranodal natural killer/T-cell lymphoma, nasal type. <i>OncoTargets and Therapy</i> , 2016, 9, 1281.	1.0	4

#	ARTICLE	IF	CITATIONS
2196	Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Blood Research</i> , 2016, 51, 113.	0.5	12
2197	Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 145-151.	1.0	4
2198	Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2016, 56, 28-33.	0.3	5
2199	High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. <i>Oncotarget</i> , 2016, 7, 33035-33045.	0.8	46
2200	Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. <i>Oncotarget</i> , 2016, 7, 32519-32531.	0.8	14
2201	IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017010.	0.5	9
2202	Predictors of survival of natural killer/T-cell lymphoma, nasal type, in a non-Asian population: a single cancer centre experience. <i>Ecancermedicalsecience</i> , 2016, 10, 688.	0.6	8
2203	Treatment outcomes of IMEP as a front-line chemotherapy for patients with peripheral T-cell lymphomas. <i>Blood Research</i> , 2016, 51, 187.	0.5	1
2204	Burkitt lymphoma in adolescents and young adults: management challenges. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 11-29.	0.7	54
2205	Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. <i>BMC Cancer</i> , 2016, 16, 537.	1.1	11
2206	ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5349-5360.	1.0	21
2207	Primary breast diffuse large B-cell lymphoma in the era of rituximab. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6093-6097.	1.0	8
2208	Adjudication Rates between Readers in Blinded Independent Central Review of Oncology Studies. <i>Journal of Clinical Trials</i> , 2016, 06, .	0.1	7
2209	GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. <i>Medicine (United States)</i> , 2016, 95, e2787.	0.4	32
2210	Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome. <i>European Journal of Haematology</i> , 2016, 96, 252-259.	1.1	39
2211	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 923-930.	2.0	79
2212	A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. <i>British Journal of Haematology</i> , 2016, 174, 571-581.	1.2	43
2213	Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. <i>Clinical Cancer Research</i> , 2016, 22, 4559-4566.	3.2	56

#	ARTICLE	IF	CITATIONS
2214	High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma. <i>Journal of Medical Virology</i> , 2016, 88, 1010-1017.	2.5	50
2216	Phase II trial of CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. <i>British Journal of Haematology</i> , 2016, 172, 208-218.	1.2	45
2217	Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network international prognostic index and positron emission tomography-defined remission status; a population-based analysis. <i>British Journal of Haematology</i> , 2016, 172, 246-254.	1.2	28
2218	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. <i>British Journal of Haematology</i> , 2016, 173, 236-244.	1.2	28
2219	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. <i>British Journal of Haematology</i> , 2016, 173, 274-282.	1.2	12
2220	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016, 91, 894-899.	2.0	15
2221	Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1521-1535.	0.8	9
2222	The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≥ 12 months. <i>British Journal of Haematology</i> , 2016, 173, 260-264.	1.2	12
2223	Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. <i>British Journal of Haematology</i> , 2016, 173, 867-875.	1.2	36
2224	Why do subjects on clinical trials discontinue therapy? Do we really know?. <i>Leukemia Research</i> , 2016, 51, 19-21.	0.4	0
2225	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. <i>Blood</i> , 2016, 128, 1814-1820.	0.6	75
2227	Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelines. <i>Pediatric Hematology and Oncology</i> , 2016, 33, 423-437.	0.3	4
2228	Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30 ⁺ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. <i>Haematologica</i> , 2016, 101, 466-473.	1.7	35
2229	Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, 16002.	7.1	110
2230	Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. <i>Annals of Hematology</i> , 2016, 95, 893-899.	0.8	10
2231	Role of follow-up endoscopic examination in treatment response assessment for patients with gastric diffuse large B cell lymphoma. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1111-1117.	0.6	2
2232	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2484-2492.	0.8	106
2233	Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy. <i>Annals of Hematology</i> , 2016, 95, 1259-1269.	0.8	11

#	ARTICLE	IF	CITATIONS
2234	The impact of Fc γ RIIa and Fc γ RIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients. <i>Oncology Letters</i> , 2016, 11, 3332-3336.	0.8	1
2235	PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP. <i>Leukemia</i> , 2016, 30, 1799-1800.	3.3	1
2236	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199.	1.7	15
2237	A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320. <i>Leukemia and Lymphoma</i> , 2016, 57, 2232-2234.	0.6	3
2238	Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2016, 51, 928-932.	1.3	9
2239	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 225-240.	1.0	12
2240	Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 2784-2790.	0.6	15
2241	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. <i>Leukemia and Lymphoma</i> , 2016, 57, 2359-2369.	0.6	33
2242	Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 2402-2411.	6.3	157
2243	Response Assessment Criteria and Their Applications in Lymphoma: Part 1. <i>Journal of Nuclear Medicine</i> , 2016, 57, 928-935.	2.8	21
2244	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. <i>Annals of Hematology</i> , 2016, 95, 1107-1114.	0.8	25
2245	Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04). <i>International Journal of Hematology</i> , 2016, 103, 676-685.	0.7	6
2246	Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. <i>Haematologica</i> , 2016, 101, 474-481.	1.7	44
2247	Eight Cycles of ABVD Versus Four Cycles of BEACOPP_{escalated} Plus Four Cycles of BEACOPP_{baseline} in Stage III to IV, International Prognostic Score \geq 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2028-2036.	0.8	111
2248	High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1129-1136.	0.8	3
2249	Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma. <i>Acta Haematologica</i> , 2016, 136, 52-61.	0.7	34
2250	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , 2016, 127, 411-419.	0.6	231
2251	TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. <i>Blood</i> , 2016, 128, 72-81.	0.6	29

#	ARTICLE	IF	CITATIONS
2252	Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases. <i>International Journal of Hematology</i> , 2016, 104, 669-681.	0.7	24
2253	Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. <i>Clinical Epigenetics</i> , 2016, 8, 79.	1.8	35
2254	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1582-1587.	2.0	20
2255	FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma. <i>International Journal of Hematology</i> , 2016, 104, 692-699.	0.7	7
2256	Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden. <i>International Journal of Hematology</i> , 2016, 104, 700-708.	0.7	7
2257	Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?. <i>Oncologist</i> , 2016, 21, 1107-1112.	1.9	33
2258	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. <i>British Journal of Haematology</i> , 2016, 175, 668-672.	1.2	38
2259	Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. <i>Haematologica</i> , 2016, 101, 976-984.	1.7	70
2260	R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1705-1714.	0.8	30
2261	Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. <i>International Journal of Cancer</i> , 2016, 139, 2519-2528.	2.3	32
2262	18F-Fluorodeoxyglucose PET/MR Imaging in Lymphoma. <i>PET Clinics</i> , 2016, 11, 363-373.	1.5	8
2263	First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2016, 6, e452-e452.	2.8	58
2264	Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. <i>British Journal of Haematology</i> , 2016, 175, 531-533.	1.2	7
2265	Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. <i>British Journal of Haematology</i> , 2016, 174, 692-699.	1.2	26
2266	Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. <i>European Journal of Haematology</i> , 2016, 96, 447-460.	1.1	95
2267	Clinicobiological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy. <i>British Journal of Haematology</i> , 2016, 172, 470-473.	1.2	14
2268	Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016, 172, 80-88.	1.2	82
2269	Clinical pretreatment risk factors and prediction of outcome using gallium 67 scintigraphy in patients with Hodgkin's lymphoma. <i>Molecular and Clinical Oncology</i> , 2016, 4, 93-99.	0.4	2

#	ARTICLE	IF	CITATIONS
2270	Impaired functional responses in follicular lymphoma CD8 ⁺ TIM-3 ⁺ T lymphocytes following TCR engagement. <i>OncImmunology</i> , 2016, 5, e1224044.	2.1	32
2271	Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis. <i>Leukemia and Lymphoma</i> , 2016, 57, 1945-1948.	0.6	4
2272	Treatment Response and Outcomes in Post-transplantation Lymphoproliferative Disease vs Lymphoma in Immunocompetent Patients. <i>Transplantation Proceedings</i> , 2016, 48, 1927-1933.	0.3	5
2273	Radioimmunotherapy with ¹³¹ I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 825-831.	1.1	5
2274	Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. <i>Oncology Letters</i> , 2016, 12, 825-836.	0.8	8
2275	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016, 128, 2489-2496.	0.6	370
2276	Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma. <i>Scientific Reports</i> , 2016, 6, 23996.	1.6	7
2277	Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies. <i>Acta Haematologica</i> , 2016, 136, 244-255.	0.7	10
2278	Adrenal lymphoma: presentation, management and prognosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 110, hcw174.	0.2	40
2279	Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. <i>Drugs</i> , 2016, 76, 1579-1586.	4.9	11
2280	Is the lymphoma better? Not easy to determine. <i>Blood</i> , 2016, 128, 2481-2482.	0.6	1
2281	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. <i>Haematologica</i> , 2016, 101, 235-240.	1.7	24
2283	Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy "SAKK 38/08". <i>British Journal of Haematology</i> , 2016, 174, 255-263.	1.2	10
2284	Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2016, 16, 267.	1.1	9
2285	Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2016, 9, 22.	6.9	38
2286	A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy. <i>Annals of Hematology</i> , 2016, 95, 1249-1258.	0.8	13
2287	Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2016, 104, 236-244.	0.7	17
2288	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	6.3	328

#	ARTICLE	IF	CITATIONS
2289	Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. <i>British Journal of Radiology</i> , 2016, 89, 20160086.	1.0	2
2290	Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1397-1402.	2.0	6
2291	Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 247-251.	0.7	2
2292	Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 18-28.e4.	0.2	15
2293	RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	1.3	211
2294	Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. <i>Annals of Hematology</i> , 2016, 95, 1271-1280.	0.8	8
2295	Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. <i>Acta Haematologica</i> , 2016, 136, 76-84.	0.7	6
2296	A phase 2 study of Rituximab+ Bendamustine and Rituximab+ Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	1.2	51
2297	Efficacy of the GemOx regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma. <i>British Journal of Haematology</i> , 2016, 174, 899-910.	1.2	13
2298	Zevalin and BEAM (Z+BEAM) versus rituximab and BEAM (R+BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma. <i>Hematological Oncology</i> , 2016, 34, 133-139.	0.8	14
2299	DHAP plus filgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory lymphoma: A single center experience. <i>Transfusion and Apheresis Science</i> , 2016, 54, 48-52.	0.5	1
2300	Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 498-505.	1.0	17
2301	Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 572-580.	0.8	76
2302	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	13.9	1,532
2303	Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2016, 101, 226-234.	1.7	31
2304	The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and High CD44 Tumor Cell Expression in Non Hodgkin Lymphomas. <i>Pathology and Oncology Research</i> , 2016, 22, 567-577.	0.9	8
2305	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002); Tj ETQq0 0 0 rBT /Overlock 10 Tf 5	8.1	185
2306	Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1104-1111.	0.8	359

#	ARTICLE	IF	CITATIONS
2307	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016, 57, 2370-2374.	0.6	5
2308	High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan. <i>Acta Haematologica</i> , 2016, 135, 156-161.	0.7	9
2309	90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 82-88.	0.2	6
2310	Chemoradiotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type, using a shrinking-field radiation strategy: multi-institutional experience. <i>Japanese Journal of Radiology</i> , 2016, 34, 292-299.	1.0	4
2311	LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy. <i>International Journal of Hematology</i> , 2016, 103, 292-298.	0.7	12
2312	Radiation Therapy for Diffuse Large B-Cell Lymphoma: Indications, Outcomes, and Controversies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 641-644.	0.4	6
2313	CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 191-196.	0.2	5
2314	Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. <i>Lancet Haematology</i> , 2016, 3, e107-e118.	2.2	48
2315	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage II Follicular Lymphoma: Results of a Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 783-791.	0.4	35
2316	Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization. <i>Oncolmmunology</i> , 2016, 5, e1143995.	2.1	9
2317	Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology. <i>Radiographics</i> , 2016, 36, 481-496.	1.4	80
2318	Prognostic value of negative interim 2-[18F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma. <i>Clinical Radiology</i> , 2016, 71, 280-286.	0.5	12
2319	Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. <i>Journal of Clinical Oncology</i> , 2016, 34, 495-500.	0.8	49
2320	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1823-1830.	0.6	30
2321	Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. <i>Leukemia</i> , 2016, 30, 1428-1430.	3.3	19
2322	The possible benefit from total tumour resection in primary diffuse large B-cell lymphoma of central nervous system – a one-decade single-centre experience. <i>British Journal of Neurosurgery</i> , 2016, 30, 80-85.	0.4	22
2323	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 1406-1412.	0.6	4
2324	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016, 51, 51-57.	1.3	216

#	ARTICLE	IF	CITATIONS
2325	Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial. <i>Leukemia</i> , 2016, 30, 984-987.	3.3	11
2326	FDG PET/CT Response Assessment Criteria for Patients with Hodgkin's and Non-Hodgkin's Lymphoma at End of Therapy: A Multiparametric Approach. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 46-53.	0.6	13
2327	Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 1335-1341.	0.6	19
2328	A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 1059-1066.	3.2	71
2329	Role of WB-MR/DWIBS compared to 18F-FDG PET/CT in the therapy response assessment of lymphoma. <i>Radiologia Medica</i> , 2016, 121, 132-143.	4.7	28
2330	A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 216-218.	0.6	24
2331	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	0.6	17
2332	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. <i>European Journal of Haematology</i> , 2016, 96, 128-135.	1.1	19
2333	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. <i>Leukemia</i> , 2016, 30, 361-372.	3.3	55
2334	PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. <i>Leukemia</i> , 2016, 30, 238-242.	3.3	43
2335	Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 445-447.	0.6	5
2336	CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin. <i>Hematological Oncology</i> , 2017, 35, 163-171.	0.8	7
2337	Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 324-332.	0.6	32
2338	FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. <i>Leukemia and Lymphoma</i> , 2017, 58, 372-381.	0.6	13
2339	Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 357-365.	0.6	4
2340	Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. <i>Cancer Letters</i> , 2017, 387, 25-31.	3.2	24
2341	FCGR3A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	0.8	9
2342	Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*. <i>Leukemia and Lymphoma</i> , 2017, 58, 64-69.	0.6	11

#	ARTICLE	IF	CITATIONS
2343	A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemother. <i>Hematological Oncology</i> , 2017, 35, 288-295.	0.8	8
2344	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Åyears follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	0.8	7
2345	Results of a phase lâ€ł study of fenretinide and rituximab for patients with indolent Bâ€łcell lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2017, 176, 583-590.	1.2	10
2346	Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 367-373.	1.9	6
2347	Pharmacokinetics of obinutuzumab in Chinese patients with Bâ€łcell lymphomas. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1446-1456.	1.1	8
2348	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2017, 52, 689-696.	1.3	31
2349	Second cancer incidence in primary mediastinal Bâ€łcell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of longâ€łterm survivors. <i>Hematological Oncology</i> , 2017, 35, 554-560.	0.8	6
2350	Analysis of prognostic value of complete response by PETâ€łCT and further stratification by clinical and biological markers in DLBCL patients. <i>Medical Oncology</i> , 2017, 34, 29.	1.2	9
2351	Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience. <i>Journal of International Medical Research</i> , 2017, 45, 290-302.	0.4	14
2352	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.	2.0	26
2353	Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. <i>Leukemia and Lymphoma</i> , 2017, 58, 2335-2341.	0.6	13
2354	BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. <i>American Journal of Hematology</i> , 2017, 92, 515-519.	2.0	22
2355	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study. <i>EBioMedicine</i> , 2017, 16, 106-114.	2.7	15
2356	Comparison of CBV, BEAM and BEAC highâ€łdose chemotherapy followed by autologous hematopoietic stem cell transplantation in nonâ€łHodgkin lymphoma: Efficacy and toxicity. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e423-e429.	0.7	19
2357	Allogeneic hematopoietic stem cell transplantation for non-Hodgkinâ€łTMs lymphomas: a retrospective analysis of 77 cases. <i>Annals of Hematology</i> , 2017, 96, 787-796.	0.8	3
2358	Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. <i>Molecular and Clinical Oncology</i> , 2017, 6, 627-633.	0.4	7
2359	Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2319-2327.	0.6	23
2360	Prognostic impact of absolute lymphocyte count/absolute monocyte count ratio and prognostic score in patients with nasal-type, extranodal natural killer/T-cell lymphoma. <i>Tumor Biology</i> , 2017, 39, 101042831770550.	0.8	14

#	ARTICLE	IF	CITATIONS
2361	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas: long term results. <i>British Journal of Haematology</i> , 2017, 178, 561-570.	1.2	12
2362	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e272-e282.	2.2	91
2363	Toward common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST?. <i>Annals of Oncology</i> , 2017, 28, 1409-1411.	0.6	6
2364	Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 342-349.	0.4	14
2365	A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 434-441.	1.2	86
2366	Beyond Correlations, Sensitivities, and Specificities. <i>Academic Radiology</i> , 2017, 24, 1027-1035.	1.3	6
2367	Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 492-499.	0.3	6
2368	A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. <i>Hematology</i> , 2017, 22, 258-264.	0.7	8
2369	Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients. <i>European Journal of Haematology</i> , 2017, 98, 355-362.	1.1	2
2370	L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 759-768.	1.1	29
2371	Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2845-2851.	0.6	0
2372	Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2607-2614.	0.6	16
2373	Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 472-477.	0.6	65
2374	Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2169-2178.	0.6	207
2375	Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. <i>BMC Cancer</i> , 2017, 17, 359.	1.1	16
2376	Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1631-1640.	2.0	32
2377	Evolution of lymphoma staging and response evaluation: current limitations and future directions. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 631-645.	12.5	26
2378	Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 608-638.	2.3	81

#	ARTICLE	IF	CITATIONS
2379	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC). <i>American Journal of Hematology</i> , 2017, 92, 1004-1010.	2.0	7
2380	Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 2017, 96, 943-950.	0.8	13
2381	Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2017, 7, 44282.	1.6	9
2382	High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. <i>British Journal of Haematology</i> , 2017, 177, 263-270.	1.2	14
2383	Lymphoblastic lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 304-317.	2.0	81
2384	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	0.6	249
2385	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4127-4137.	3.2	135
2386	Primary breast lymphoma: A single center study. <i>Oncology Letters</i> , 2017, 13, 1014-1018.	0.8	21
2387	Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. <i>Annals of Hematology</i> , 2017, 96, 411-420.	0.8	19
2388	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-ecpratumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	2.2	33
2389	Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China. <i>Leukemia and Lymphoma</i> , 2017, 58, 1624-1629.	0.6	8
2390	Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. <i>Annals of Oncology</i> , 2017, 28, 843-848.	0.6	83
2391	Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). <i>Annals of Oncology</i> , 2017, 28, 836-842.	0.6	87
2392	Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. <i>Journal of Clinical Oncology</i> , 2017, 35, 32-39.	0.8	122
2393	Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Annals of Hematology</i> , 2017, 96, 405-410.	0.8	12
2394	Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. <i>Lancet Haematology</i> , 2017, 4, e46-e55.	2.2	83
2395	Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan. <i>International Journal of Hematology</i> , 2017, 105, 470-477.	0.7	12
2396	Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. <i>British Journal of Haematology</i> , 2017, 176, 591-599.	1.2	46

#	ARTICLE	IF	CITATIONS
2397	How I manage peripheral Tâ€cell lymphoma, not otherwise specified and angioimmunoblastic Tâ€cell lymphoma: current practice and a glimpse into the future. <i>British Journal of Haematology</i> , 2017, 176, 851-866.	1.2	49
2398	The survival outcome of patients with relapsed/refractory peripheral Tâ€cell lymphomaâ€not otherwise specified and angioimmunoblastic Tâ€cell lymphoma. <i>British Journal of Haematology</i> , 2017, 176, 750-758.	1.2	78
2399	Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral Tâ€cell lymphoma. <i>Cancer Medicine</i> , 2017, 6, 36-44.	1.3	17
2400	Checkpoint Inhibition in Non-Hodgkin's Lymphoma. <i>Oncology Research and Treatment</i> , 2017, 40, 662-672.	0.8	4
2401	Histological transformation from gastric mucosa-associated lymphoid tissue lymphoma to gastric diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2017, 14, 2244-2248.	0.8	3
2402	Optimization of rituximab for the treatment of <scp>DLBCL</scp>: increasing the dose for elderly male patients. <i>British Journal of Haematology</i> , 2017, 179, 410-420.	1.2	42
2403	Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. <i>Haematologica</i> , 2017, 102, 1913-1922.	1.7	52
2404	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	13.9	313
2405	Results of Upfront Therapy for Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 879-883.	0.2	3
2406	Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. <i>Haematologica</i> , 2017, 102, 2097-2103.	1.7	34
2407	Phase I<scp>II</scp> study of pralatrexate in Japanese patients with relapsed or refractory peripheral Tâ€cell lymphoma. <i>Cancer Science</i> , 2017, 108, 2061-2068.	1.7	29
2408	Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?. <i>Transplantation Proceedings</i> , 2017, 49, 1911-1915.	0.3	7
2409	Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. <i>Lancet Haematology</i> , 2017, 4, e350-e361.	2.2	69
2410	Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials. <i>British Journal of Haematology</i> , 2017, 179, 242-245.	1.2	12
2411	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e362-e373.	2.2	70
2412	Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 631-636.	0.2	19
2413	Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 797-803.	0.2	15
2414	Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study. <i>Scientific Reports</i> , 2017, 7, 1905.	1.6	11

#	ARTICLE	IF	CITATIONS
2415	Interim FDG-PET in lymphoma, a questionable practice in hematology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2014-2017.	3.3	2
2416	Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. <i>Anti-Cancer Drugs</i> , 2017, 28, 341-349.	0.7	10
2417	Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. <i>British Journal of Haematology</i> , 2017, 178, 699-708.	1.2	61
2418	Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017, 130, 1772-1774.	0.6	60
2419	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	0.6	1,084
2420	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2017, 377, 2545-2554.	13.9	1,390
2422	Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma. <i>Medicine (United States)</i> , 2017, 96, e8494.	0.4	8
2423	Progression-free survival at 2 years post autologous transplant: a surrogate end point for overall survival in follicular lymphoma. <i>Cancer Medicine</i> , 2017, 6, 2766-2774.	1.3	11
2424	Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP 14 compared to first-line autologous transplantation. <i>British Journal of Haematology</i> , 2017, 178, 927-935.	1.2	8
2425	Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , 2017, 96, 1477-1483.	0.8	20
2426	Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. <i>International Journal of Hematology</i> , 2017, 106, 655-665.	0.7	33
2427	Relationship Between Dual Time Point FDG PET/CT and Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 323-330.	0.6	13
2428	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2017, 18, 1076-1088.	5.1	100
2429	Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial. <i>Annals of Oncology</i> , 2017, 28, 622-627.	0.6	17
2430	Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). <i>Annals of Oncology</i> , 2017, 28, 2185-2190.	0.6	26
2431	Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). <i>Annals of Hematology</i> , 2017, 96, 1323-1330.	0.8	5
2432	How to Approach a Patient With Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 710-715.	0.2	2
2433	The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. <i>BMC Cancer</i> , 2017, 17, 276.	1.1	10

#	ARTICLE	IF	CITATIONS
2434	Imaging for Oncologic Response Assessment in Lymphoma. American Journal of Roentgenology, 2017, 208, 18-31.	1.0	22
2435	A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. Acta Haematologica, 2017, 137, 7-14.	0.7	4
2436	Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP. Annals of Hematology, 2017, 96, 227-235.	0.8	5
2437	Peripheral blood lymphocyte/monocyte ratio following completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. Annals of Hematology, 2017, 96, 237-243.	0.8	3
2438	A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China. Hematological Oncology, 2017, 35, 619-629.	0.8	19
2439	Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma not otherwise specified. Annals of Hematology, 2017, 96, 245-251.	0.8	18
2440	Targeting histone deacetylases in T-cell lymphoma. Leukemia and Lymphoma, 2017, 58, 1306-1319.	0.6	84
2441	Does end-of-treatment ^{FDG} PET provide any additional prognostic value to the pre-treatment ^{NCCN} IPI score?. British Journal of Haematology, 2017, 177, 319-320.	1.2	4
2442	Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. Clinical Cancer Research, 2017, 23, 35-42.	3.2	31
2443	Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leukemia and Lymphoma, 2017, 58, 623-632.	0.6	5
2444	Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-HAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematological Oncology, 2017, 35, 497-503.	0.8	36
2445	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplantation, 2017, 52, 216-221.	1.3	102
2446	A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biology of Blood and Marrow Transplantation, 2017, 23, 38-43.	2.0	21
2447	Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database. Leukemia and Lymphoma, 2017, 58, 601-613.	0.6	7
2448	Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematological Oncology, 2017, 35, 914-917.	0.8	50
2449	Rebound Thymic Hyperplasia after Chemotherapy in Children with Lymphoma. Pediatrics and Neonatology, 2017, 58, 151-157.	0.3	20
2453	Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma, nasal type: a triple-center study. Chinese Journal of Cancer, 2017, 36, 62.	4.9	6
2454	An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. Seminars in Oncology, 2017, 44, 404-419.	0.8	14

#	ARTICLE	IF	CITATIONS
2455	Significance of imaging and clinical features in the differentiation between primary and secondary pulmonary lymphoma. <i>Oncology Letters</i> , 2017, 14, 6224-6230.	0.8	6
2456	Upfront high-dose chemotherapy combined with autologous stem cell transplantation: Potential survival benefit for patients with high-risk diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2017, 14, 3803-3808.	0.8	6
2457	Red blood cell distribution width as a predictor of survival in nasal-type, extranodal natural killer/T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92522-92535.	0.8	14
2458	Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients. <i>Oncotarget</i> , 2017, 8, 80073-80082.	0.8	12
2459	Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. <i>Blood Advances</i> , 2017, 1, 2138-2146.	2.5	27
2460	Lymphocyte/Monocyte Ratio is a Novel Predictor for Early Stage Extranodal Natural Killer/T-cell Lymphoma, Nasal Type. <i>Journal of Cancer</i> , 2017, 8, 1030-1037.	1.2	9
2461	Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients. <i>Blood Research</i> , 2017, 52, 125.	0.5	7
2462	Serum Cystatin C as a Biomarker in Diffuse Large B-Cell Lymphoma. <i>Scientia Pharmaceutica</i> , 2017, 85, 9.	0.7	10
2463	Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	1.4	3
2464	Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1719-1728.	2.0	69
2465	Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers. <i>PLoS ONE</i> , 2017, 12, e0186983.	1.1	16
2466	3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis. <i>Internal Medicine</i> , 2017, 56, 2407-2413.	0.3	3
2467	TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP. <i>BMC Cancer</i> , 2017, 17, 743.	1.1	9
2468	Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). <i>Journal of Hematology and Oncology</i> , 2017, 10, 171.	6.9	41
2469	Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin's lymphoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5727-5738.	1.0	7
2470	Retrospective analysis of primary gastric diffuse large B-cell lymphoma: a single center study from Turkey. <i>Turkish Journal of Medical Sciences</i> , 2017, 47, 240-245.	0.4	3
2471	IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. <i>Journal of Cancer</i> , 2017, 8, 1018-1024.	1.2	14
2472	Early Positron Emission Tomography Response—Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1786-1794.	0.8	397

#	ARTICLE	IF	CITATIONS
2473	Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome. <i>Journal of Global Oncology</i> , 2017, 3, 545-554.	0.5	15
2474	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	0.8	143
2475	Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3215-3221.	0.8	315
2476	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , The, 2018, 19, 549-561.	5.1	165
2477	Updated Results of Rituximab Pre- and Post-BEAM with or without ⁹⁰ Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2018, 24, 2304-2311.	3.2	11
2478	Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant. <i>Annals of Hematology</i> , 2018, 97, 1229-1240.	0.8	6
2479	Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 191-198.	0.2	10
2480	Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 343-353.	0.1	1
2481	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , the, 2018, 5, e190-e200.	2.2	50
2482	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	0.6	11
2483	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	0.8	16
2484	Diagnostic accuracy of diffusion-weighted imaging-magnetic resonance imaging compared to positron emission tomography/computed tomography in evaluating and assessing pathological response to treatment in adult patients with lymphoma: A systematic review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 530-539.	0.9	7
2485	Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 12-20.	1.1	3
2486	A Phase I Dose Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. <i>Oncologist</i> , 2018, 23, 397.	1.9	0
2487	Stem cell transplantation for T-cell lymphomas in Taiwan. <i>Bone Marrow Transplantation</i> , 2018, 53, 993-1000.	1.3	5
2488	Checkpoint-Inhibition bei Non-Hodgkin-Lymphom. <i>Karger Kompass Onkologie</i> , 2018, 5, 12-20.	0.0	0
2489	Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. <i>Haematologica</i> , 2018, 103, 857-864.	1.7	27
2490	Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review. <i>Annals of Hematology</i> , 2018, 97, 821-829.	0.8	7

#	ARTICLE	IF	CITATIONS
2491	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. <i>Cancer</i> , 2018, 124, 1733-1742.	2.0	58
2492	Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngsters. <i>Scientific Reports</i> , 2018, 8, 1088.	1.6	10
2493	Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 347-351.	1.3	1
2494	Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 125-135.e3.	0.2	6
2495	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 700-707.	2.0	16
2496	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 681-697.	4.2	65
2497	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 400-409.	1.3	34
2498	Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. <i>Annals of Oncology</i> , 2018, 29, 715-723.	0.6	110
2499	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <i>Oncologist</i> , 2018, 23, 454-460.	1.9	22
2500	The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders. <i>Annals of Hematology</i> , 2018, 97, 1611-1618.	0.8	12
2501	Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2856-2859.	0.6	25
2502	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. <i>Cancer</i> , 2018, 124, 2561-2569.	2.0	14
2503	Refractory diffuse large B-cell lymphoma after first-line immunochemotherapy: Treatment options and outcomes. <i>Hematological Oncology</i> , 2018, 36, 533-542.	0.8	5
2504	Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	1.2	49
2505	Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with rituximab, ibritumomab tiuxetan in a phase II study. <i>Hematological Oncology</i> , 2018, 36, 525-532.	0.8	4
2507	Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. <i>Blood</i> , 2018, 132, 245-253.	0.6	52
2508	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	1.7	90
2509	Clinical characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults. <i>International Journal of Hematology</i> , 2018, 108, 161-166.	0.7	7

#	ARTICLE	IF	CITATIONS
2510	Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. <i>Haematologica</i> , 2018, 103, e356-e359.	1.7	7
2511	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
2512	The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. <i>Annals of Hematology</i> , 2018, 97, 1241-1250.	0.8	31
2513	A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma. <i>Journal of Immunotherapy</i> , 2018, 41, 151-157.	1.2	9
2514	Absolute monocyte count at diagnosis could improve the prognostic role of early ^{FDG}^{PET} in classical Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , 2018, 180, 600-602.	1.2	2
2515	Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years. <i>Hematological Oncology</i> , 2018, 36, 217-223.	0.8	13
2516	Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. <i>Hematological Oncology</i> , 2018, 36, 28-36.	0.8	23
2517	Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores. <i>Leukemia and Lymphoma</i> , 2018, 59, 340-347.	0.6	22
2518	Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry. <i>Hematological Oncology</i> , 2018, 36, 189-195.	0.8	15
2519	Outcome of patients older than 80 years with diffuse large ^B-cell lymphoma (^{DLBCL}) treated with standard immunochemotherapy: A large retrospective study from 4 institutions. <i>Hematological Oncology</i> , 2018, 36, 84-92.	0.8	8
2520	Mean platelet volume predicts prognosis in patients with diffuse large ^B-cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 104-109.	0.8	13
2521	Clinicopathologic characteristics and outcomes of transformed diffuse large ^B-cell lymphoma in hepatitis ^C virus-infected patients. <i>International Journal of Cancer</i> , 2018, 142, 940-948.	2.3	13
2522	Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients: An analysis from the Brazilian Hodgkin Lymphoma Registry. <i>International Journal of Cancer</i> , 2018, 142, 883-890.	2.3	17
2523	Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14). <i>Leukemia and Lymphoma</i> , 2018, 59, 1606-1613.	0.6	1
2524	Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1451-1460.	0.6	16
2525	PET/CT in Lymphoma: Current Overview and Future Directions. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 76-81.	2.5	57
2526	A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 13-25.e6.	0.2	14
2527	Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1420-1426.	0.6	10

#	ARTICLE	IF	CITATIONS
2528	Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. <i>Modern Pathology</i> , 2018, 31, 313-326.	2.9	42
2529	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 880-887.	0.6	28
2530	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
2531	VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e61-e67.	0.2	13
2532	Prospective subgroup analyses of the randomized <scp>MCL</scp>â€œ002 (<scp>SPRINT</scp>) study: lenalidomide <i>versus</i> investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 224-235.	1.2	10
2533	Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. <i>Annals of Hematology</i> , 2018, 97, 255-266.	0.8	30
2534	Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e103-e108.	0.2	3
2535	Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities. <i>Annals of Hematology</i> , 2018, 97, 267-276.	0.8	11
2536	Characteristics of primary extranodal marginal zone B-cell lymphoma in Korea: conjunctiva versus other ocular adnexa. <i>British Journal of Ophthalmology</i> , 2018, 102, 502-508.	2.1	14
2537	Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 670-678.	0.6	8
2538	Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China. <i>Chinese Medical Journal</i> , 2018, 131, 1767-1775.	0.9	9
2539	A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D2); Tj ETQq1 1 0.784314 rgBT /Overlook	0.8	110
2540	Monoclonal gammopathies regardless of subtypes are associated with poor prognosis of diffuse large B-cell lymphoma. <i>Medicine (United States)</i> , 2018, 97, e11719.	0.4	6
2541	Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. <i>Journal of Clinical Oncology</i> , 2018, 36, 3315-3323.	0.8	42
2542	Treatment outcomes of adult Burkitt lymphoma: results with a modified LMB protocol in Brazil and feasibility of outpatient administration. <i>Journal of Chemotherapy</i> , 2018, 30, 375-379.	0.7	2
2543	Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	28
2544	Rituximab With Involved Field Irradiation for Earlyâ€œstage Nodal Follicular Lymphoma. <i>HemaSphere</i> , 2018, 2, e160.	1.2	33
2545	Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma. <i>Current Clinical Pharmacology</i> , 2018, 13, 55-64.	0.2	19

#	ARTICLE	IF	CITATIONS
2546	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e543-e553.	2.2	53
2547	Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. <i>Lancet Haematology</i> , 2018, 5, e520-e531.	2.2	14
2548	Definitive salvage chemotherapy for the treatment of refractory/relapsed non-Hodgkin lymphoma, a single center experience. <i>Alexandria Journal of Medicine</i> , 2018, 54, 679-683.	0.4	4
2549	Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I extranodal natural killer/T-cell lymphoma. <i>Cancer Medicine</i> , 2018, 7, 5863-5869.	1.3	7
2550	Lymphomas: The Role of CT and MRI in Staging and Restaging. , 2018, , 609-618.		0
2551	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1530-1542.	5.1	91
2552	An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. <i>Oncotarget</i> , 2018, 9, 19079-19099.	0.8	11
2553	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , 2018, 132, 2115-2124.	0.6	232
2554	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 934-947.	13.9	264
2555	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e403-e410.	2.2	21
2556	The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group. <i>Leukemia Research</i> , 2018, 73, 29-38.	0.4	3
2557	HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey. <i>Oncology Letters</i> , 2018, 16, 3923-3928.	0.8	3
2558	Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 805-819.	3.3	38
2559	Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy. <i>Clinical and Translational Imaging</i> , 2018, 6, 417-427.	1.1	8
2560	Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study. <i>Blood Advances</i> , 2018, 2, 1562-1571.	2.5	10
2561	An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 508-518.e14.	0.2	11
2562	Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 267-274.	2.5	14
2563	Dual-energy CT-based iodine quantification to differentiate abdominal malignant lymphoma from lymph node metastasis. <i>European Journal of Radiology</i> , 2018, 105, 255-260.	1.2	21

#	ARTICLE	IF	CITATIONS
2564	Selective contrast-enhanced computed tomography is appropriate in diffuse large B-cell lymphoma therapy response assessment. <i>European Journal of Haematology</i> , 2018, 101, 613-619.	1.1	2
2565	Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. , 2018, , 951-973.		0
2566	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	0.6	25
2567	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
2568	Multimodality imaging using PET/CT (18F)-fluorodeoxyglucose for radiotherapy field delineation of localized Hodgkin lymphoma. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2018, 22, 384-392.	0.6	3
2569	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2211-2215.	2.0	9
2570	Radiological Evaluation of Response and Resistance of Ibritumomab. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 67-77.	0.1	0
2571	Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 285-292.	0.7	6
2572	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	1.2	19
2573	Role of FDG PET-CT in the treatment management of Hodgkin lymphoma. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2018, 22, 393-400.	0.6	7
2574	Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. <i>Annals of Hematology</i> , 2018, 97, 1641-1647.	0.8	26
2575	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2018, 103, 1345-1350.	1.7	45
2576	Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. <i>British Journal of Haematology</i> , 2018, 181, 782-790.	1.2	15
2577	Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma. <i>International Journal of Cancer</i> , 2018, 143, 1884-1895.	2.3	27
2578	Bendamustine and rituximab in elderly patients with low tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study. <i>British Journal of Haematology</i> , 2018, 183, 76-86.	1.2	14
2579	Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome. <i>Annals of Hematology</i> , 2018, 97, 2381-2389.	0.8	8
2580	A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 6185-6194.	3.2	177
2581	Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. <i>Cancer Communications</i> , 2018, 38, 1-9.	3.7	7

#	ARTICLE	IF	CITATIONS
2582	Salvage radiotherapy improves survival in patients with locoregionally relapsed stage I–II extranodal natural killer/T-cell lymphoma, nasal type. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1083-1090.	0.9	0
2583	Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 61-70.	0.4	15
2584	R-ICE Chemotherapy with or without Autologous Transplantation for Elderly Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas. <i>Oncology Research and Treatment</i> , 2018, 41, 534-538.	0.8	2
2585	Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. <i>Hematological Oncology</i> , 2018, 36, 765-772.	0.8	15
2586	Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. <i>Hematological Oncology</i> , 2018, 36, 645-650.	0.8	6
2587	Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2133-2138.	2.0	24
2588	Extranodal involvement of diffuse large B-cell lymphoma in the head and neck: An indicator of good prognosis. <i>Auris Nasus Larynx</i> , 2019, 46, 114-121.	0.5	18
2589	Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria. <i>Leukemia and Lymphoma</i> , 2019, 60, 326-333.	0.6	12
2590	Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma. <i>Hematology</i> , 2019, 24, 52-59.	0.7	7
2591	Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group*. <i>Leukemia and Lymphoma</i> , 2019, 60, 341-348.	0.6	6
2592	Synthesis, crystal structure and DNA binding interactions of ethyl 2-(2-acetamidothiazol-4-yl) acetate: Theoretical and experimental investigations. <i>Journal of Molecular Structure</i> , 2019, 1198, 126903.	1.8	0
2593	Pitfalls of a Mixed Metabolic Response at PET/CT. <i>Radiographics</i> , 2019, 39, 1461-1475.	1.4	12
2594	The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2595-2604.	1.2	12
2595	A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3461-3469.	0.6	16
2596	Oral CHOP-like chemotherapy in 60â€“80-year-old patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e175-e178.	1.2	0
2597	A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 776-783.	0.2	1
2598	Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 194-203.	0.6	4
2599	Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1012-1021.	0.4	105

#	ARTICLE	IF	CITATIONS
2600	Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. <i>Annals of Hematology</i> , 2019, 98, 2131-2138.	0.8	3
2601	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e429-e437.	2.2	64
2602	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2815-2824.	0.8	173
2604	Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Multicenter Study of 272 Cases from the China Lymphoma Patient Registry. <i>International Journal of Medical Sciences</i> , 2019, 16, 1023-1031.	1.1	10
2605	Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e581-e587.	0.2	3
2606	Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe). <i>Clinical Cancer Research</i> , 2019, 25, 6073-6079.	3.2	14
2607	Diagnostic and prognostic factors for patients with primary pulmonary non-Hodgkin's lymphoma: A 16-year single-center retrospective study. <i>Oncology Letters</i> , 2019, 18, 2082-2090.	0.8	5
2608	CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 626-635.	0.6	59
2609	Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. <i>Cancer Medicine</i> , 2019, 8, 6955-6966.	1.3	3
2610	Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study. <i>Annals of Hematology</i> , 2019, 98, 2729-2737.	0.8	9
2611	Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. <i>Clinical Therapeutics</i> , 2019, 41, 2357-2379.e1.	1.1	10
2612	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 33-43.	1.2	6
2613	Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and Tj ETQq0 0,0,rgBT /Oyerlock 10 open, national, multi-center phase II trial. <i>Trials</i> , 2019, 20, 544.	0.7	0
2614	Treatment Outcome in Patients with Primary or Secondary Transformed Indolent B-Cell Lymphomas. <i>Oncology Research and Treatment</i> , 2019, 42, 580-588.	0.8	4
2615	The role of obinutuzumab in the management of follicular lymphoma. <i>Future Oncology</i> , 2019, 15, 3565-3578.	1.1	7
2616	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019, 79, 1609-1624.	4.9	10
2617	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. <i>Blood Cancer Journal</i> , 2019, 9, 52.	2.8	11
2618	The role of PET/CT in the modern treatment of Hodgkin lymphoma. <i>Cancer Treatment Reviews</i> , 2019, 77, 44-56.	3.4	51

#	ARTICLE	IF	CITATIONS
2619	Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. <i>International Journal of Hematology</i> , 2019, 110, 77-85.	0.7	6
2620	Response Assessment in Pediatric Non-Hodgkin Lymphoma. , 2019, , 113-118.		0
2621	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma“overview. <i>International Journal of Hematology</i> , 2019, 110, 3-10.	0.7	3
2622	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1732-1741.	0.8	38
2623	First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. <i>Annals of Hematology</i> , 2019, 98, 1961-1972.	0.8	23
2624	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. <i>Blood</i> , 2019, 134, 353-362.	0.6	45
2625	Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. <i>European Journal of Cancer</i> , 2019, 115, 47-56.	1.3	33
2626	Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma“an analysis of 386 Portuguese patients. <i>Annals of Hematology</i> , 2019, 98, 1937-1946.	0.8	4
2627	Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: a multicenter retrospective cohort study. <i>Hematology</i> , 2019, 24, 225-231.	0.7	2
2628	Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIIE extranodal natural killer/T“cell lymphoma, nasal type. <i>Cancer Medicine</i> , 2019, 8, 3349-3358.	1.3	8
2629	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. <i>Haematologica</i> , 2019, 104, 2241-2248.	1.7	13
2630	Relative dose intensity of R“CHOP therapy and patient outcomes in advanced follicular lymphoma. <i>Hematological Oncology</i> , 2019, 37, 303-307.	0.8	1
2631	Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T“cell lymphoma. <i>European Journal of Haematology</i> , 2019, 103, 35-42.	1.1	24
2632	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant“eligible patients with previously untreated mantle cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 253-260.	0.8	5
2633	Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. <i>Targeted Oncology</i> , 2019, 14, 149-158.	1.7	14
2634	Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. <i>Cancer Management and Research</i> . 2019. Volume 11. 1363-1372.	0.9	8
2635	Long-term overall and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 670-678.	1.2	7
2637	Reply to H.J.A. Adams et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 526-527.	0.8	0

#	ARTICLE	IF	CITATIONS
2638	Lenalidomide plus rituximab (R ²) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. <i>British Journal of Haematology</i> , 2019, 185, 874-882.	1.2	37
2639	Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 649-662.	5.1	187
2640	Phase I study of tirabrutinib (ONO4059/GS4059) in patients with relapsed or refractory B-cell malignancies in Japan. <i>Cancer Science</i> , 2019, 110, 1686-1694.	1.7	43
2641	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	0.8	266
2642	Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 303-318.	2.1	34
2643	Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. <i>British Journal of Haematology</i> , 2019, 185, 480-491.	1.2	26
2644	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1553-1561.	1.3	6
2645	A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG) Tj ETQq1 1 0.784314sgBT /Over	0.7	14
2646	Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial. <i>Leukemia and Lymphoma</i> , 2019, 60, 2291-2294.	0.6	2
2647	Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. <i>Blood Advances</i> , 2019, 3, 2491-2498.	2.5	68
2648	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	2.5	12
2649	Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 187-197.	2.5	40
2650	Multi-b value diffusion-weighted magnetic resonance imaging and intravoxel incoherent motion modeling. <i>Medicine (United States)</i> , 2019, 98, e14459.	0.4	4
2651	AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast: a prospective randomized study. <i>BMC Cancer</i> , 2019, 19, 1247.	1.1	8
2652	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet</i> , The, 2019, 394, 2271-2281.	6.3	155
2653	Simplified MIPI-B prognostic stratification method can predict the outcome well – retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China. <i>Medicine (United States)</i> , 2019, 98, e13741.	0.4	5
2654	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	1.6	12
2655	Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years. <i>Leukemia and Lymphoma</i> , 2019, 60, 856-859.	0.6	4

#	ARTICLE	IF	CITATIONS
2656	Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry. <i>Leukemia and Lymphoma</i> , 2019, 60, 748-755.	0.6	7
2657	Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1237-1244.	1.3	5
2658	A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 904-911.	0.6	8
2659	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 906-911.	2.0	6
2660	Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 594-604.	1.2	13
2661	Efficacy of the GMALL/ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin lymphomas with or without CNS involvement. <i>European Journal of Haematology</i> , 2019, 102, 241-250.	1.1	7
2662	Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol. <i>Leukemia and Lymphoma</i> , 2019, 60, 1917-1925.	0.6	13
2663	Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 1259-1266.	0.8	5
2664	Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. <i>Leukemia and Lymphoma</i> , 2019, 60, 2062-2066.	0.6	6
2665	Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma. <i>Acta Haematologica</i> , 2019, 141, 84-90.	0.7	10
2666	Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 129-136.	1.2	8
2667	Doubling rituximab in high-risk patients with aggressive B-cell lymphoma - results of the DENSE-Mega-CHOEP trial. <i>British Journal of Haematology</i> , 2019, 184, 760-768.	1.2	9
2668	Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas. <i>Annals of Hematology</i> , 2019, 98, 1237-1247.	0.8	8
2669	Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2019, 60, 1576-1579.	0.6	0
2670	Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2019, 184, 753-759.	1.2	49
2671	Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. <i>Leukemia</i> , 2019, 33, 776-780.	3.3	16
2672	The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor. <i>Leukemia and Lymphoma</i> , 2019, 60, 927-933.	0.6	23
2673	Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. <i>British Journal of Haematology</i> , 2019, 184, 647-650.	1.2	1

#	ARTICLE	IF	CITATIONS
2674	Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 749-756.e1.	0.2	4
2675	Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 91-97.	0.6	6
2676	<i>De novo</i> CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. <i>Leukemia and Lymphoma</i> , 2020, 61, 328-336.	0.6	7
2677	A new therapeutic approach in very refractory diffuse large B-cell lymphoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 703-707.	1.2	0
2678	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020, 11, 37-40.	0.5	14
2679	PET/Computed Tomography in Treatment Response Assessment in Cancer. <i>PET Clinics</i> , 2020, 15, 101-123.	1.5	8
2680	The clinical impact of <i>Stenotrophomonas maltophilia</i> bacteremia on the 30-day mortality rate in patients with hematologic disorders: a single-institution experience. <i>Infection</i> , 2020, 48, 205-212.	2.3	21
2681	Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 44-49.	2.0	4
2682	Non-Hodgkin Lymphomas. , 2020, , 1926-1947.e5.		0
2683	Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype. <i>Leukemia and Lymphoma</i> , 2020, 61, 1108-1118.	0.6	6
2684	Extranodal marginal zone Bâ€cell lymphoma of mucosaâ€associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients. <i>Cancer Medicine</i> , 2020, 9, 194-203.	1.3	13
2685	Firstâ€line Râ€CVP <i>versus</i> Râ€CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. <i>British Journal of Haematology</i> , 2020, 188, 898-906.	1.2	16
2686	Evaluation of the MD Anderson tumor score for diffuse large Bâ€cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020, 104, 400-408.	1.1	3
2687	Highâ€dose cyclophosphamide for hardâ€toâ€treat patients with relapsed or refractory Bâ€cell nonâ€Hodgkin's lymphoma, a phase II result. <i>European Journal of Haematology</i> , 2020, 104, 281-290.	1.1	3
2688	Cutaneous extranodal natural killer (NK) / T - cell lymphoma: A comprehensive clinical features and outcomes analysis of 71 cases. <i>Leukemia Research</i> , 2020, 88, 106284.	0.4	10
2689	Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates â€ A multicenter cohort study. <i>Leukemia Research</i> , 2020, 89, 106287.	0.4	12
2690	Production of CAR-T Cells for Clinical Applications. , 2020, , 51-62.		0
2691	The Utility of PET/CT in Guiding Radiotherapy Reduction for Children With Hodgkin Lymphoma Treated With ABVD. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e87-e93.	0.3	4

#	ARTICLE	IF	CITATIONS
2692	Autologous peripheral blood stem cell transplantation for relapsed/refractory HIV-associated lymphoma: a phase II clinical study. <i>International Journal of Hematology</i> , 2020, 111, 434-439.	0.7	3
2693	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	0.8	73
2694	Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions. <i>European Journal of Haematology</i> , 2020, 104, 198-206.	1.1	3
2695	Mantle cell lymphoma with gastrointestinal involvement and the role of endoscopic examinations. <i>PLoS ONE</i> , 2020, 15, e0239740.	1.1	12
2696	High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 235-241.	0.1	0
2697	Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product. <i>Targeted Oncology</i> , 2020, 15, 599-611.	1.7	12
2698	A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Advances in Therapy</i> , 2020, 37, 4877-4893.	1.3	8
2699	Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI ≥ 5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. <i>Annals of Oncology</i> , 2020, 31, 1251-1259.	0.6	41
2700	Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study. <i>Scientific Reports</i> , 2020, 10, 11676.	1.6	4
2701	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. <i>Blood Advances</i> , 2020, 4, 5762-5771.	2.5	3
2702	Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. <i>Cancers</i> , 2020, 12, 2120.	1.7	24
2703	Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2346-2358.	2.0	4
2704	High viral loads of circulating Epstein-Barr virus DNA copy number in peripheral blood is associated with inferior prognosis in patients with mantle cell lymphoma. <i>Journal of Cancer</i> , 2020, 11, 4980-4988.	1.2	4
2705	Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma. <i>Medicine (United States)</i> , 2020, 99, e22788.	0.4	4
2706	Phase 1/2a study of ¹⁷⁷ Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4091-4101.	2.5	33
2707	Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP. <i>EJHaem</i> , 2020, 1, 170-180.	0.4	0
2708	Neck Nodal Disease. <i>Medical Radiology</i> , 2020, , 405-440.	0.0	0
2709	Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3905-3913.	0.8	36

#	ARTICLE	IF	CITATIONS
2710	Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2020, 112, 817-824.	0.7	4
2711	Identifying high-risk patients with natural killer/T-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 3404-3411.	0.6	2
2712	A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021, 137, 2646-2656.	0.6	39
2713	Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients. <i>Annals of Hematology</i> , 2021, 100, 2261-2268.	0.8	4
2714	Prognostic Role of the Red Blood Cell Distribution Width (RDW) in Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 3262.	1.7	20
2716	High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma. <i>Medicina Clínica</i> , 2020, 155, 235-241.	0.3	1
2717	Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. <i>Blood Cancer Journal</i> , 2020, 10, 49.	2.8	31
2718	Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2113-2121.	0.6	3
2719	<p>>Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population</p><p>>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3003-3012.	0.9	13
2720	Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 705-714.	1.0	8
2721	A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 652-660.	0.2	7
2722	A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival. <i>Hematology</i> , 2020, 25, 203-210.	0.7	4
2723	Development of a core outcome set for myelodysplastic syndromes â€“ a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , 2020, 191, 405-417.	1.2	10
2724	Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group. <i>Annals of Hematology</i> , 2020, 99, 1627-1634.	0.8	5
2725	Favourable outcomes for highâ€risk Burkitt lymphoma patients (IPI 3â€5) treated with rituximab plus CODOXâ€M/IVAC: Results of a phase 2 UK NCRI trial. <i>EJHaem</i> , 2020, 1, 133-141.	0.4	5
2726	The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL). <i>Annals of Hematology</i> , 2020, 99, 1583-1594.	0.8	0
2727	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	2.5	40
2728	Nonpegylated liposomal doxorubicin combination regimen (<sc>Râ€COMP</sc>) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020, 38, 478-486.	0.8	15

#	ARTICLE	IF	CITATIONS
2729	Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort. <i>Leukemia and Lymphoma</i> , 2020, 61, 2584-2594.	0.6	11
2730	Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Investigational New Drugs</i> , 2020, 38, 1472-1482.	1.2	8
2731	Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China. <i>BMC Cancer</i> , 2020, 20, 220.	1.1	20
2732	Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. <i>British Journal of Haematology</i> , 2020, 190, 385-393.	1.2	11
2733	The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival. <i>British Journal of Haematology</i> , 2020, 190, 545-554.	1.2	5
2734	Genomic Alterations and MYD88 MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib. <i>Targeted Oncology</i> , 2020, 15, 221-230.	1.7	4
2736	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. <i>American Journal of Hematology</i> , 2020, 95, 583-593.	2.0	18
2737	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 593-602.	5.1	55
2738	Increasing Diluent Volume Decreases Bendamustine-Induced Venous Irritation without Reducing the Therapeutic Efficacy. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 488-492.	0.6	1
2739	Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090291.	1.1	21
2740	BCL11A Is Oncogenic and Predicts Poor Outcomes in Natural Killer/T-Cell Lymphoma. <i>Frontiers in Pharmacology</i> , 2020, 11, 820.	1.6	12
2741	Repeated courses of low-dose 2-2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas. <i>Cancer Medicine</i> , 2020, 9, 3725-3732.	1.3	8
2742	Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience. <i>Internal Medicine Journal</i> , 2021, 51, 1825-1834.	0.5	0
2743	Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma. <i>Annals of Hematology</i> , 2020, 99, 1823-1831.	0.8	14
2744	Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study. <i>Oncologist</i> , 2020, 25, e1725-e1731.	1.9	10
2745	Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 593.	1.0	13
2746	The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1857-1863.	0.5	3
2747	Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens. <i>Journal of Cancer</i> , 2020, 11, 1516-1524.	1.2	8

#	ARTICLE	IF	CITATIONS
2748	Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study. <i>International Journal of Hematology</i> , 2020, 111, 567-573.	0.7	0
2749	Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 1539-1547.	1.2	2
2750	Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patients. <i>Cancer Medicine</i> , 2020, 9, 1966-1977.	1.3	17
2751	Outcome of elderly patients with classical Hodgkin's lymphoma. <i>Leukemia Research</i> , 2020, 90, 106311.	0.4	8
2752	Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. <i>Hematological Oncology</i> , 2020, 38, 137-145.	0.8	3
2753	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. <i>Bone Marrow Transplantation</i> , 2020, 55, 1076-1084.	1.3	20
2754	Criteria-Based Imaging and Response Evaluation of Lymphoma 20 Years After Cheson: What is New?. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 657-668.	0.7	5
2755	Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. <i>Blood Advances</i> , 2020, 4, 1589-1593.	2.5	16
2756	Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 563-571.	0.2	10
2757	Breast Implant-associated Anaplastic Large Cell Lymphoma: Review and Multiparametric Imaging Paradigms. <i>Radiographics</i> , 2020, 40, 609-628.	1.4	46
2758	The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent. <i>Journal of Clinical Medicine</i> , 2020, 9, 1005.	1.0	3
2759	Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. <i>Haematologica</i> , 2021, 106, 730-735.	1.7	8
2760	Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. <i>Leukemia</i> , 2021, 35, 143-155.	3.3	52
2761	Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. <i>Haematologica</i> , 2021, 106, 859-862.	1.7	12
2762	FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome—final result of a UK National Cancer Research Institute prospective study. <i>British Journal of Haematology</i> , 2021, 192, 504-513.	1.2	27
2763	Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 347-356.	1.3	9
2764	Primary Bone Lymphoma: A 13 Year Retrospective Institutional Analysis in the Chemo-Immunotherapy Era. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 240-248.	0.3	4
2765	Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 82-89.	0.3	1

#	ARTICLE	IF	CITATIONS
2766	Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/ MYC rearrangement in Japan. <i>Hematological Oncology</i> , 2021, 39, 66-74.	0.8	2
2767	Safety and efficacy of navitoclax, a BCL-2 and BCL-X _L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. <i>Leukemia and Lymphoma</i> , 2021, 62, 810-818.	0.6	37
2769	A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1414-1420.	0.4	5
2770	Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. <i>Hematological Oncology</i> , 2021, 39, 196-204.	0.8	5
2771	Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 429-437.	1.0	1
2772	Initial report of a phase II study with R-FND followed by ibrutinomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 58-67.	0.6	2
2773	Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. <i>Blood</i> , 2021, 137, 1124-1129.	0.6	7
2774	A comparison of R-EPOCH and R-CHOP as a first-line regimen in <i>de novo</i> DLBCL patients with high Ki-67 expression in a single institution. <i>Oncotarget</i> , 0, 7, 41242-41250.	0.8	11
2776	A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 162-167.	0.3	0
2777	Changes and Significance of Serum Sialic Acid Levels in Patients with Lymphoma. <i>Advances in Clinical Medicine</i> , 2021, 11, 2941-2950.	0.0	0
2778	Epidemiology and Clinical Characteristics of Non-Hodgkin Lymphoma in Mexico. <i>World Journal of Oncology</i> , 2021, 12, 28-33.	0.6	5
2779	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	0.8	10
2780	Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e227-e247.	0.2	8
2781	Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study. <i>Internal Medicine</i> , 2021, 60, 709-718.	0.3	1
2782	Conditional survival and hazards of death for peripheral T-cell lymphomas. <i>Aging</i> , 2021, 13, 10225-10239.	1.4	6
2783	Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. <i>Cancer Science</i> , 2021, 112, 1943-1954.	1.7	11
2784	Comparison of mitoxantrone-melphalan and BEAM conditioning regimens in patients with lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	0
2785	Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. <i>International Journal of Hematology</i> , 2021, 114, 205-216.	0.7	3

#	ARTICLE	IF	CITATIONS
2786	Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East. <i>BMC Cancer</i> , 2021, 21, 351.	1.1	1
2787	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. <i>Journal of Clinical Oncology</i> , 2021, 39, 1203-1213.	0.8	39
2789	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4159.	1.8	41
2790	Prognostic Value of 2-Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography/Computed Tomography after Autologous Hematopoietic Stem Cell Transplantation in Lymphoma Using Deauville Scores. <i>Contrast Media and Molecular Imaging</i> , 2021, 2021, 1-8.	0.4	3
2791	Comparison of 18F-labelled fluoro-2-deoxyglucose-PET with conventional computed tomography for staging and response assessment in paediatric and adult patients with nodular lymphocyte-predominant Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 899-906.	0.5	0
2792	Does Up-front Autologous Stem-Cell Transplantation at First Relapse Improve Outcome in Transplant-Eligible Follicular Lymphoma Patients Whose Disease Relapses Within 24 Months?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e423-e427.	0.2	1
2793	Current and future best practice in imaging, staging, and response assessment for Non-Hodgkin's lymphomas: the Specialist Integrated Haematological Malignancy Imaging Reporting (SIHMIR) paradigm shift. <i>Clinical Radiology</i> , 2021, 76, 391.e1-391.e18.	0.5	4
2794	Clinical impact of lymphatic spread in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma. <i>Blood Research</i> , 2021, 56, 72-78.	0.5	0
2795	Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 95.	2.8	4
2796	Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study. <i>British Journal of Haematology</i> , 2021, 193, 906-914.	1.2	12
2797	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. <i>Cancer Medicine</i> , 2021, 10, 5101-5109.	1.3	4
2798	Comparative evaluation of the effectiveness of primary treatment regimens in patients with classical Hodgkin's lymphoma from the group of unfavorable prognosis. <i>Oncogematologiya</i> , 2021, 16, 28-39.	0.1	0
2799	Imaging Assessment of Tumor Response in the Era of Immunotherapy. <i>Diagnostics</i> , 2021, 11, 1041.	1.3	3
2800	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	1.9	15
2801	R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 205-214.	1.2	5
2802	Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	0
2803	Treating Early-Stage DLBCL on the FLYER: What Lesson for Radiation Therapy?. <i>Frontiers in Oncology</i> , 2021, 11, 686223.	1.3	1
2804	Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group. <i>HemaSphere</i> , 2021, 5, e600.	1.2	3

#	ARTICLE	IF	CITATIONS
2805	A case of lymphomatoid granulomatosis with central nervous system involvement successfully treated with IFNÎ±. <i>International Journal of Hematology</i> , 2021, 114, 502-508.	0.7	1
2806	Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 4726-4736.	3.2	1
2807	Imaging biomarkers for evaluating tumor response: RECIST and beyond. <i>Biomarker Research</i> , 2021, 9, 52.	2.8	55
2808	The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	1
2809	Positron emission tomography/computed tomography in the management of Hodgkin and Bâ€cell nonâ€Hodgkin lymphoma: An update. <i>Cancer</i> , 2021, 127, 3727-3741.	2.0	10
2810	Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3119-3129.	0.6	3
2811	Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15. <i>European Journal of Cancer</i> , 2021, 152, 129-138.	1.3	6
2812	Romidepsin Treatment in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, .	0.5	0
2813	Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103377.	2.0	10
2814	A picture is worth a thousand words: a history of diagnostic imaging for lymphoma. <i>British Journal of Radiology</i> , 2021, 94, 20210285.	1.0	1
2815	Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study. <i>Annals of Hematology</i> , 2021, 100, 2961-2968.	0.8	4
2816	The optimal use of PET/CT in the management of lymphoma patients. <i>British Journal of Radiology</i> , 2021, 94, 20210470.	1.0	8
2817	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 89-97.	0.2	6
2818	A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups. <i>Frontiers in Oncology</i> , 2021, 11, 696147.	1.3	10
2819	A randomized phase II study comparing consolidation with a single dose of ⁹⁰ Y ibritumomab tiuxetan <i>vs.</i> maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. <i>Leukemia and Lymphoma</i> , 2022, 63, 93-100.	0.6	5
2820	FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma. <i>Cancers</i> , 2021, 13, 3952.	1.7	4
2821	Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma. <i>British Journal of Radiology</i> , 2021, 94, 20210360.	1.0	2
2822	Clinicopathologic features and therapy outcome in childhood Hodgkinâ€™s lymphoma: a report from tertiary care center in Saudi Arabia. <i>Journal of the Egyptian National Cancer Institute</i> , 2021, 33, 21.	0.6	3

#	ARTICLE	IF	CITATIONS
2823	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <i>Clinical Cancer Research</i> , 2021, 27, 5847-5856.	3.2	3
2824	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4149-4155.	2.5	42
2825	The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL â€” Results From the Phase-II STORM Trial. <i>HemaSphere</i> , 2021, 5, e636.	1.2	7
2826	Disparity analysis and prognostic value of pretreatment whole blood <scp>Epsteinâ€Barr</scp> virus <scp>DNA</scp> load and Epsteinâ€Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group. <i>International Journal of Cancer</i> , 2022, 150, 327-334.	2.3	10
2827	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , 2021, 5, 3354-3361.	2.5	6
2828	Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study. <i>Nutrients</i> , 2021, 13, 3243.	1.7	7
2829	Clinicoâ€biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. <i>British Journal of Haematology</i> , 2022, 196, 146-155.	1.2	17
2830	Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. <i>Leukemia Research</i> , 2021, 108, 106627.	0.4	6
2831	Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphomas: A Single Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e149-e160.	0.2	3
2832	Using PAMPs and DAMPs as adjuvants in cancer vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5546-5557.	1.4	16
2833	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e648-e657.	2.2	27
2834	The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 1335-1343.	0.6	5
2835	PET CT in Non-Hodgkin Lymphoma. , 2021, , 55-69.		0
2836	Assessment of Treatment Response by FDG-PET. , 2006, , 387-412.		2
2837	Monoclonal Antibodies in Cancer Therapy. , 2007, , 453-484.		1
2838	Current Epigenetic Therapy for T-Cell Lymphoma. , 2013, , 279-296.		2
2839	HTLV-1-Associated T-cell Diseases. , 2013, , 113-135.		2
2840	Clinical Evaluation. <i>Hematologic Malignancies</i> , 2015, , 95-106.	0.2	1

#	ARTICLE	IF	CITATIONS
2841	FDG-PET and PET/CT in Malignant Lymphoma. Recent Results in Cancer Research, 2008, 170, 93-107.	1.8	5
2842	Background and Rationale for Radiotherapy in Early-Stage Hodgkin Lymphoma. , 2011, , 7-20.		1
2843	The Treated Thorax in Patients with Hematological Malignancies. Medical Radiology, 2004, , 443-472.	0.0	1
2844	Monoclonal antibody therapy. , 2003, , 329-390.		3
2845	Non-Hodgkin's Lymphoma. , 2008, , 2371-2404.		3
2846	Diagnostic Radiology. , 2006, , 167-188.		1
2847	Malignant Lymphomas and Lymphadenopathies. , 2009, , 417-505.		5
2848	Non-Hodgkin Lymphoma. , 2014, , 2033-2059.e8.		1
2849	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1107-1115.	2.0	9
2852	Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. The Hematology Journal, 2001, 2, 279-285.	2.0	10
2853	Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma. , 0, .		1
2854	Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. , 0, .		1
2855	Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients. Scientific Reports, 2016, 6, 28834.	1.6	17
2856	Non-Hodgkin's Lymphoma of the Ocular Adnexa. Acta Oncol ³ gica, 2001, 40, 485-490.	0.8	57
2857	High Dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low Grade Non-Hodgkin's Lymphoma: CALGB 9150. Leukemia and Lymphoma, 2001, 42, 1255-1264.	0.6	3
2858	High-dose Chemotherapy with Hematopoietic Stem Cell Transplantation is Effective for Nasal and Nasal-type CD56 + Natural Killer Cell Lymphomas. Leukemia and Lymphoma, 2001, 42, 1297-1303.	0.6	38
2859	Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. Aids, 2002, 16, 1973-1976.	1.0	32
2860	PET/CT in oncology: for which tumours is it the reference standard?. Cancer Imaging, 2007, 7, S77-S87.	1.2	38

#	ARTICLE	IF	CITATIONS
2861	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020, 189, 661-671.	1.2	12
2862	Comparison of CART19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin's lymphoma. <i>JCI Insight</i> , 2019, 4, .	2.3	14
2863	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. <i>European Radiology Experimental</i> , 2020, 4, 63.	1.7	38
2864	Primary Gastrointestinal Non-Hodgkin's Lymphoma: II. Combined Surgical and Conservative or Conservative Management Only in Localized Gastric Lymphoma—Results of the Prospective German Multicenter Study GIT NHL 01/92. <i>Journal of Clinical Oncology</i> , 2001, 19, 3874-3883.	0.8	204
2865	Human T Cell Leukemia Virus Reactivation with Progression of Adult T-Cell Leukemia-Lymphoma. <i>PLoS ONE</i> , 2009, 4, e4420.	1.1	40
2866	Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>PLoS ONE</i> , 2012, 7, e41658.	1.1	129
2867	Expression of BAFF and BAFF-R in Follicular Lymphoma: Correlation with Clinicopathologic Characteristics and Survival Outcomes. <i>PLoS ONE</i> , 2012, 7, e50936.	1.1	22
2868	Study of Regulatory T-Cells in Patients with Gastric Malt Lymphoma: Influence on Treatment Response and Outcome. <i>PLoS ONE</i> , 2012, 7, e51681.	1.1	35
2869	Serum Levels of Interleukin-9 Correlate with Negative Prognostic Factors in Extranodal NK/T-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e94637.	1.1	22
2870	Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas. <i>PLoS ONE</i> , 2015, 10, e0121822.	1.1	9
2871	Analysis of the role of intrathecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience. <i>PLoS ONE</i> , 2017, 12, e0179595.	1.1	5
2873	Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival. <i>Oncotarget</i> , 2013, 4, 899-910.	0.8	19
2874	Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma. <i>Oncotarget</i> , 2016, 7, 56574-56583.	0.8	7
2875	Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). <i>Oncotarget</i> , 2016, 7, 85584-85591.	0.8	36
2876	Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type. <i>Oncotarget</i> , 2017, 8, 4245-4256.	0.8	7
2877	A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 50155-50163.	0.8	28
2878	mRNA in exosomes as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish Lymphoma Oncology Group. <i>Oncotarget</i> , 2017, 8, 50949-50957.	0.8	31
2879	Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients. <i>Oncotarget</i> , 2017, 8, 40724-40731.	0.8	20

#	ARTICLE	IF	CITATIONS
2880	<i>ABCG2</i> and <i>NCF4</i> polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Oncotarget</i> , 2017, 8, 58292-58303.	0.8	18
2881	Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 47790-47800.	0.8	11
2882	Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92312-92323.	0.8	11
2883	Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. <i>Oncotarget</i> , 2015, 6, 30317-30326.	0.8	53
2884	Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. <i>Oncotarget</i> , 2016, 7, 33331-33339.	0.8	6
2885	Extranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 57-65.	0.7	9
2886	Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2017, 10, 271-281.	0.1	1
2887	Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients. <i>Current Cancer Drug Targets</i> , 2020, 20, 638-645.	0.8	4
2888	Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 1229-1236.	0.5	9
2889	Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 681-695.	0.8	3
2890	Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma. <i>Radiology and Oncology</i> , 2007, 41, .	0.6	2
2891	Precision of Histological Bone Marrow Staging in Follicular Lymphoma and Diffuse Large B-cell Lymphoma. <i>Clinical and Investigative Medicine</i> , 2012, 35, 358.	0.3	5
2892	Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. <i>Health Technology Assessment</i> , 2009, 13, 41-8.	1.3	33
2893	A Case of Recurred Follicular Lymphoma in Sublingual Gland after Complete Remission. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2014, 57, 469.	0.0	1
2894	Prediction of lymph node metastases in NSCLC. <i>Nuklearmedizin - NuclearMedicine</i> , 2010, 49, 41-8; quiz N1.	0.3	9
2895	Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 2526.	1.4	27
2896	Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement. <i>World Journal of Gastroenterology</i> , 2010, 16, 4661.	1.4	35
2897	Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma. <i>Korean Journal of Internal Medicine</i> , 2009, 24, 37.	0.7	7

#	ARTICLE	IF	CITATIONS
2898	Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma. <i>Korean Journal of Internal Medicine</i> , 2010, 25, 301.	0.7	13
2899	Staging and response assessment in lymphomas: the new Lugano classification. <i>Chinese Clinical Oncology</i> , 2015, 4, 5.	0.4	99
2900	Primary gastrointestinal Non Hodgkin's lymphoma chemotherapy alone an effective treatment modality: Experience from a single centre in India. <i>Indian Journal of Cancer</i> , 2006, 43, 30.	0.2	15
2901	Indian Council of Medical Research consensus document for the management of non-hodgkin's lymphoma (high grade). <i>Indian Journal of Medical and Paediatric Oncology</i> , 2017, 38, 51.	0.1	4
2902	Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma. <i>Advanced Biomedical Research</i> , 2017, 6, 30.	0.2	6
2903	Comparison of Bone Marrow Biopsy Specimens Obtained Using a Motorized Device and Manual Biopsy Systems. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 394-398.	0.7	5
2904	Prognostic Factors in Non-Hodgkin's Lymphoma Patients Treated by Autologous Stem Cell Transplantation: A Single Center Experience. <i>Cancer Research and Treatment</i> , 2005, 37, 294.	1.3	3
2905	Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents. <i>Cancer Research and Treatment</i> , 2014, 46, 358-365.	1.3	30
2906	Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma. <i>Cancer Research and Treatment</i> , 2017, 49, 92-103.	1.3	4
2907	The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH. <i>Cancer Research and Treatment</i> , 2019, 51, 150-157.	1.3	14
2908	Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 919-932.	1.3	14
2909	Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma. <i>World Journal of Hepatology</i> , 2011, 3, 278.	0.8	42
2910	The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study. <i>Turkish Journal of Haematology</i> , 2015, 32, 152-157.	0.2	3
2911	Prognostic value of miRNA-155 expression in B-cell Non-Hodgkin's lymphoma. <i>Turkish Journal of Haematology</i> , 2017, 34, 207-212.	0.2	22
2912	Evaluation of cancer treatment in the abdomen: Trends and advances. <i>World Journal of Radiology</i> , 2013, 5, 126.	0.5	2
2913	VPDL Chemotherapy for T-cell Lymphoblastic Lymphoma (T-LBL) in Adults: Comparison with Upfront Autologous Stem Cell Transplantation in a Single Center. <i>The Korean Journal of Hematology</i> , 2008, 43, 138.	0.7	2
2914	Peripheral T-cell lymphoma, unspecified - the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2007, 151, 103-107.	0.2	7
2915	PROLONGED SURVIVAL OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA AFTER FIRST-LINE INTENSIVE SEQUENTIAL CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2009, 153, 63-66.	0.2	11

#	ARTICLE	IF	CITATIONS
2916	RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2009, 153, 211-214.	0.2	6
2917	LONG-TERM OUTCOME OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA TREATED WITH FIRST-LINE INTENSIVE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2011, 155, 63-69.	0.2	15
2918	PROGNOSTIC FACTORS IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: HOW TO IDENTIFY A HIGH-RISK PATIENT?. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2011, 155, 99-108.	0.2	4
2919	Secondary infiltration of the central nervous system in patients with diffuse large B-cell lymphoma. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 256-62.	0.7	6
2920	Clinical characteristics of the patients with Hodgkin's lymphoma involving extranodal sites. Chinese Journal of Cancer, 2012, 31, 342-347.	4.9	12
2921	Follicular Lymphoma in Staging Bone Marrow Specimens: Correlation of Histologic Findings With the Results of Flow Cytometry Immunophenotypic Analysis. Archives of Pathology and Laboratory Medicine, 2007, 131, 282-287.	1.2	26
2922	NCCN Task Force Report: Positron Emission Tomography (PET)/Computed Tomography (CT) Scanning in Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, S-1-S-22.	2.3	72
2923	Quantitative Imaging Assessment for Clinical Trials in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1505-1511.	2.3	4
2924	Comparison of WHO and RECIST Criteria for Evaluation of Clinical Response to Chemotherapy in Patients with Advanced Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2012, 13, 3213-3218.	0.5	35
2925	"Sandwich" Chemotherapy (CT) with Radiotherapy (RT) Improves Outcomes in Patients with Stage IE/IIExtranodal Natural Killer (NK)/T-cell Lymphomas. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4061-4066.	0.5	6
2926	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood, 2000, 96, 864-869.	0.6	1
2928	Non-Hodgkinâ€™s Lymphoma. , 2003, , 295-318.		0
2929	Disease-free Survival and Quality of Life as End-points in Clinical Trials. Update in Intensive Care Medicine, 2003, , 155-168.	0.0	0
2930	Nodal Involvement in Non-Hodgkin Lymphoma. Medical Radiology, 2004, , 71-83.	0.0	0
2931	Pediatric Lymphoma. Medical Radiology, 2004, , 247-288.	0.0	0
2932	Evidence-based management of cutaneous lymphomas: salvage therapy for chemorefractory or relapsed mycosis fungoides/Sezary syndrome. Skin Cancer, 2004, 19, 64-71.	0.1	0
2933	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA. Journal of Clinical Oncology, 2004, 22, 6529-6529.	0.8	1
2934	Acute myeloid leukaemia. , 2004, , 203-229.		1

#	ARTICLE	IF	CITATIONS
2935	BEAC or BEAM Chemotherapy Followed by Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients: Comparative Analysis on Efficacy and Toxicity.. Blood, 2005, 106, 5291-5291.	0.6	0
2936	430 LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE, AND ETOPOSIDE AND ANTIRETROVIRAL THERAPY FOR PATIENTS WITH AIDS-RELATED LYMPHOMA: A PILOT STUDY.. Journal of Investigative Medicine, 2006, 54, S153.5-S153.	0.7	0
2937	Primary Extranodal Non-Hodgkin's Lymphomas. , 2006, , 325-347.		17
2938	Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study. Acta Medica (Hradec Kralove), 2007, 50, 113-118.	0.2	0
2939	Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma. Cancer Research and Treatment, 2007, 39, 54.	1.3	1
2940	Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced intensity allogeneic hematopoietic cell transplantation. Journal of Clinical Oncology, 2007, 25, 7096-7096.	0.8	0
2941	New Chemotherapy Protocol (P-CAN) for Treatment of Aggressive Non-Hodgkin's Lymphoma. Qatar Medical Journal, 2007, 2007, .	0.2	0
2943	Dendritic cells and T lymphocyte interactions in patients with lymphoid malignancies. Physiological Research, 2008, 57, 289-298.	0.4	1
2944	Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement. Korean Journal of Internal Medicine, 2008, 23, 182.	0.7	3
2946	Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: a retrospective diagnostic test study. Radiology and Oncology, 2009, 43, .	0.6	0
2947	Efficacy and Adverse Effects of Rituximab Combined with a TCOP Regimen in Patients with Untreated Diffuse Large B-cell Lymphoma and Follicular Lymphoma. The Showa University Journal of Medical Sciences, 2009, 21, 215-225.	0.1	0
2949	The issue of refractory disease in follicular and other lymphoma subtypes. Revista Brasileira De Hematologia E Hemoterapia, 0, 31, .	0.7	0
2950	Non-Hodgkin's Lymphomas. , 2010, , 1371-1379.		0
2951	Evaluation of Response After Radiotherapy for Hodgkin Lymphoma. , 2011, , 161-166.		0
2952	Clinical Evaluation. , 2011, , 65-76.		0
2953	PET-CT Imaging of Lymphoma. , 2011, , 265-291.		0
2955	Lymphomas of the Bone Marrow. , 2011, , 341-393.		0
2956	Evaluation of sonographic findings of superficial lymph nodes in the diagnosis of non-Hodgkin lymphoma recurrence by multivariate logistic regression analysis. Choonpa Igaku, 2011, 38, 119-127.	0.0	0

#	ARTICLE	IF	CITATIONS
2957	Lymphoma: Differential Diagnosis of Mediastinal Masses and Response. , 2011, , 193-198.		0
2958	Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. <i>Leukemia and Lymphoma</i> , 0, , 1-6.	0.6	0
2960	Novel Targeted Therapeutics for Peripheral T-Cell Lymphoma. , 2012, , 349-372.		0
2961	Bortezomib Combined with Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-VFND) for the Treatment of Relapsed/Refractory Follicular Lymphoma. <i>Journal of Clinical Trials</i> , 2012, 02, .	0.1	0
2962	Diagnostic and Treatment Response Imaging in Lymphomas. , 0, , .		1
2963	Lymphomas. , 2013, , 153-187.		0
2964	Gemcitabine and Oxaliplatinum (GemOx): An Effective Regimen in Patients with Refractory and Relapsing Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 4845-4845.	0.6	0
2965	Diffuse Large B-Cell Lymphoma. , 2013, , 177-202.		0
2966	PATHOLOGIE TUMORALE DU PARENCHYME PULMONAIRE. , 2013, , 277-451.		0
2967	Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after a new induction regimen in intermediate and high-risk follicular lymphoma patients according to the follicular lymphoma international prognostic index (FLIPI): A multicenter, prospective Phase II trial of Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 0, , 1-16.	0.6	0
2968	Lymphomas: The Role of CT and MRI in Staging and Restaging. , 2014, , 239-247.		1
2969	Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature. <i>Blood</i> , 2013, 122, 5093-5093.	0.6	0
2970	Monitoring Responses to Therapy in Oncology. , 2014, , 155-171.		1
2971	Imaging Review Charters and Operational Considerations. , 2014, , 65-82.		1
2972	Adult T-Cell Leukemia-Lymphoma. , 2014, , 2076-2092.e4.		0
2973	Clinical features and treatment outcomes of patients with Hodgkin lymphoma: A single-center study of 36 cases. <i>Tenri Medical Bulletin</i> , 2014, 17, 15-24.	0.1	0
2974	Lymphomes : principes th�rapeutiques et imagerie post-th�rapeutique. , 2014, , 265-298.		0
2975	Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature. <i>Journal of Cancer Therapy</i> , 2015, 06, 1-11.	0.1	0

#	ARTICLE	IF	CITATIONS
2976	Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4515-4520.	0.5	2
2977	Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?. Turkish Journal of Haematology, 2015, 32, 213-9.	0.2	3
2978	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2016, , 1-42.		0
2979	The Clinical Significance of Both IgM and IgG Anticardiolipin Antibodies in Non-Hodgkin's Lymphoma. Journal of Clinical & Cellular Immunology, 2016, 7, .	1.5	1
2981	The Use of the Cytokines EMAP-II, IL-19 and IL-10 as Biomarkers to Determine Prognosis of Non Hodgkin's Lymphoma. Journal of Clinical & Cellular Immunology, 2016, 7, .	1.5	2
2982	PET Response-Adapted Treatment in Hodgkin Lymphoma. , 2016, , 31-64.		0
2983	PET Scan for HL Restaging. , 2016, , 15-30.		0
2985	Retrospective Analysis of Toxicity Profiles of two Platinum-Based Salvage Regimens in Relapsed/Refractory Lymphoma: DHAP versus ESHAP.. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2016, 26, 1-9.	0.1	1
2986	REFRACTORY FOLLICULAR LYMPHOMA AND SHORT-TERM PATIENTS SURVIVAL IN THE ERA OF TARGETED TREATMENT. WHAT IS THE REASON?. , 2016, 15, 79-86.	0.3	0
2987	INTOXICATION SYMPTOMS IN FOLLICULAR LYMPHOMA: PROBABLE PATHOGENESIS AND CLINICAL SIGNIFICANCE. , 2016, 15, 117-122.	0.3	0
2988	Radiological Imaging in Lymphoma. , 2017, , 25-31.		0
2989	Fc-Epsilon Receptor (CD23) Expressing Follicular Dendritic Cells as a Main Prognostic Factor in Follicular Lymphoma. Advances in Biological Chemistry, 2017, 07, 107-121.	0.2	0
2990	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2017, , 353-393.		0
2991	COMPARISON IMMUNOCHEMOTHERAPY AND CHEMOTHERAPY EFFICACY IN FOLLICULAR LYMPHOMA. , 2017, 16, 24-31.	0.3	0
2992	Efficacy of ESHAP Regimen in Transplant Ineligible Patients With Relapsed/Refractory T-Cell Lymphoma. Journal of Hematology (Brossard, Quebec), 2018, 7, 131-139.	0.4	4
2993	Conventional and Conformal Radiotherapy with and without Beam Intensity Modulation in Patients with Stage II Hodgkin's Lymphoma with Supradiaphragmal Lesions. Klinicheskaya Onkologematologiya/Clinical Oncohematology, 2018, 11, 70-77.	0.1	0
2994	ANALYSIS OF UNFAVORABLE PROGNOSTIC FACTORS IN PATIENTS WHO RECEIVED HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL HEMOPOIETIC STEM CELLS TRANSPLANTATION FOR RELAPSES AND RESISTANT FORMS OF HODGKIN'S LYMPHOMA. Voprosy Onkologii, 2018, 64, 414-418.	0.1	0
2995	A Retrospective Comparison of TECAM and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplant in Lymphoma Patients: Efficacy and Toxicity. Experimental and Clinical Transplantation, 2018, , .	0.2	0

#	ARTICLE	IF	CITATIONS
2996	EFFICACY AND SIDE EFFECTS OF R-CHOP REGIMEN IN PATIENTS WITH DIFFUSE LARGE B-CELL CD20 POSITIVE LYMPHOMA AT HUE UNIVERSITY OF MEDICINE AND PHARMACY HOSPITAL. Journal of Medicine and Pharmacy, 2018, 8, 48-53.	0.0	1
2997	Effectiveness of the Initial Escalation of Immunochemotherapy in Patients with High Risk MALT-Lymphoma: Pilot Study Results. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 338-348.	0.1	0
2998	Extranodal Localization of Aggressive Lymphoma. Springer Reference Medizin, 2019, , 201-212.	0.0	0
2999	The Effect of Synthesis of Pegylated Nanoliposome Containing DNAi on Reduction of BCL-2 Gene Expression in DLCL2 Cell Line. Majallah-i DAnishgAh-i UlAm-i PizishkAi Qum, 2018, 12, 16-26.	0.2	0
3000	Clinical and Hematological Predictors of Response to First-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 68-72.	0.1	2
3001	Hybrid Imaging and Radionuclide Therapy in Hemato-oncology. , 2019, , 655-705.		0
3002	Clinical Application of 18F-FDG PET/CT in Lymphoma. , 2019, , 47-59.		1
3003	Development of methods to evaluate probability of reviewerâ€™s assessment bias in blinded independent central review (BICR) imaging studies. , 2019, , .		0
3004	Agresif B h1/4creli Hodgkin dA±AY± ve Hodgkin lenfomada ilk basamak tedavi yanA±tA±nA±n FDG-PET/BT ile deAYerlendirilmesinde rezidA1/4el SUVmax. UludaAY Aœniversitesi TA±p FakA1/4ltesi Dergisi, 0, , .	0.2	0
3005	Primary Bone Lymphomas: Long-Term Results of a Prospective Single-Center Trial. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 247-262.	0.1	2
3006	Evaluation of R-CHOP and R-CVP in the treatment of elderly patient with non-Hodgkin lymphoma. Y Hoc Thanh Pho Ho Chi Minh, 2017, 3, 1-6.	0.1	0
3009	Prognostic Factors in Follicular Lymphoma. , 2020, , 83-99.		0
3010	Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. Leukemia and Lymphoma, 2022, 63, 599-607.	0.6	0
3011	F-18 FDG PET Tests in Malignant Lymphoma. , 2021, , 135-147.		0
3012	Comorbidity in patients with lymphoproliferative diseases. Klinicheskaya Meditsina, 2020, 96, 508-514.	0.2	0
3013	Radioimmunotherapy. , 2020, , 917-949.		1
3014	PET in Lymphoma. , 2020, , 685-729.		0
3015	Therapy Response Imaging in Lymphoma and Hematologic Malignancies. Medical Radiology, 2020, , 177-200.	0.0	0

#	ARTICLE	IF	CITATIONS
3016	Functional Imaging in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 113-143.	0.2	0
3017	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323.	1.3	12
3018	Current Role of Functional Imaging in the Management of Lymphoma. <i>Current Oncology Reports</i> , 2021, 23, 144.	1.8	11
3019	Neck Lymphoma. <i>Medical Radiology</i> , 2008, , 311-328.	0.0	0
3020	Tuberculosis Coexistence in Pediatric Hodgkin's Lymphoma: A Tropical Country Experience. <i>South Asian Journal of Cancer</i> , 2020, 09, 236-239.	0.2	4
3021	Primary Bone Lymphoma: An Experience of a Regional Cancer Center from India. <i>South Asian Journal of Cancer</i> , 2020, 09, 227-229.	0.2	0
3022	High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. <i>GMS German Medical Science</i> , 2007, 5, Doc02.	2.7	0
3023	NHL (diffuse large B cell lymphoma). <i>Clinical Evidence</i> , 2008, 2008, .	0.2	2
3024	NHL (diffuse large B-cell lymphoma). <i>Clinical Evidence</i> , 2010, 2010, .	0.2	2
3025	The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma. <i>European Journal of Clinical & Medical Oncology</i> , 2010, 2, 131-138.	0.0	4
3026	C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma. <i>American Journal of Blood Research</i> , 2011, 1, 204-14.	0.6	1
3027	Genome-wide DNA methylation profiles according to <i>Chlamydomonas reinhardtii</i> infection and the response to doxycycline treatment in ocular adnexal lymphoma. <i>Molecular Vision</i> , 2014, 20, 1037-47.	1.1	17
3028	Clinical characteristics of 26 patients with primary extranodal Hodgkin lymphoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 5045-50.	0.5	16
3029	Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 66-73.	0.7	7
3030	Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 16308-14.	1.3	5
3031	Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 17515-22.	1.3	10
3032	Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-Cell lymphoma: a retrospective study in China. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 22497-502.	1.3	10
3034	Prognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2015, 3, 91-8.	0.1	1

#	ARTICLE	IF	CITATIONS
3041	Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 1412-1424.	2.5	1
3042	Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110564.	0.8	3
3043	Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients. <i>Current Oncology</i> , 2021, 28, 4655-4672.	0.9	1
3044	Assessment of Early Therapy Response of Non-Hodgkin's and Hodgkin's Lymphoma Using Mode Ultrasound and Dynamic Contrast-Enhanced Ultrasound. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 2033-2040.	0.8	2
3045	Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma. <i>Cancer Science</i> , 2021, , .	1.7	5
3046	The Use of PET in Evaluating the Efficacy of Immunotherapy in Oncology. , 2022, , 471-493.		0
3047	Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. <i>Leukemia and Lymphoma</i> , 2022, 63, 813-820.	0.6	5
3048	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	0.8	90
3049	18F FDG IMAGING " RESPONSE CRITERIA IN TUMORS. <i>European Journal of Radiology</i> , 2021, 147, 110054.	1.2	3
3050	Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 616-626.	0.7	10
3051	Clinicopathological characteristics and treatment outcome in obese patients with diffuse large B-cell lymphoma. <i>Translational Cancer Research</i> , 2020, 9, 6116-6127.	0.4	0
3052	Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). <i>Annals of Hematology</i> , 2022, 101, 789.	0.8	0
3053	Serum Albumin Levels Strongly Predict Survival Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Combined Chemotherapy. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 0, , .	0.3	1
3054	PET imaging of hematological neoplasia. , 2022, , .		0
3055	Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 2536-2547.	2.5	8
3056	Lymphoblastic Lymphoma: a Concise Review. <i>Current Oncology Reports</i> , 2022, 24, 1-12.	1.8	13
3057	Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 155.	1.0	19
3058	Sinonasal B-cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 160-171.	0.8	8

#	ARTICLE	IF	CITATIONS
3059	90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. <i>Annals of Hematology</i> , 2022, 101, 781-788.	0.8	6
3060	Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. <i>Bone Marrow Transplantation</i> , 2022, 57, 627-632.	1.3	4
3061	Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 2667-2680.	2.5	17
3062	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210875.	1.1	9
3063	Thoracic Imaging Manifestations of Treated Lymphomas. <i>Journal of Thoracic Imaging</i> , 2022, 37, 67-79.	0.8	0
3064	Dual-Layer Spectral Detector CT in Comparison with FDG-PET/CT for the Assessment of Lymphoma Activity. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2022, 194, 747-754.	0.7	3
3065	Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2022, 12, 3124.	1.6	4
3066	Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. <i>American Journal of Hematology</i> , 2022, 97, 583-591.	2.0	7
3067	Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. <i>Cancer</i> , 2022, 128, 1595-1604.	2.0	2
3068	Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL). <i>Cancer Research and Treatment</i> , 2022, 55, 204-212.	1.3	1
3069	CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase. <i>Frontiers in Immunology</i> , 2022, 13, 829366.	2.2	1
3070	Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study. <i>Haematologica</i> , 2022, 107, 2675-2684.	1.7	11
3071	Primary radiation therapy in stage I/II indolent orbital lymphoma – a comprehensive retrospective recurrence and toxicity analysis. <i>European Journal of Haematology</i> , 2022, , .	1.1	0
3072	Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. <i>Leukemia</i> , 2022, 36, 1361-1370.	3.3	5
3073	Possibility of PET/CT in Patients with Extranodal Diffuse Large B-Cell Lymphoma of Stomach at Different Treatment Stages. <i>Journal of Oncology Diagnostic Radiology and Radiotherapy</i> , 2022, 5, 37-45.	0.1	0
3074	Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2022, , .	1.2	1
3075	Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry. <i>British Journal of Haematology</i> , 2022, 198, 50-61.	1.2	8
3076	Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2023, 41, 230-238.	0.8	6

#	ARTICLE	IF	CITATIONS
3077	Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e738-e744.	0.2	3
3078	Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment. <i>Cancers</i> , 2022, 14, 141.	1.7	8
3079	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. <i>Blood</i> , 2022, 139, 2338-2346.	0.6	18
3080	90Y-ibritumomab tiuxetan in B-cell non-Hodgkin lymphomas: Real-world data from the United Arab Emirates. <i>Advances in Radiation Oncology</i> , 2021, , 100882.	0.6	0
3081	Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 5285-5294.	2.5	7
3082	International staging and response criteria for lymphomas. , 0, , 277-285.		0
3083	Treatment approach to diffuse large B-cell lymphomas. , 0, , 286-307.		0
3084	Follicular lymphomas. , 0, , 338-366.		0
3090	Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory SÅ@zary syndrome: a systematic review. <i>European Journal of Dermatology</i> , 2018, 28, 764-774.	0.3	4
3098	Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkinâ€™s lymphoma: phase I safety and efficacy. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	4
3099	Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT. <i>Blood Research</i> , 2022, 57, S75-S78.	0.5	6
3100	Exploring hypoxic biology to improve radiotherapy outcomes. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e21.	1.6	4
3101	FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphomaâ€”Are We Hitting the Target?. <i>Molecular Imaging and Biology</i> , 2022, 24, 807-817.	1.3	3
3102	Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India. <i>JCO Global Oncology</i> , 2022, 8, e2100383.	0.8	1
3103	Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007, 12, 931-940.	0.6	26
3104	Monitoring Gastrointestinal Tumor Response to Therapy. , 2015, , 2295-2305.		0
3105	The role of surveillance computed tomography in patients with follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210959.	1.1	1
3107	Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study). <i>Hematological Oncology</i> , 2022, 40, 609-616.	0.8	0

#	ARTICLE	IF	CITATIONS
3108	Less Intensive Regimens May Still Be Suitable for the Initial Treatment of Primary Mediastinal B-Cell Lymphoma in Resource-Limited Settings. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	2
3109	High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
3110	Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. <i>Blood Advances</i> , 2022, 6, 6169-6179.	2.5	5
3111	NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980â€”2017: a nationwide cohort study. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	0.6	2

3112

#	ARTICLE	IF	CITATIONS
3127	Multi-Objective Cluster Ensemble Based on Filter Refinement Scheme. IEEE Transactions on Knowledge and Data Engineering, 2022, , 1-14.	4.0	0
3128	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2022, , 431-474.		0
3129	CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS IN PRIMARY BREAST DIFFUSE LARGE B-CELL LYMPHOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022066.	0.5	2
3130	EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma. Journal of Immunology Research, 2022, 2022, 1-16.	0.9	1
3131	Meta-Analysis of the Testâ€“Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response. Clinical Cancer Research, 2023, 29, 143-153.	3.2	1
3132	Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge. Transplantation and Cellular Therapy, 2023, 29, 34.e1-34.e7.	0.6	3
3133	Early progression in follicular lymphoma in the absence of histological transformation or highâ€“risk Follicular Lymphoma International Prognostic Index still has a favourable outcome. British Journal of Haematology, 2023, 200, 306-314.	1.2	3
3134	Low absolute CD4+ T cell counts in peripheral blood: an independent predictor of inferior survival in natural killer/T-cell lymphomaâ€“a retrospective cohort study. Annals of Translational Medicine, 2022, 10, 1119-1119.	0.7	0
3135	A systematic review of contemporary phase I trials in patients with lymphoma. Critical Reviews in Oncology/Hematology, 2022, 180, 103860.	2.0	1
3136	The Prognostic Impact of Pretreatment Geriatric Nutritional Risk Index in Patients with Diffuse Large B-Cell Lymphoma. Nutrition and Cancer, 2023, 75, 591-598.	0.9	6
3139	Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma. Journal of Comparative Effectiveness Research, 2023, 12, .	0.6	1
3141	Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Advances, 2023, 7, 602-610.	2.5	2
3142	Proteomic Portrait of Human Lymphoma Reveals Protein Molecular Fingerprint of Disease Specific Subtypes and Progression. Phenomics, 2023, 3, 148-166.	0.9	6
3143	Outcome of limitedâ€“stage peripheral <sc>Tâ€“Cell</sc> lymphoma after <sc>CHOP</sc> (â”like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group. American Journal of Hematology, 2023, 98, 388-397.	2.0	2
3144	Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis. Frontiers in Immunology, 0, 13, .	2.2	1
3145	Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies. International Journal of Hematology, 2023, 117, 553-562.	0.7	5
3147	Clinical outcomes in patients relapsed/refractory after â‰¥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis. BMC Cancer, 2023, 23, .	1.1	6
3148	Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma. Journal of Immunology Research, 2023, 2023, 1-17.	0.9	0

#	ARTICLE	IF	CITATIONS
3149	Impact of risk factors and long term survival analysis of patients with primary refractory Hodgkin lymphoma who underwent high dose chemotherapy and autologous stem cell transplant. Transplantation and Cellular Therapy, 2023, , .	0.6	0

3151	FDG PET/CT-based Response Assessment in Malignancies. Radiographics, 2023, 43, .	1.4	8
------	--	-----	---

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic,

3152